Document:

EX-10.1

 Exhibit 10.1 

CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY
WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS
AMENDED. 
 CONFIDENTIAL 
  

			
	REGENERON PHARMACEUTICALS, INC.	  	INTELLIA THERAPEUTICS, INC.
	777 Old Saw Mill River Road	  	40 Erie St., Suite 130
	Tarrytown, New York 10591	  	Cambridge, Massachusetts 02139

 July 20, 2018 

On April 11, 2016, Regeneron Pharmaceuticals, Inc. (“Regeneron”) and Intellia Therapeutics, Inc.
(“Intellia”) entered into a License and Collaboration Agreement (the “Collaboration Agreement”). Under the Collaboration Agreement, the Parties agreed to collaborate to research and develop improvements to CRISPR-Cas technology and to engage in a research and development program in which they will research and develop CRISPR Products Directed to certain Targets. In addition, each Party granted to the other Party
certain options to enter into a worldwide cost and profit share arrangement for the development and commercialization of certain CRISPR Products and to enter into a Co-Co Agreement related thereto. Pursuant to
Section 5.3 of the Collaboration Agreement, the Parties agreed to negotiate the terms of a Form of Co-Co Agreement. Having agreed to the Form of Co-Co Agreement,
the Parties desire to enter into this letter agreement (this “Letter Agreement”), as of July 20, 2018 (the “Effective Date”) regarding the Form of Co-Co Agreement. Except
as explicitly stated in this Letter Agreement (excluding Exhibit A), capitalized terms used but not defined in this Letter Agreement will have the meaning ascribed to them in the Collaboration Agreement. 

The Parties hereby agree that the Form of Co-Development and
Co-Promotion Agreement attached hereto as Exhibit A will be the Form of Co-Co Agreement for all purposes contemplated by the Collaboration Agreement. Promptly
after the Regeneron Option Exercise Notice or Intellia Option Exercise Notice, as applicable, is delivered to the other Party in accordance with Section 5.1(e)(i) or Section 5.2(c)(i) of the Collaboration Agreement, respectively, the
Parties will execute a Co-Development and Co-Promotion Agreement covering the applicable Regeneron Target or Intellia Liver Target [***]. 

The Parties agree that, subject to the exceptions in Section 13.2 of the Collaboration Agreement, this Letter Agreement (including
Exhibit A) is Confidential Information of both Parties under the Collaboration Agreement. The Parties do not intend to issue a press release announcing the execution of this Letter Agreement. Section 13.5(a) of the Collaboration
Agreement, excluding the first sentence, and Sections 13.5(b) and 13.5(c) of the Collaboration Agreement, each applied mutatis mutandis, are hereby incorporated by reference into this Letter Agreement. 

Each Party acknowledges that the other Party, as a publicly traded company, is legally obligated to make timely disclosures of all material
events relating to its business. Therefore, the 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Parties acknowledge that either or both Parties may be obligated to file a copy of this Letter Agreement (including, for clarity, the Form of
Co-Development and Co-Promotion Agreement attached hereto as Exhibit A) with the United States Securities and Exchange Commission or its equivalent (the
“SEC”). The Parties agree that the form of the redacted version of this Letter Agreement (the “Redacted Letter Agreement”), which shall be mutually agreed by the Parties in good faith within [***], may be used as
its filing (or submission) of this Letter Agreement to the SEC, and the Parties shall cooperate with one another and use reasonable efforts to obtain confidential treatment of confidential information (including any information that constitutes a
trade secret or a sensitive commercial term), including with respect to any comments received from the SEC with respect to the proposed redactions. The Parties further agree that, following the initial filing (or submission) of the Redacted Letter
Agreement, the filing Party will (i) promptly deliver to the non-filing Party any written correspondence received by the filing Party or its representatives from the SEC with respect to such confidential
treatment request and promptly advise the non-filing Party of any other communications between the filing Party or its representatives with the SEC with respect to such confidential treatment request, allowing
a reasonable time for the non-filing Party to review and comment; (ii) upon the written request of the non-filing Party, request an appropriate extension of the
term of the confidential treatment period; and (iii) if the SEC requests any changes to the redactions set forth in the Redacted Letter Agreement, to the extent reasonably practicable, not agree to any changes to the Redacted Letter Agreement
without first discussing such changes with the non-filing Party and taking the non-filing Party’s comments into consideration when deciding whether to agree to such
changes. In addition, each Party will provide the other Party with an advance copy of any securities filings in which the Letter Agreement is discussed or disclosed, in each case only to the extent describing this Letter Agreement or
referencing the other Party, allowing a reasonable time for the other Party to review and comment, and will reasonably consider and, to the extent permitted by a Governmental Authority, or Applicable Law (including the rules and regulations of any
stock exchange or trading market on which a Party’s (or its parent entity’s) securities are or will be traded), incorporate the other Party’s timely comments thereon [***]. 

The Parties agree that the provisions of Article 17 of the Collaboration Agreement, applied mutatis mutandis, are hereby incorporated
by reference into this Letter Agreement. 
 [Remainder of page intentionally left blank. Signature page follows.] 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 IN WITNESS WHEREOF, Regeneron and Intellia have caused this Letter Agreement to be executed
by their duly authorized representatives as of the Effective Date. 
  

					
	REGENERON PHARMACEUTICALS, INC.
		
	By	  	 /s/ Kerry K. Reinersten, Ph.D.

		  	Name:	 	Kerry K. Reinertsen, Ph.D.
		  	Title:	 	Vice President, Strategic Alliances
	
	INTELLIA THERAPEUTICS, INC.
		
	By	  	 /s/ John Leonard

		  	Name:	 	John Leonard
		  	Title:	 	Chief Executive Officer

  
 [Signature Page to
Letter Agreement re: Form of Co-Development and Co-Promotion Agreement] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 EXHIBIT A 

FORM OF CO-DEVELOPMENT AND CO-PROMOTION AGREEMENT 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 EXECUTION COPY 

CONFIDENTIAL 
 FORM OF CO-DEVELOPMENT AND CO-PROMOTION AGREEMENT 
 By and Between

 REGENERON PHARMACEUTICALS, INC. 

and 
 INTELLIA
THERAPEUTICS, INC. 

[                    ]
[        ], [        ] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
	 ARTICLE 1 DEFINITIONS
	  	 	1	 
		
	 ARTICLE 2 AGREEMENT OVERVIEW AND COLLABORATION GOVERNANCE
	  	 	23	 
			
	 2.1
	 	Lead Party and Participating Party	  	 	23	 
			
	 2.2
	 	Modification of the Collaboration Agreement by this Agreement, Conflicts, Drafting Principles; Incorporation by Reference	  	 	23	 
			
	 2.3
	 	Committees/Management	  	 	24	 
			
	 2.4
	 	Joint Steering Committee	  	 	26	 
			
	 2.5
	 	Joint Development Committee	  	 	27	 
			
	 2.6
	 	Joint Commercialization Committee	  	 	28	 
			
	 2.7
	 	Joint Finance Committee	  	 	29	 
			
	 2.8
	 	Joint Manufacturing Committee	  	 	29	 
			
	 2.9
	 	[See Annex 1.]	  	 	29	 
			
	 2.10
	 	Resolution of Committee Disputes	  	 	29	 
			
	 2.11
	 	Alliance Management	  	 	30	 
		
	 ARTICLE 3 DEVELOPMENT ACTIVITIES FOR
CO-FUNDING PRODUCTS
	  	 	30	 
			
	 3.1
	 	Development of Co-Funding Products	  	 	30	 
			
	 3.2
	 	Existing Product R&D Programs and Associated Product R&D Plans	  	 	30	 
			
	 3.3
	 	New Product R&D Programs and Associated Product R&D Plans	  	 	30	 
			
	 3.4
	 	[See Annex 1.]	  	 	30	 
			
	 3.5
	 	Transition of Patent Prosecution Responsibilities. [See Annex 1.]	  	 	30	 
			
	 3.6
	 	Preparation, Updates and Approval of Global Development Plans	  	 	30	 
			
	 3.7
	 	Global Development Budgets	  	 	31	 
			
	 3.8
	 	[See Annex 1.]	  	 	32	 
		
	 ARTICLE 4 COMMERCIALIZATION OF
CO-FUNDING PRODUCTS
	  	 	32	 
			
	 4.1
	 	Commercialization of Co-Funding Products	  	 	32	 
			
	 4.2
	 	Preparation, Updates and Approval of Global Commercialization Plans	  	 	32	 
			
	 4.3
	 	Global Commercialization Budget	  	 	32	 
			
	 4.4
	 	Country/Region Commercialization Plans	  	 	33	 
			
	 4.5
	 	Commercialization Efforts; Sharing of Commercial Information	  	 	33	 
			
	 4.6
	 	Promotional Materials	  	 	34	 
			
	 4.7
	 	Promotional Claims/Compliance	  	 	34	 

  
 i 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
	 4.8
	 	Restriction on Bundling	  	 	34	 
			
	 4.9
	 	Market Exclusivity Extensions	  	 	34	 
			
	 4.10
	 	Post Marketing Approval Obligations	  	 	34	 
			
	 4.11
	 	The Participating Party’s Co-Promotion Option in the United States	  	 	35	 
		
	 ARTICLE 5 CLINICAL AND REGULATORY AFFAIRS
	  	 	35	 
			
	 5.1
	 	Regulatory Coordination	  	 	35	 
			
	 5.2
	 	Labeling	  	 	36	 
			
	 5.3
	 	Regulatory Events	  	 	36	 
			
	 5.4
	 	Recalls and Other Corrective Actions	  	 	37	 
		
	 ARTICLE 6 LICENSES
	  	 	37	 
			
	 6.1
	 	Intellia License to Regeneron for Regeneron Co-Funding Products	  	 	37	 
			
	 6.2
	 	Regeneron License to Intellia for Regeneron Co-Funding Products	  	 	37	 
			
	 6.3
	 	Regeneron License to Intellia for Intellia Co-Funding Products	  	 	38	 
			
	 6.4
	 	Unblocking License	  	 	38	 
			
	 6.5
	 	Intellia License to Regeneron for Intellia Co-Funding Products	  	 	38	 
			
	 6.6
	 	Mutual License to Materials	  	 	38	 
			
	 6.7
	 	Ex-Vivo Field	  	 	38	 
			
	 6.8
	 	Restrictions on the Participating Party	  	 	38	 
			
	 6.9
	 	Discussion of Additional License	  	 	38	 
		
	 ARTICLE 7 PERFORMANCE AND PERFORMANCE STANDARDS
	  	 	38	 
			
	 7.1
	 	Licenses Generally; No Implied License	  	 	38	 
			
	 7.2
	 	Performance Standards	  	 	39	 
			
	 7.3
	 	Third Party Agreements	  	 	40	 
			
	 7.4
	 	Coordination of Third Party Intellectual Property Licensing	  	 	41	 
			
	 7.5
	 	Third Party License Payments	  	 	41	 
			
	 7.6
	 	Records	  	 	41	 
			
	 7.7
	 	Materials for Development Plans	  	 	42	 
			
	 7.8
	 	Debarment	  	 	42	 
			
	 7.9
	 	No Use of Non-Controlled IP in Performance of Activities under this Agreement	  	 	42	 
			
	 7.10
	 	Further Assurances and Transaction Approvals	  	 	42	 
			
	 7.11
	 	[See Annex 1.]	  	 	42	 
			
	 7.12
	 	[See Annex 1.]	  	 	42	 

  
 ii 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
		
	 ARTICLE 8 CO-FUNDING PRODUCT
MANUFACTURING
	  	 	42	 
			
	 8.1
	 	Non-GMP Manufacture of Co-Funding Products	  	 	42	 
			
	 8.2
	 	Supply for Product R&D Program or its Equivalent	  	 	42	 
			
	 8.3
	 	Supply Beyond Pre-Clinical	  	 	43	 
			
	 8.4
	 	[See Annex 1.]	  	 	43	 
			
	 8.5
	 	Clinical and Commercial Supply	  	 	43	 
			
	 8.6
	 	Manufacturing Plans	  	 	43	 
			
	 8.7
	 	Manufacturing Shortfall	  	 	43	 
		
	 ARTICLE 9 PAYMENTS
	  	 	44	 
			
	 9.1
	 	Reimbursement for Past Expenses	  	 	44	 
			
	 9.2
	 	Sharing of Profits and Development Costs from Co-Funding Products	  	 	44	 
			
	 9.3
	 	Adjustment to the Co-Funding Percentage for the Co-Funding Target by the Participating Party	  	 	44	 
			
	 9.4
	 	Periodic Reports	  	 	44	 
			
	 9.5
	 	Adjustments to FTE Rates	  	 	45	 
			
	 9.6
	 	Funds Flow	  	 	45	 
			
	 9.7
	 	Invoices and Documentation	  	 	46	 
			
	 9.8
	 	Payment Method and Currency	  	 	46	 
			
	 9.9
	 	Taxes	  	 	46	 
			
	 9.10
	 	Resolution of Payment Disputes	  	 	46	 
			
	 9.11
	 	Late Fee	  	 	46	 
			
	 9.12
	 	Effect of Intellia Option Exercise	  	 	46	 
			
	 9.13
	 	[See Annex 1.]	  	 	47	 
			
	 9.14
	 	[See Annex 1.]	  	 	47	 
		
	 ARTICLE 10 INTELLECTUAL PROPERTY
	  	 	47	 
			
	 10.1
	 	Newly Created Intellectual Property	  	 	47	 
			
	 10.2
	 	Prosecution and Maintenance of Patent Rights	  	 	48	 
			
	 10.3
	 	Administrative Patent Proceedings	  	 	51	 
			
	 10.4
	 	Third Party Infringement Suits	  	 	51	 

  
 iii 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
	 10.5
	 	BPCIA and Biosimilar Applications	  	 	53	 
			
	 10.6
	 	Extensions and Other Protections	  	 	54	 
			
	 10.7
	 	Patent Marking	  	 	54	 
			
	 10.8
	 	Third Party Claims Related to Technology Collaboration, Regeneron Target Evaluation Program, Intellia Target Evaluation Program or Product R&D Program	  	 	54	 
			
	 10.9
	 	Infringement of Third Party Patent Rights or Third Party Know-How	  	 	54	 
			
	 10.10
	 	Product Trademarks	  	 	55	 
			
	 10.11
	 	Use of Corporate Names	  	 	55	 
			
	 10.12
	 	Third Party Rights	  	 	55	 
		
	 ARTICLE 11 BOOKS, RECORDS AND INSPECTIONS; AUDITS AND ADJUSTMENTS
	  	 	55	 
			
	 11.1
	 	Books and Records	  	 	55	 
			
	 11.2
	 	Audits and Adjustments	  	 	56	 
			
	 11.3
	 	GAAP	  	 	56	 
		
	 ARTICLE 12 REPRESENTATIONS, WARRANTIES AND COVENANTS
	  	 	56	 
			
	 12.1
	 	Joint Representations and Warranties	  	 	56	 
			
	 12.2
	 	Additional Representations and Warranties of the Parties	  	 	56	 
			
	 12.3
	 	Covenants	  	 	56	 
			
	 12.4
	 	Compliance with Laws	  	 	57	 
			
	 12.5
	 	Disclaimer of Warranties	  	 	57	 
			
	 12.6
	 	Exclusivity	  	 	57	 
		
	 ARTICLE 13 CONFIDENTIALITY
	  	 	58	 
			
	 13.1
	 	Confidential Information	  	 	58	 
			
	 13.2
	 	Exceptions	  	 	60	 
			
	 13.3
	 	Injunctive Relief	  	 	60	 
			
	 13.4
	 	Publications	  	 	60	 
			
	 13.5
	 	Disclosures Concerning this Agreement	  	 	61	 
		
	 ARTICLE 14 INDEMNITY
	  	 	62	 
			
	 14.1
	 	Indemnity and Insurance	  	 	62	 
			
	 14.2
	 	Indemnity Procedure	  	 	63	 
			
	 14.3
	 	Insurance	  	 	65	 

  
 iv 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
	 ARTICLE 15 FORCE MAJEURE
	  	 	65	 
		
	 ARTICLE 16 TERM AND TERMINATION
	  	 	65	 
			
	 16.1
	 	Term	  	 	65	 
			
	 16.2
	 	Termination for Insolvency	  	 	65	 
			
	 16.3
	 	Termination of Co-Funding Target for which a Party is the Lead Party for Convenience	  	 	66	 
			
	 16.4
	 	Termination of Co-Funding Target by the Participating Party for Convenience	  	 	66	 
			
	 16.5
	 	Breach of the Agreement	  	 	67	 
			
	 16.6
	 	Termination for IP Challenge	  	 	67	 
			
	 16.7
	 	Termination for Suspension of Development or Commercialization	  	 	67	 
			
	 16.8
	 	Effects of Termination of the Agreement where Regeneron is the Lead Party, except if the Agreement is Terminated by Intellia pursuant to Section 16.4	  	 	68	 
			
	 16.9
	 	Effects of Termination of the Agreement where Regeneron is the Lead Party if the Agreement is Terminated by Intellia pursuant to Section 16.4	  	 	69	 
			
	 16.10
	 	Effects of Termination of the Agreement where Intellia is the Lead Party, except if the Agreement is Terminated by Intellia pursuant to Section 16.3 or Section 16.7 or the Agreement is Terminated by Regeneron pursuant
to Section 16.4	  	 	69	 
			
	 16.11
	 	Effects of Termination of the Agreement where Intellia is the Lead Party if this Agreement is Terminated by Intellia pursuant to Section 16.3 or Section 16.7	  	 	70	 
			
	 16.12
	 	Effects of Termination of the Agreement where Intellia is the Lead Party if this Agreement is Terminated by Regeneron pursuant to Section 16.4	  	 	70	 
			
	 16.13
	 	Participating Party’s Remedies in lieu of Termination	  	 	72	 
			
	 16.14
	 	Change of Control of the Participating Party	  	 	73	 
			
	 16.15
	 	Survival of Obligations	  	 	73	 
			
	 16.16
	 	Return of Confidential Information	  	 	74	 
		
	 ARTICLE 17 MISCELLANEOUS
	  	 	74	 
			
	 17.1
	 	Governing Law; Dispute Resolution; Submission to Jurisdiction	  	 	74	 
			
	 17.2
	 	Waiver	  	 	74	 
			
	 17.3
	 	Notices	  	 	74	 
			
	 17.4
	 	Entire Agreement	  	 	75	 
			
	 17.5
	 	Amendments	  	 	75	 
			
	 17.6
	 	Interpretation	  	 	75	 

  
 v 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

							
	 17.7
	 	Construction	  	 	75	 
			
	 17.8
	 	Severability	  	 	75	 
			
	 17.9
	 	Assignment	  	 	75	 
			
	 17.10
	 	Successors and Assigns	  	 	75	 
			
	 17.11
	 	Counterparts	  	 	75	 
			
	 17.12
	 	Third Party Beneficiaries	  	 	75	 
			
	 17.13
	 	Relationship of the Parties	  	 	75	 
			
	 17.14
	 	Limitation of Damages	  	 	75	 
			
	 17.15
	 	Injunctive or Other Equity Relief	  	 	75	 
			
	 17.16
	 	Non-Exclusive Remedies	  	 	75	 

  

			
	Schedules:	  	
		
	Schedule 1.18	  	Co-Funding Target
	Schedule 1.102	  	Manufacturing Cost
	Schedule 9.2	  	Key Terms for Aggregate [***] True-Up
		
	Annexes:1	  	
		
	ANNEX 1	  	Provisions Specific to Categories of Products

  
  

	1 	 NTD: To be deleted prior to execution of the Agreement for the applicable Co-Funding Target.

  
 vi 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 FORM OF CO-DEVELOPMENT AND CO-PROMOTION AGREEMENT 
 THIS FORM OF CO-DEVELOPMENT AND CO-PROMOTION AGREEMENT (this “Agreement”), dated as of [                    ]
[        ], [        ] (the “Effective Date”), is by and between REGENERON PHARMACEUTICALS, INC., a corporation organized under the laws of New York and
having a principal place of business at 777 Old Saw Mill River Road, Tarrytown, New York 10591 (“Regeneron”), and INTELLIA THERAPEUTICS, INC., a corporation organized under the laws of Delaware and having a principal place of
business at 40 Erie St., Suite 130, Cambridge, Massachusetts 02139 (“Intellia”) (with each of Regeneron and Intellia referred to herein individually as a “Party” and collectively as the “Parties”).

 WHEREAS, the Parties have entered into that certain License and Collaboration Agreement, dated April 11, 2016 (the
“Collaboration Agreement”), whereby the Parties agreed to collaborate to research and develop improvements to CRISPR-Cas (as defined below) technology and to engage in a research and
development program in which they will research and develop CRISPR Products Directed to certain Targets (as each such term is defined below); 

WHEREAS, under the terms of the Collaboration Agreement, each Party granted to the other Party certain options to enter into a worldwide cost
and profit share arrangement for the development and commercialization of certain CRISPR Products; 
 WHEREAS, the Parties have entered into
a Letter Agreement, dated July 20, 2018, whereby the Parties agreed to a Form of Co-Development and Co-Promotion Agreement (“Form of Co-Co Agreement”); and 
 WHEREAS, this Agreement shall govern the relationship between the Parties
with respect to the worldwide cost and profit share arrangement for the development and commercialization of the applicable Co-Funding Products Directed to the applicable
Co-Funding Target that is the subject of a Party’s option exercised under and in accordance with the Collaboration Agreement. 

NOW, THEREFORE, in consideration for the following mutual promises and obligations, and for other good and valuable consideration the adequacy
and sufficiency of which are hereby acknowledged, the Parties agree as follows: 
 ARTICLE 1 

DEFINITIONS 
 Capitalized
terms used in this Agreement, whether used in the singular or plural, except as expressly set forth herein, shall have the meanings set forth below: 

1.1    “Affiliate” shall have the meaning ascribed to such term in the Collaboration Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.2    “Anti-Corruption Laws” shall have the meaning
ascribed to such term in the Collaboration Agreement. 
 1.3    “Anticipated First Commercial Sale”
shall mean, with respect to a Co-Funding Product, the date agreed upon in advance by the JSC as the expected date of First Commercial Sale of such Co-Funding Product in such country or Region (as applicable)
of the world if specified or, otherwise, any country in the world. The JSC shall attempt to agree upon such date [***] in advance of its expected occurrence. In the event that Development timelines are accelerated such that the JSC is unable to
agree on the expected date of First Commercial Sale [***] in advance of its expected occurrence, the JSC shall attempt to agree upon the Anticipated First Commercial Sale as soon as practicable after the [***]. 

1.4    “API” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.5    “Applicable Law” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.6    “Approval” shall mean, with respect to each Co-Funding Product, any approval, registration,
license or authorization from an applicable Regulatory Authority required for the Development, Manufacture or Commercialization of such Co-Funding Product in a regulatory jurisdiction, and shall include any such approval, registration, license or
authorization granted for any Marketing Approval. 
 1.7    “Biosimilar Application” shall mean an
application or submission filed with a Regulatory Authority for Marketing Approval of a pharmaceutical or biological product claimed to be biosimilar or interchangeable to any Co-Funding Product or otherwise relying on the approval of such
Co-Funding Product, including, for example, an application filed under 42 U.S.C. §262(k). 
 1.8    
“BPCIA” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.9    “Business Day” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.10    “Caribou-Intellia License Agreement” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.11    “Change of Control” shall mean, with respect to a Party, (a) a
merger or consolidation of such Party with a Third Party that results in the voting securities of such Party outstanding immediately prior thereto, or any securities into which such voting securities have been converted or exchanged, ceasing to
represent more than fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately 

  
 2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
after such merger or consolidation; (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, (i) becomes the direct or indirect beneficial owner
of more than fifty percent (50%) of the combined voting power of the outstanding securities, and (ii) acquires the ability to appoint a majority of the board of directors, of such Party; or (c) the sale or other transfer to a
Third Party of all or substantially all of such Party’s and its Affiliates’ assets. 
 1.12    “Claim
Date” shall mean the date on which any claim or assertion covered by Section 10.9 or any Claim covered by Section 14.1 is filed or threatened in writing. 

1.13    “Clinical Supply Costs” shall mean, the Manufacturing Costs for Clinical Supply Requirements,
[***].  
 1.14    “Clinical Supply Requirements” shall mean, with respect to a Co-Funding
Product, (a) the quantities of such Co-Funding Product (or placebo or comparator agent, as the case may be) required by a Party or the Parties for Development in the Field under this Agreement in
connection with the Global Development Plan and (b) quantities of the Co-Funding Product that are required by a Party for submission to a Regulatory Authority, including in connection with any
Registration Filing or Approval in the Field in any regulatory jurisdiction in the world or in connection with any request by such Regulatory Authority. 

1.15    “Co-Funding Percentage” shall mean, with respect to the Co-Funding Target and all Co-Funding Products, the [***] share of financial investment, expenses, costs, profit and loss as between the Parties on a world-wide basis in
accordance with and subject to Section 9.2 as may be modified by the Participating Party pursuant to Section 9.3. 

1.16    “Co-Funding Product Invention” shall mean [***]. 

1.17    “Co-Funding Product” [See Annex 1.] 

1.18    “Co-Funding Target” shall mean the Target that is the
subject of the Exercised Option as set forth on Schedule 1.18. 
 1.19    “Combination Product” shall
mean a Co-Funding Product incorporating or comprising at least [***] CP that is developed under this Agreement and at least [***]. 

1.20    “Commercialize” or “Commercialization” shall mean, with respect to a Co-Funding Product, the following activities undertaken or performed for such Co-Funding Product from and after the Option Exercise Date: [***]. 

1.21    “Commercially Reasonable Efforts” shall mean, with respect to the efforts to be expended by a
Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder, those reasonable, good faith efforts and resources to accomplish such objective, activity or decision consistent with those efforts and resources
the relevant Party 

  
 3 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
would normally use to accomplish a similar objective, activity or decision under similar circumstances, it being understood and agreed that with respect to the research, Development, Manufacture,
seeking and obtaining Marketing Approval, or Commercialization of a product, such efforts and resources shall be consistent with the usual practices of such [***]. 

1.22    “Commercial Overhead Charge” shall mean, [***]. 

1.23    “Commercial Supply Costs” shall mean the Manufacturing Costs for Commercial Supply Requirements
of the applicable Co-Funding Products. [***] Commercial Supply Costs shall be determined [***] Commercial Supply Costs for a Co-Funding Product shall be [***]. 

1.24    “Commercial Supply Requirements” shall mean, with respect to a Co-Funding Product, the quantities
of such Co-Funding Product as are required to fulfill requirements for [***] in the world as approved by the JSC. 

1.25    “Contract Year” shall mean the period beginning on the Effective Date and ending on
December 31, 2017, and each succeeding twelve (12) month period thereafter during the Term (except that the last Contract Year shall end on the effective date of any termination or expiration of the Term). 

1.26    “Control” shall mean, with respect to any Material, Confidential Information, Intellectual
Property right, or trademark that a Party (a) owns such Material, Confidential Information, Intellectual Property right, or trademark, or (b) has a license or right to use to such Material, Confidential Information, Intellectual Property right,
or trademark, in each case of (a) or (b), with the ability to grant to the other Party access to, or a license or a sublicense (as applicable) of such rights to such Material, Confidential Information, Intellectual Property right, or trademark on
the terms and conditions set forth herein, without (i) violating the terms of any agreement with any Third Party in existence as of the Effective Date or (ii) with respect to any such Material, Confidential Information, Intellectual Property right,
or trademark that Intellia (or its Affiliate) in-licenses pursuant to an in-license agreement entered into by Intellia (or its Affiliate) with a Third Party after the Effective Date, having an obligation to pay any royalties or other consideration
or being subject to additional conditions that are applicable to a sublicensee under such in-license, and with respect to a Regeneron Co-Funding Product unless included pursuant to the procedures set forth in Section 7.3, as applicable, or (iii)
with respect to any such Material, Confidential Information, Intellectual Property Right, or trademark that Intellia (or its Affiliate) comes to own after the Effective Date that was invented [***] or (iv) with respect to any such Material,
Confidential Information, Intellectual Property right, or trademark that Regeneron (or its Affiliate) in-licenses pursuant to an in-license agreement entered into by Regeneron (or its Affiliate) with a Third Party after the Effective Date, having an
obligation to pay any royalties or other consideration or being subject to additional conditions that are applicable to a sublicensee under such in-license, and with respect to an Intellia Co-Funding Product unless Intellia agrees to assume the
applicable obligations under such in-licenses, as applicable, or (v) with respect to any such Material, Confidential Information, Intellectual Property Right, or trademark that Regeneron (or its Affiliate) comes to own after the Effective

  
 4 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Date, [***], in each of (i), (ii), (iii),(iv) and (v), as of the time such Party or its Affiliates would first be required hereunder to grant the other Party such access, license or (sub)license;
provided that, for clarity, Intellia will be deemed to Control such Intellectual Property as is licensed to it under the Intellia Existing Third Party Agreements (but subject to the terms and conditions of the Intellia Existing Third Party
Agreements and with respect to Regeneron Co-Funding Products as and to the extent set forth in Section 7.3(e) and 10.12 of this Agreement with respect to such Intellia Existing Third Party Agreements). Notwithstanding anything in this Agreement
to the contrary, in the event of a Change of Control of a Party, a Party will be deemed not to Control any Material, Confidential Information, Intellectual Property right, or trademark that are owned or in-licensed by a Third Party described in the
definition of “Change of Control” or such Third Party’s Affiliates (other than such Party or such Party’s Affiliates immediately prior to the closing of such Change of Control) (y) prior to the closing of such Change
of Control, except to the extent that any such Patent Rights, Know-How or Materials were Controlled by such Party or any of its Affiliates prior to such Change of Control, or (z) after such Change of Control to the extent that such
Patent Rights, Know-How or Materials are invented or created by such Third Party or its Affiliates (other than such Party or such Party’s Affiliates immediately prior to the closing of such Change of Control) after such Change of Control
without using or incorporating any Patent Rights, Know-How or Materials licensed hereunder, provided that, notwithstanding the foregoing, following such Change of Control, such Party shall in all cases be deemed to Control all Patent Rights,
Know-How and Materials (1) arising from the performance of activities under this Agreement or performance of activities under the Collaboration Agreement, including the Technology Collaboration, Regeneron Target Evaluation Programs,
Intellia Target Evaluation Programs or Product R&D Programs on the terms as set forth in the Collaboration Agreement, or (2) that are improvements to, or derivatives of, or are otherwise based on or incorporates, any Patent Rights,
Know-How or Materials Controlled by such Party or any of its Affiliates prior to such Change of Control or (3) that such Party or its Affiliates chooses to make available for the conduct of activities under this Agreement or actually
uses in the conduct of activities under this Agreement. 
 1.27    “Converted CFP Inventions” [See
Annex 1.] 
 1.28    “Co-Promote” or “Co-Promotion” shall mean the joint Detailing of
Co-Funding Product(s) by the Parties (or their respective Affiliates) under the same trademark in the United States pursuant to the U.S. Co-Promotion Agreement. 

1.29    “Country/Region Commercialization Budget” shall mean the budget(s) for a particular Contract Year
developed by the Lead Party, reviewed by the JCC and JSC, and approved by the JSC for the applicable Country/Region Commercialization Plan. 

1.30    “Country/Region Commercialization Plan” shall mean for a Co-Funding Product, for each Major
Market Country and any other country mutually agreed to pursuant to the last sentence of this Section 1.30, [***]. Each Country/Region Commercialization Plan shall set forth, for each Co-Funding Product, the information, plans and forecasts set
forth in Section 4.4. The JCC shall propose and the JSC shall approve the number of Country/Region Commercialization Plans for each Co-Funding Product and the geographic scope of each such Plan. 

  
 5 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.31    “Cost of Goods Sold” shall mean, with respect to
a given Quarter, the aggregate Manufacturing Costs (calculated in accordance with GAAP and Schedule 1.102) for all Co-Funding Products sold worldwide during such Quarter. 

1.32    “CPI” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.33    “CPI Adjustment” shall mean the percentage increase or decrease, if any, in the CPI applicable to
the applicable personnel for the [***] of the Contract Year prior to the Contract Year for which the adjustment is being made. 

1.34    “CRISPR-Cas” and “CRISPR-Cas Materials” shall have the meaning ascribed to such
term in the Collaboration Agreement. 
 1.35    “CRISPR Product” or “CP” shall have
the meaning ascribed to such term in the Collaboration Agreement. 
 1.36    “Detail” shall mean, with
respect to each Co-Funding Product, [***]. 
 1.37    “Develop”
or “Development” shall mean, with respect to a Co-Funding Product, the following activities undertaken or performed for such Co-Funding Product from and after the Option Exercise Date: (a) activities relating to research,
pre-clinical and clinical development of such Co-Funding Product, including test method development and stability testing, assay development, toxicology, pharmacology, formulation, quality assurance/quality control development, technology transfer,
statistical analysis, process development and scale-up, pharmacokinetic studies, data collection and management, clinical studies (including research to design clinical studies), regulatory affairs, project management, drug safety surveillance
activities related to clinical studies, the preparation and submission of Registration Filings, but excluding activities necessary to obtain a Pricing Approval, reimbursement and/or listing on health care providers’ and payers’
formularies; and (b) any other research and development activities with respect to such Co-Funding Product, including, activities to support the discovery of biomarkers and activities to support new product formulations, delivery
technologies and/or new indications, either before or after the First Commercial Sale. 
 1.38    “Development
Costs” shall mean, with respect to a Co-Funding Product, those costs incurred by a Party for the Development of such Co-Funding Product in accordance with this Agreement and the applicable Global Development Plan [***] for the following
items: 
  

	 	(a)	 Out-of-Pocket Costs [***] under
this Agreement; 

  

	 	(b)	 Development FTE Costs; 

  
 6 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (c)    Clinical Supply Costs; 

(d)    Out-of-Pocket Costs incurred for
[***]; 
 (e)    [***]; 

(f)    Out-of-Pocket Costs and
Development FTE Costs incurred pursuant to Section 3.7; and 
 (g)    any other costs or expenses for such Co-Funding Product directly related and specifically attributable to [***] specifically identified and included in the applicable [***] or included as Development Costs under this Agreement. 

[***]: 
  

	 	1.	 [***]. 

  

	 	2.	 [***]. 

  

	 	3.	 [***]. 

  

	 	4.	 [See Annex 1.] 

  

	 	5.	 In no event shall a Party charge the other Party more than once for the same Development Costs under this
Agreement, even if such costs are of benefit to multiple Co-Funding Products. 

1.39    “Development Cost Forecast” shall mean the [***]. 

1.40    “Development FTE Cost” shall mean, for a given period, the number of FTEs for such period
multiplied by the applicable Development FTE Rate. 
 1.41    “Development FTE Rate” shall mean
(a) for each FTE based in the US, $[***] per FTE per Contract Year, adjusted each Contract Year on January 1 (commencing on January 1, 2019) in accordance with any CPI Adjustment, and (b) for each FTE based
outside the U.S., such amount as the Parties shall agree to, in writing, in the local currency in the country where such FTE is based (which shall be converted into United States Dollars in accordance with Section 9.8). [***]. 

1.42    “Development Payment Report” on a Co-Funding Product-by-Co-Funding Product basis, shall mean the
[***] report prepared by the Lead Party in accordance with Section 9.2 which sets forth in reasonable detail, for each Co-Funding Product individually (a) the Development Costs incurred by the Parties for such [***] and
(b) the [***] Development True-Up calculated in accordance with Schedule 9.2. 

  
 7 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.43    “Directed to” shall have the meaning ascribed to
such term in the Collaboration Agreement. 
 1.44    “Exercised Option” [See Annex 1.] 

1.45    “Executive Officers” shall mean the [***] of Regeneron and the [***] of Intellia, or their
respective designees with equivalent decision-making authority with respect to matters under this Agreement. 

1.46    “Ex-Vivo Field” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.47    “FCPA” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.48    “FDA” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.49    “Field” shall mean [***] uses of CPs for therapeutic, palliative, prophylactic, and diagnostics
purposes but excluding the [***]; provided that, for clarity, the Field shall include [***]. The Field shall specifically [***]. 

1.50    “Field Force Cost” shall mean, for a given Co-Funding Product in the applicable country or
Region, the product of (a) a percentage of the number of Lead Party’s FTEs [***] and (b) the applicable Field Force FTE Rate(s), in each case, with respect to such country or Region, as applicable. [***]. 

1.51    “Field Force FTE Rates” shall mean, on a country-by-country or Region-by-Region (as proposed by
JCC and reviewed and approved by the JSC) basis (determined based on the location of the field force representative), a rate or rates proposed by the JCC and reviewed and approved by the JSC [***], as applicable, based upon the [***]. 

1.52    “Financial Dispute” shall mean any dispute related to [***]. 

1.53    “First Commercial Sale” shall mean, with respect to a given Co-Funding Product and a given
country, the first commercial sale by or on behalf of the Lead Party or any of its Affiliates or sublicenses to a Third Party for use or consumption by the general public (including through public or private means or markets) of such Co-Funding
Product in the Field in such country after Marketing Approval for commercial sale of such Co-Funding Product has been obtained in such country or where Marketing Approval in such country is not required, but where such sale is permitted to occur
under, or is dependent upon, Marketing Approval for such Co-Funding Product in another major market country, such as so called “named patient sales” or any compassionate use. Sales for test marketing or clinical trial purposes shall not be
construed as a First Commercial Sale. 

  
 8 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.54    “FTE” shall mean a full time equivalent employee
[***] employed by Party (or its Affiliate) who performs activities under a Plan, with such commitment of time and effort to constitute [***] employee performing such work on a full-time basis, which for purposes hereof shall be [***] hours per
Contract Year (pro-rated for any Contract Year that is less than twelve (12) months). 

1.55    “GAAP” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.56    “Gene” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.57    “Global Commercialization Budget” shall mean the budget(s) for a particular Contract Year
developed by the Lead Party, reviewed by the JCC and JSC, and approved by the JSC for the applicable Global Commercialization Plan. 

1.58    “Global Commercialization Plan” shall mean, with respect to a Co-Funding Product, the [***], and
approved by the JSC for the worldwide Commercialization of such Co-Funding Products in the Field and shall include the following: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; and 

  

	 	(i)	 [***]. 

1.59    “Global Development Budget” shall mean the budget(s) for a particular Calendar Year (and a
non-binding budget forecast for the next [***] developed by the Lead Party, reviewed by the JDC and JSC, and approved by the JSC pursuant to Section 3.7(a) for the applicable Global Development Plan. 

  
 9 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.60    “Global Development Plan” shall mean, with
respect to a Co-Funding Product, the [***], reviewed by the JDC and JSC, and approved by the JSC for the worldwide Development of such Co-Funding Product, which shall
include the following: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; and 

  

	 	(f)	 [***]. 

1.61    “GLP Toxicology Study” shall mean a toxicology study, in a species that satisfies applicable
requirements of a Regulatory Authority, using applicable Good Laboratory Practices (“GLP”), which meets the standard necessary for submission as part of an IND filing with the applicable Regulatory Authority. 

1.62    “Good Practices” shall have the meaning ascribed to such term in the Collaboration Agreement.

 1.63    “Governmental Authority” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.64    “HSC” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.65    “ICH” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.66    “IND” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.67    “IND Acceptance” shall mean, with respect to a particular Co-Funding Product, that the particular IND for such Co-Funding Product was accepted by the FDA (or other applicable Regulatory Authority outside the United States if the IND
was submitted to such Regulatory Authority outside the United States), as evidenced by no objection by the FDA (or such other applicable Regulatory Authority outside the United States) within [***] days after the date of the IND submission (or any
amended submission if such amendment restarted the applicable [***] day period). 

  
 10 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.68    “Initiation of GLP Toxicology Batch” shall mean,
with respect to a particular Co-Funding Product, commencement of Manufacturing activities for an initial batch of Co-Funding Product intended to be used in a GLP
Toxicology Study for such Co-Funding Product. For purposes of this paragraph, “commencement” means the start of any Manufacturing activities directly or via a Third Party manufacturer. 

1.69    “Intellectual Property” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.70    “Intellia Background Patent Rights” shall mean those Patent Rights that
(a) are Controlled by Intellia or any of its Affiliates (i) as of the Effective Date or (ii) during the Term [***], or (iii) during the IP Term, [***], or (iv) any (A) Patent Rights claiming
priority to the Patent Rights, or (B) foreign equivalents of the Patent Rights, in each case of (A) and (B), in subclauses (i), (ii), or (iii), but in each of (i), (ii), (iii), and (iv) excluding Patent Rights to the
extent within the [***], Intellia Materials Improvements, Intellia CRISPR-Cas IP, [***], Co-Funding Product Inventions (including Intellia Liver Product Inventions that become Co-Funding Product Inventions), Regeneron Materials Improvements, [***]
and (b) are necessary or useful for the research, Development, Manufacturing, using, Commercialization, exploitation or selling of (i) a Co-Funding Product or (ii) CRISPR-Cas. The Intellia Background Patent Rights
as of the Effective Date include those set forth on Schedule 1.47 of the Collaboration Agreement. 

1.71    “Intellia Co-Funding Product” shall mean [***]. 

1.72    “Intellia Co-Funding Product Invention” shall mean a
Co-Funding Product Invention that relates to or covers an Intellia Co-Funding Product. 

1.73    “Intellia Co-Funding Target” shall mean with respect to
an Intellia Co-Funding Product, [***]. 
 1.74    “Intellia CRISPR-Cas IP” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.75    “Intellia Existing Third Party Agreements” shall mean the Caribou-Intellia License Agreement,
including any amendments or restatements thereto as of the Effective Date or amendments following the Effective Date in accordance with Section 12.3, and the Invention Management Agreement under which Intellia is granted rights which are then
sublicensed to Regeneron hereunder as Intellia Patent Rights, Intellia Know-How or Intellia Materials. 

1.76    “Intellia Intellectual Property” shall mean the Intellia Patent Rights and the Intellia Know-How.

 1.77    “Intellia Know-How” shall mean any and all Know-How that (a) is Controlled by Intellia
or any of its Affiliates (i) as of the Effective Date or (ii) during the Term [***], and (b) is necessary or useful for the research, Development, Manufacturing, using Commercialization,

  
 11 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
exploitation or selling of (A) a Co-Funding Product or (B) CRISPR-Cas. Intellia Know-How shall include Know-How created during the Term in or related to Intellia Materials,
Intellia Materials Improvements or Intellia CRISPR-Cas IP, Intellia Co-Funding Product Inventions as well as Intellia’s interests in any [***]. 

1.78    “Intellia Liver Product” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.79    “Intellia Liver Product Invention” shall mean (a) all Intellectual Property
that is invented by or on behalf of either Party (or by the Parties jointly) in the performance of Development, Manufacture or Commercialization of any Intellia Liver Product Directed to an Intellia Liver Target for which Regeneron exercised the
Exercised Option and such invention is made prior to the Option Exercise Date, in each case that solely relates to or covers one or more Intellia Liver Products or components thereof (provided any such component is specific to such Intellia Liver
Product), including (i) composition of matter or other chemical structure of such Intellia Liver Product(s), (ii) a method of making or using such Intellia Liver Product(s), or (iii) any gRNAs and crRNAs for one or more
Intellia Liver Products, and (b) Patent Rights within any of the foregoing Intellectual Property. For clarity, an Intellia Liver Product Invention may constitute or comprise the combination of Intellia Materials and Regeneron Materials.

 1.80    “Intellia Liver Target” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.81    “Intellia Materials” shall mean Intellia’s (or its Affiliate’s)
proprietary [***] that are used in the performance of this Agreement or the Collaboration Agreement or otherwise licensed to Regeneron hereunder. [***]. 

1.82    “Intellia Materials Improvement” shall mean (a) any Intellectual Property that is invented
by or on behalf of either Party (solely or jointly with the other) under this Agreement during the Term that constitutes or comprises an improvement, enhancement or other modification to any Intellia Materials [***] including any such Intellectual
Property that comprises a composition of, or any method of using or making, Intellia Materials [***], (b) any Patent Rights to the extent within the Intellectual Property in the foregoing clause (a), in each case of (a) and (b) other
than Co-Funding Product Inventions, Regeneron Materials Improvements, [***], Intellia CRISPR-Cas IP or [***] and (c) any Intellectual Property or Patents Rights that are covered by the definition of Intellia Materials Improvement in the
Collaboration Agreement. 
 1.83    “Intellia Option” shall have the meaning ascribed to such term in
the Collaboration Agreement. 
 1.84    “Intellia Option Exercise Notice” shall have the meaning
ascribed to such term in the Collaboration Agreement. 

  
 12 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.85    “Intellia Patent Rights” shall mean the Intellia
Background Patent Rights, Patent Rights to the extent within the Intellia Co-Funding Product Inventions and Intellia’s interest in Patent Rights to the extent within the [***]. Intellia Patent Rights
shall include the Patent Rights listed on Schedule 1.47 of the Collaboration Agreement as and to the extent pertaining to the Co-Funding Target and Co-Funding Products
hereunder. 
 1.86    “Intellia Platform In-License” shall have the meaning ascribed to such term in
the Collaboration Agreement. 
 1.87    “Intellia Target Evaluation Program Inventions” shall have the
meaning ascribed to such term in the Collaboration Agreement. 
 1.88    “Invention Management
Agreement” shall mean that certain Consent to Assignments, Licensing and Common Ownership and Invention Management Agreement for a Programmable DNA Restriction Enzyme for Genome Editing, by and among Dr. Emmanuelle Charpentier, The
Regents of the University of California, University of Vienna, CRISPR Therapeutics AG, ERS Genomics Ltd., TRACR Hematology Ltd., Caribou Biosciences, Inc. and Intellia dated December 15, 2016, including any amendments or restatements
thereto as of the Effective Date or amendments following the Effective Date. 
 1.89    “IP Term” [See
Annex 1.] 
 1.90    “Joint Improvement” shall mean, in each case of the following clauses (a) and
(b) [***]: 
 (a)    (i) any Intellectual Property that is invented by or on behalf of either Party (solely or jointly
with the other) under this Agreement during the Term that constitutes or comprises a composition of, or any method of using or making, a combination of Intellia Materials and Regeneron Materials, including an improvement, enhancement or other
modification to the combination of Intellia Materials and Regeneron Materials (i.e., such Intellectual Property necessarily involves both Intellia Materials and Regeneron Materials), and (ii) any Patent Rights to the extent within the
Intellectual Property in the foregoing clause (i); and 
 (b)    (i) any improvement, enhancement or modification to
any CRISPR-Cas, including any composition of, or any method of using or making, CRISPR-Cas Materials, and (ii) any Intellectual Property in and to the foregoing clause (i), in each of (i) and (ii) that is invented by or on behalf of
a Party alone or jointly by or on behalf of the Parties in performance under this Agreement during the Term (“Joint CRISPR-Cas Improvements”). 

1.91    “Joint Steering Committee” or “JSC” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.92    “Key Components” means, with respect to a Co-Funding Product:
[***]. 

  
 13 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.93    “Know-How” shall have the meaning ascribed to
such term in the Collaboration Agreement. 
 1.94    “Lead Party” [See Annex 1.] 

1.95    “Legal Dispute” shall mean any dispute related to a Party’s alleged material breach of this
Agreement or the validity, breach, termination or interpretation of this Agreement, or Intellectual Property-related disputes. 

1.96    “Liver Cell” shall have the meaning ascribed to such term in the Collaboration Agreement 

1.97    “Liver Product” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.98    “Liver Target” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.99    “MAA Acceptance” shall mean, with respect to a particular Co-Funding Product, that the particular
biologics application, new drug application, or its equivalent for such Co-Funding Product was accepted by the FDA (or other applicable Regulatory Authority outside the United States if the particular biologics application, new drug application, or
its equivalent was submitted to such Regulatory Authority outside the United States). 
 1.100    “Major Market
Country” shall mean any of the following: [***] and, with respect to any Co-Funding Product, [***]. 

1.101    “Manufacture” or “Manufacturing” shall mean activities directed to [***]
Co-Funding Product [***], as the case may be. 
 1.102    “Manufacturing Cost” shall mean the fully
burdened cost (without mark-up by the charging Party) of Manufacturing a Co-Funding Product [***] as calculated in accordance with Schedule 1.102. 

1.103    “Manufacturing Plan” shall mean, with respect to a Co-Funding Product, the plan developed by the
Lead Party, in consultation with the JMC, and reviewed and approved by the JSC as described in Section 8.6 for the Manufacture of such Co-Funding Product. 

1.104    “Marketing Approval” shall mean all approvals of the applicable Regulatory Authority necessary
for the marketing and sale of a Co-Funding Product in a given country (or other jurisdiction). 

1.105    “Modulate” shall have the meaning ascribed to such term in the Collaboration Agreement. 

  
 14 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.106    “Net Sales” shall mean, with respect to a
Co-Funding Product, the gross amount invoiced for bona fide arms’ length sales of all units of such Co-Funding Product in the Field by or on behalf of the Lead Party or its Affiliates or sublicensees (but excluding distributors) to the first
Third Party (including distributors), less the following deductions, consistently applied: 
  

	 	(a)	 [***]; 

  

	 	(b)	 [***]; 

  

	 	(c)	 [***]; 

  

	 	(d)	 [***]; 

  

	 	(e)	 [***]; 

  

	 	(f)	 [***]; 

  

	 	(g)	 [***]; 

  

	 	(h)	 [***]; 

  

	 	(i)	 [***]; 

  

	 	(j)	 [***]; and 

  

	 	(k)	 [***]. 

Such amounts will be determined from the books and records of a Lead Party, its Affiliates and sublicensees, maintained in accordance with GAAP. Net Sales in
currency other than United States Dollars shall be converted into United States Dollars according to the provisions of Section 9.8 of this Agreement. 

Sales between the Lead Party and its Affiliates or sublicensees, for resale, shall be disregarded for purposes of calculating Net Sales. Any of the items set
forth above that would otherwise be deducted from the invoice price in the calculation of Net Sales but which are separately charged to and paid by Third Parties shall not be deducted from the invoice price in the calculation of Net Sales. In the
case of any sale of a Co-Funding Product for consideration other than cash, such as barter or countertrade, Net Sales shall be calculated based [***]. 

Solely for purposes of calculating Net Sales, if the Lead Party or any of its Affiliates or sublicensees sells any
Co-Funding Product in the form of a Combination Product, then [***]. 

1.107    “Non-Approval Trials” shall mean any surveys, registries and clinical trials, each of which are
not intended to gain additional labeled indications. 

  
 15 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.108    [***]. 

1.109    “Novartis Agreement” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.110    “Option Exercise Date” shall mean, with respect to the Exercised Option, the
date the Regeneron Option Exercise Notice or Intellia Option Exercise Notice, as applicable, is delivered to the other Party in accordance with Section 5.1(e)(i) or Section 5.2(c)(i) of the Collaboration Agreement, respectively.

 1.111    “Option Package” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.112    “Other Co-Funding Agreement Inventions” shall mean (a) all Intellectual
Property that is invented [***]. 
 1.113    “Other Shared Expenses” shall mean, with respect to a
Co-Funding Product, those costs and expenses incurred by a Party that are specifically referred to in Sections 5.4, 7.11, 8.4, 10.2(b), 10.3(c), 10.4(c), 10.5(b), 10.9, 10.10, and 14.1(c) and other costs agreed between the Parties to be included
therein, to the extent that such costs and expenses do not include any costs and expenses included in Development Costs or Shared Commercial Expenses. [***]. 

1.114    “Out-of-Pocket Costs” shall mean costs and expenses paid to Third Parties (or payable to Third
Parties and accrued in accordance with GAAP) by Regeneron (or its Affiliate) or Intellia (or its Affiliate) directly in connection with the performance of its obligations under a Plan as applicable, in accordance with this Agreement and such Plan,
[***]. 
 1.115    “Participating Party” [See Annex 1.] 

1.116    “Patent Application” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.117    “Patent Rights” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.118    “Patents” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.119    “Person” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.120    “Phase I Trial” shall have the meaning ascribed to such term in
the Collaboration Agreement. 

  
 16 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.121    “Phase II Trial” shall have the meaning
ascribed to such term in the Collaboration Agreement. 
 1.122    “Phase III Trial” shall mean a human
clinical trial that would satisfy the requirements of 21 C.F.R. 312.21(c) (as amended or any replacement thereof), including, to the extent satisfying the foregoing requirements (a) a human clinical trial that becomes a registration trial
sufficient for filing an application for a Marketing Approval for such product in the United States or (b) an equivalent clinical trial in conducted in a country other than the United States. 

1.123    “Plan” shall mean any Country/Region Commercialization Plan, U.S. Commercialization Plan, Global
Commercialization Plan, Global Development Plan, Manufacturing Plan or other plan approved through the Committee process relating to the Development, Manufacture or Commercialization of any Co-Funding Product under this Agreement. 

1.124    “Pricing Approval” shall mean such approval, agreement, determination or governmental decision
establishing prices for a [***] that can be charged to consumers and will be reimbursed by Governmental Authorities in countries where Governmental Authorities or Regulatory Authorities of such country approve or determine pricing for pharmaceutical
products for reimbursement or otherwise. 
 1.125    “Product R&D Plan” shall mean a written plan
and [***] budget associated with the discovery, research, pre-clinical Development, and Manufacture of a Regeneron Co-Funding Product as originally agreed to under the Collaboration Agreement (that was formerly referred to as a Regeneron Product
under the Collaboration Agreement), which plans shall be incorporated and made a part of the Global Development Plan for the relevant Regeneron Co-Funding Product in accordance with Section 3.2. 

1.126    “Product R&D Program” shall mean collectively, or individually, as applicable, the research
and development program(s) to be performed under the Collaboration Agreement that was intended to discover, research, Manufacture and Develop Regeneron Co-Funding Products Directed to a Regeneron Target that is a Liver Target as originally agreed to
under the Collaboration Agreement (that was formerly referred to as a Regeneron Product under the Collaboration Agreement), as set forth in the applicable Product R&D Plan(s) which program shall be incorporated and made a part of the Development
for the relevant Regeneron Co-Funding Product in accordance with Section 3.2. 
 1.127    “Product
Trademark” shall mean, with respect to each Co-Funding Product, the trademark(s) proposed by the Lead Party, reviewed by the JCC and JSC, and approved by the JSC for use on such Co-Funding Product
throughout the world and/or accompanying logos, slogans, trade names, trade dress and/or other indicia of origin, in each case as selected by the Lead Party, reviewed by the JCC and JSC, and approved by the JSC. 

  
 17 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.128    “Profit Payment Report” shall mean a
consolidated [***] report prepared by the Lead Party (based on information reported under Section 9.4) setting forth in reasonable detail, for each Major Market Country, and in the aggregate, worldwide as a whole, [***]. If an item is included
in one [***] report, in no event shall the same item be included in a subsequent [***] Report. 

1.129    “Promotional Materials” shall mean, with respect to each Co-Funding Product and country in which
such Co-Funding Product is or will be sold, promotional, advertising, communication and educational materials relating to such Co-Funding Product for use in connection with the marketing, promotion and sale of such Co-Funding Product in such
country, and the content thereof, and shall include promotional literature, product support materials and promotional giveaways. 

1.130    “Quarter” or “Quarterly” shall refer to a calendar quarter, except that the
first (1st) Quarter shall commence on the Effective Date and extend to the end of the then-current calendar quarter and the last calendar quarter shall extend from the first day of such calendar quarter until the effective date of the termination or
expiration of this Agreement. 
 1.131    “Regeneron Co-Funding Product” shall mean (a)(i) with respect
to the Regeneron Target that is the subject of the Exercised Option, the Regeneron Product developed under the Collaboration Agreement that is Directed to such Regeneron Target or (ii) with respect to an Intellia Liver Target that is the
subject of the Exercised Option under Section 5.1(e) of the Collaboration Agreement and for which Regeneron is designated as the Lead Party, [***]. 

1.132    “Regeneron Co-Funding Product Invention” shall mean [***]. 

1.133    “Regeneron Co-Funding Target” shall mean with respect to a Regeneron Co-Funding Product, [***].

 1.134    “Regeneron Contributed IP” shall mean (a) Know-How within the Regeneron Contributed
Technology and (b) Patents to the extent claiming the Know-How in clause (a), in each case of (a) and (b), that is Controlled by Regeneron or its Affiliate. 

1.135    “Regeneron Contributed Technology” shall mean (a) technology that is covered under the
definition of Regeneron Contributed Technology in the Collaboration Agreement and (b) technology Controlled by Regeneron or its Affiliates that Regeneron chooses to contribute under this Agreement for its or Intellia’s use in the
performance of this Agreement, but excluding, for clarity, Regeneron’s interest in [***]. 
 1.136    [***]. 

1.137    “Regeneron Material Relationship” shall have the meaning ascribed to such term in the
Collaboration Agreement. 

  
 18 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.138    “Regeneron Materials” shall mean
Regeneron’s (or its Affiliate’s) proprietary [***], that are used in the performance of this Agreement or the Collaboration Agreement or otherwise included in the Regeneron Contributed Technology. [***]. 

1.139    “Regeneron Materials Improvement” shall mean (a) any Intellectual Property that is invented
by or on behalf of either Party (solely or jointly with the other) under this Agreement during the Term that constitutes or comprises an improvement, enhancement or other modification to any Regeneron Materials [***], including any such Intellectual
Property that comprises a composition of, or any method of using or making, Regeneron Materials [***], (b) any Patent Rights to the extent within the Intellectual Property in the foregoing clause (a), in each case of (a) and (b) [***].

 1.140    “Regeneron Mice” shall mean Regeneron’s proprietary, genetically modified mice that
are used in the performance of this Agreement or the Collaboration Agreement, and any progeny or derivatives thereof shall constitute Regeneron Materials Improvements. 

1.141    “Regeneron Option” shall have the meaning ascribed to such term in the Collaboration Agreement.

 1.142    “Regeneron Option Exercise Notice” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.143    “Regeneron Product” shall mean have the meaning ascribed to such
term in the Collaboration Agreement. 
 1.144    “Regeneron Product Inventions” shall have the meaning
ascribed to such term in the Collaboration Agreement. 
 1.145    [***]. 

1.146    “Regeneron Target” shall have the meaning ascribed to such term in the Collaboration Agreement.

 1.147    “Regeneron Target Evaluation Program Inventions” shall have the meaning ascribed to such
term in the Collaboration Agreement. 
 1.148    “Region” shall mean such two (2) or more
countries that are grouped together for purposes of Commercialization of a particular Co-Funding Product as determined by the JCC. 

1.149    “Registration Filing” shall mean the submission to the relevant Regulatory Authority of an
appropriate application seeking Approval, and shall include any IND or Marketing Approval application. 

1.150    “Regulatory Authority” shall mean any federal, national, multinational, state, provincial or
local regulatory agency, department, bureau or other governmental entity anywhere in the world with authority over the activities conducted under this Agreement or the development, manufacture, or commercialization of products. 

  
 19 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.151    “Regulatory Filings” shall mean regulatory
applications, submissions, dossiers, notifications, registrations, Approvals, or other filings made to or with, or other approvals granted by, a Regulatory Authority that are necessary in order to Develop, Manufacture or Commercialize a Co-Funding
Product in a particular country or regulatory jurisdiction. 
 1.152    [***]. 

1.153    [***]. 

1.154    “Reserved Ex-Vivo Field” shall mean (a)
modification of cells using CRISPR-Cas where such modification is conducted ex vivo for the purpose of [***], (b) modification of HSCs using CRISPR-Cas where such modification is conducted ex vivo for the purpose of [***], and (c) modification of
cells using CRISPR-Cas for use in [***]. 
 1.155    “Shared Commercial Expenses” shall mean the sum of
the following items, in each case to the extent directly attributable to [***], including a U.S. Commercialization Plan, or Global Commercialization Plan, [***], and to the extent that such items do not include any costs included in Development
Costs: 
 (a)    [***]; 

(b)    [***]; 

(c)    Field Force Costs; 

(d)    Out-of-Pocket Costs related to
[***]; 
 (e)    Out-of-Pocket Costs
related to [***]; 

(f)    Out-of-Pocket Costs [***]; 

(g)    Commercial Overhead Charge; 

(h)    Out-of-Pocket Costs related to
[***]; 
 (i)     [***]; and 

(j)     [***]. 
 [***].

  
 20 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.156    “Target” shall have the meaning ascribed to
such term in the Collaboration Agreement. 
 1.157    “Technology Collaboration Inventions” shall have
the meaning ascribed to such term in the Collaboration Agreement. 
 1.158    “Terminated Co-Funding Target” shall mean the Co-Funding Target for which this Agreement is terminated in accordance with Article 16. 

1.159    “Terminated Co-Funding Products” shall mean all CPs that
are Directed to a Terminated Co-Funding Target that were formerly Co-Funding Products. 

1.160    “Third Party” shall have the meaning ascribed to such term in the Collaboration Agreement. 

1.161    “Third Party Collaboration Agreement” shall have the meaning ascribed to such term in the
Collaboration Agreement. 
 1.162    “Third Party License” shall mean any agreement between a Party and
a Third Party pursuant to which such Third Party grants a license to such Party with respect to Intellectual Property of such Third Party that pertains to a Co-Funding Product, which shall include the Intellia
Existing Third Party Agreements and New Intellia Platform Licenses. 
 1.163    “Third Party License
Payment” shall mean any payment due to any Third Party under any Third Party License, including upfront payments, royalties, milestone payments and any other payments. 

1.164    “UC Technology License” shall have the meaning ascribed to such term in the Collaboration
Agreement. 
 1.165    “United States” or “U.S.” shall have the meaning ascribed to
such term in the Collaboration Agreement. 
 1.166    “U.S. Commercialization Budget” shall mean the
budget(s) for a particular Contract Year developed by the Lead Party, reviewed by the JCC and JSC, and approved by the JSC for the U.S. Commercialization Plan. 

1.167    “U.S. Commercialization Plan” shall mean for a
Co-Funding Product, the Country/Region Commercialization Plan for the United States developed by the Lead Party in consultation with the Participating Party, reviewed by the JCC and JSC, and approved by the
JSC. 
 1.168    “U.S. Export Control Laws” shall have the meaning ascribed to such term in the
Collaboration Agreement. 

  
 21 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 1.169    The remaining capitalized terms used in this Agreement shall
have the meanings set forth in the following Sections of this Agreement: 
  

			
	 Term
	  	 Section Reference

	“Acquiring Party”	  	12.6(d)
	“Agreement”	  	Preamble
	“Alleged Party”	  	16.5(b)
	“Alleging Party”	  	16.5(b)
	“Breach Notice”	  	16.5(b)
	“Caribou”	  	1.10
	“Claim”	  	14.1(a)
	“Co-Funding [***] Notice”	  	9.3
	“Co-Promotion Exercise Note”	  	4.11(a)
	“Committees”	  	2.3(b)
	“Competing Program”	  	12.6(d)
	“Confidential Information”	  	13.1(a)
	“Consultation Party”	  	10.2(d)(i)
	“Covered Claim”	  	9.3(b)
	“CRISPR-Cas Materials”	  	1.34
	“Damages”	  	14.1(a)
	“Disclosing Party”	  	13.1(a)
	“Effective Date”	  	Preamble
	“Election Notice”	  	16.14
	“Existing Permitted Change of Control CP”	  	12.6(c)
	“Form of U.S. Co-Promotion Agreement”	  	4.11(c)
	“Global Commercialization Budget(s)”	  	4.3(a)
	“Global Development Budget(s)”	  	3.7(a)
	“Healthcare Prescriber”	  	1.36
	“Indemnified Party”	  	14.2(a)
	“Indemnifying Party”	  	14.2(a)
	“Intellia”	  	Preamble
	“Intellia Indemnitees”	  	14.1(b)
	“JCC”	  	2.3(b)
	“JDC”	  	2.3(b)
	“JFC”	  	2.3(b)
	“JMC”	  	2.3(b)
	“Joint CRISPR-Cas Improvements”	  	1.90(b)
	“Lead Litigation Party”	  	10.4(b)(v)
	“Marketing Guidelines”	  	2.6(b)(iii)
	“Materials”	  	7.7(a)
	“New Intellia Platform License”	  	7.3(c)
	“Non-Acquiring Party”	  	12.6(d)(i)

  
 22 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

			
	 Term
	  	 Section Reference

	“Participating Party Commitment Level”	  	4.11(a)
	“Party” and “Parties”	  	Preamble
	“Permitted Global Commercialization Plan Overage”	  	4.3(c)
	“Permitted Global Development Plan Overage”	  	3.7(c)
	“Product Infringement”	  	10.4(a)
	“Profit Split”	  	Schedule 9.2
	“Receiving Party”	  	13.1(a)
	“Redacted Agreement”	  	13.5(d)
	“Regeneron”	  	Preamble
	“Regeneron Agreements”	  	12.2(b) (Sub-Annex 1(A))
	“Regeneron Indemnitees”	  	14.1(a)
	“Responsible Party”	  	10.2(d)(i)
	“SEC”	  	13.5(d)
	“Subject Claim”	  	9.3(b)
	“Subject Litigation”	  	16.14
	“Term”	  	16.1
	“Third Party Acquisition”	  	12.6(d)
	“U.S. Co-Promotion Agreement”	  	4.11(b)
	“Working Group”	  	2.3(b)

 ARTICLE 2 

AGREEMENT OVERVIEW AND COLLABORATION GOVERNANCE 

2.1    Lead Party and Participating Party. For purposes of and subject to the terms and conditions of this
Agreement, the Lead Party with respect to the Co-Funding Target and all Co-Funding Products Directed to such Co-Funding Target
shall have primary responsibility and decision-making authority with respect to the Development, Commercialization and Manufacturing thereof and shall have the rights and obligations allocated to it as more fully set forth in this Agreement, and the
Participating Party shall have the rights and obligations allocated to it as more fully set forth in this Agreement. 

2.2    Modification of the Collaboration Agreement by this Agreement, Conflicts, Drafting Principles; Incorporation by
Reference. 
 (a)    As contemplated by Section 5.4 of the Collaboration Agreement, this Agreement supersedes the
Collaboration Agreement solely with respect to the particular Co-Funding Target and Co-Funding Products, as applicable, that is the subject of this Agreement. In the event there is any conflict between the
provisions of this Agreement and the provisions of the Collaboration Agreement as it relates to the Co-Funding Target or a Co-Funding Product, as applicable, this Agreement shall control. Any dispute as to whether there is a conflict between the
provisions of this Agreement and the provisions of the Collaboration Agreement shall be resolved in accordance with Section 2.9 and if applicable, Section 17.1(c) of the Collaboration Agreement (which is incorporated into this Agreement in
accordance with Section 17.1 of this Agreement).2 
  

 

	2 	 NTD: This paragraph will be included in each Co-Co Agreement, as
appropriate. 

  
 23 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    [See Annex 1.] 

There are instances where certain provisions of this Agreement are identical to those provisions in the Collaboration Agreement and for purposes of brevity
this Agreement incorporates by reference the applicable terms of the Collaboration Agreement. In such cases, references to the term “Agreement” within such provisions incorporated by reference shall be deemed to refer to this Agreement,
and unless otherwise expressly provided in this Agreement, each of the other defined terms referenced therein shall be deemed to refer to the corresponding defined term under this Agreement (e.g., Party, Term, Contract Year) and all references to
the terms “development”, “commercialization” and “manufacture” and conjugations thereof within such provisions incorporated by reference shall be deemed to refer to “Development”, “Commercialization”
and “Manufacture” and conjugations thereof respectively to the extent such terms refer to the Development, Commercialization and Manufacture of the Co-Funding Products contemplated herein (as context
requires). 
 2.3    Committees/Management. 

(a)    Joint Steering Committee. The Parties have established a JSC pursuant to the Collaboration Agreement which
shall also oversee the activities of the Parties under this Agreement. 
 (b)    Committees. In addition to the
JSC, the Parties agree to establish, for the purposes specified herein, a Joint Development Committee (the “JDC”), a Joint Commercialization Committee (the “JCC”), a Joint Manufacturing Committee
(“JMC”), a Joint Finance Committee (the “JFC”) and such other committees or sub-committees as the Parties deem appropriate. The other Committees shall be established by the JSC at the times determined appropriate by
the JSC. It is understood that the Parties may wish to establish multiple Committees reporting to the JSC, JDC, JFC and JCC with responsibility for different Co-Funding Products. The roles and responsibilities of each Committee are set forth in this
Agreement (or as may be determined by the JSC for Committees established in the future and not described herein) and may be further designated by the JSC. From time to time, each Committee may establish working groups (each, a “Working
Group”) to oversee particular projects or activities, and each such Working Group shall be constituted and shall operate as the Committee which establishes the Working Group determines. The JDC, JCC, JFC, JMC and JSC, and any other
committees the Parties establish pursuant to this Section 2.3, are the “Committees.” 

  
 24 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (c)    Decision Making. Without limiting Section 2.9, the
Committees shall have the right to determine matters that are within their scope (as set forth in Section 2.2(d) of the Collaboration Agreement or Sections 2.4-2.8) or are otherwise expressly allocated to
such Committee as set forth in this Agreement. The JSC shall operate by consensus. The Parties shall cause their respective representatives on a Committee to use their good faith efforts to give due consideration to the perspective of each
Party’s representatives and to resolve all matters presented to them as expeditiously as possible. The representatives of each Party shall have collectively one (1) vote on behalf of such Party; provided that no such vote taken at a
meeting shall be valid unless a representative of each Party is present and participating in the vote. 

(d)    Membership. Each of the Committees shall be composed of an equal number of representatives appointed by
each of Regeneron and Intellia. Each Party may replace its Committee members upon written notice (which may be via email) to the other Party. For clarity, Section 2.2(a) of the Collaboration Agreement shall continue to apply to the JSC. 

(e)    Meetings. Each Committee shall hold meetings at such times as the Parties shall determine, but in no event
less frequently than once every [***] during the Term, commencing from and after the time such Committee is established as provided herein. All Committee meetings may be conducted by telephone, video-conference or in person as determined by the
Co-Chairpersons; provided, however, that each Committee shall meet in person at least once each [***]. Unless otherwise agreed by the Parties, all in-person meetings of each Committee shall be held on an alternating basis between Regeneron’s
facilities and Intellia’s facilities. Other representatives of each Party or of Third Parties involved in the Development, Manufacture or Commercialization of any Co-Funding Product (under obligations of confidentiality) may be invited by the
Committee co-chairs to attend meetings of the Committees as nonvoting participants. Each Party shall be responsible for all of its own expenses of participating in the Committees. Either Party’s representatives on a Committee may call a special
meeting of the applicable Committee upon at least [***] Business Days’ prior written notice (which may be via email), except that emergency meetings may be called with at least [***] Business Days’ prior written notice (which may be via
email). For clarity, Section 2.4(c) of the Collaboration Agreement shall apply to meetings of the JSC with respect to this Agreement, except that the JSC shall continue to meet at least once every [***], and more frequently as either Party may
reasonably request, until the expiration or termination of the Term of this Agreement. 
 (f)    Authority. Each
Party shall retain the rights, powers and discretion granted to it under this Agreement and each Committee shall have solely the powers expressly assigned to it (as set forth in Section 2.4 of the Collaboration Agreement or Section 2.4-2.8) or are
otherwise expressly allocated to such Committee as set forth in this Agreement, and no Committee, including the JSC, shall have any power to amend, modify or waive compliance with this Agreement. 

  
 25 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 2.4    Joint Steering Committee. 

(a)    Additional Purpose. In addition to and without limiting the responsibility of the JSC under the
Collaboration Agreement, the JSC shall have overall responsibility for the oversight of the activities of the Parties under this Agreement with respect to Co-Funding Products. The JSC shall (i) review and approve the overall strategy for an
integrated worldwide Development program for each Co-Funding Product, including the Manufacture of Co-Funding Products for use in activities under the Plans and for the Commercialization of Co-Funding Products worldwide; (ii) to review the efforts
of the Parties in performing their responsibilities under the Plans; and (iii) to oversee the Committees and resolve matters referred by the other Committees to the JSC for decision-making and approval as set forth in this Agreement or otherwise,
and to resolve matters on which such Committees are unable to reach consensus on. 
 (b)    Additional Specific
Responsibilities. In addition to and without limiting the duties of the JSC under the Collaboration Agreement, the JSC shall: 

(i)    annually review and approve the Global Development Plan(s) (including reviewing and approving an updated
Development Cost Forecast), Manufacturing Plan(s), Global Commercialization Plan(s) and Country/Region Commercialization Plan(s), including the U.S. Commercialization Plan(s), if any; 

(ii)    [***], review the efforts of the Parties in performing their respective Development and Commercialization
activities under the then-effective Plans; 
 (iii)    approve the Product Trademark; 

(iv)    discuss the prospective or planned incorporation of any Intellectual Property under a Third Party License that
would trigger a Third Party License Payment in connection with the Development, Commercialization or Manufacture of a Co-Funding Product; 

(v)    review and discuss and agree to any proposal made by the Lead Party to license Development, Commercialization or
Manufacturing rights for any Co-Funding Product to any Third Party [***]; 
 (vi)    attempt in good faith to resolve
any disputes referred to it by any of the Committees and provide a single-point of communication for seeking consensus regarding key global strategy and Plan issues; 

(vii)    establish sub-committees of the JSC, as the JSC deems appropriate; 

(viii)    [See Annex 1]; and 

  
 26 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ix)    consider and act upon such other matters as are specifically
assigned to the JSC under this Agreement or otherwise agreed by the Parties. 
 (c)    Information Sharing. Each
Party will share information with the JSC in a timely manner concerning the progress of the Plans and, in any event, at least [***] days prior to each regular [***] meeting of the JSC, and in connection therewith, each Party will provide to the JSC
a written report (in electronic form) summarizing in reasonable detail the material activities undertaken by such Party in connection with such Plans since such Party’s most recent report. 

2.5    Joint Development Committee. 

(a)    Composition and Purpose. The purpose of the JDC shall be (i) to advise the JSC on the strategy for the
worldwide Development of each Co-Funding Product; (ii) to review and review and annual update and present to the JSC for approval the Global Development Plan(s) (and related Global Development Budget(s)); and (iii) to oversee the implementation of
the Global Development Plan(s) and the Development operational aspects of the activities of the Parties with respect to Co-Funding Products as directed by the JSC. The JDC shall be composed of at least [***] of each Party; provided that the total
number of representatives may be changed upon mutual agreement of the Parties (so long as each Party has an equal number of representatives). 

(b)    Specific Responsibilities. In particular, the JDC shall be responsible for: 

(i)    reviewing and advising the JSC on the overall global Development strategy for each Co-Funding Product developed by
the Lead Party; 
 (ii)    review and provide input on the draft Global Development Plan(s) and related Global
Development Budget(s) (including the Development Cost Forecast) prepared by the Lead Party and the implementation thereof, as described in Sections 3.6 and 3.7, and submitting material decisions with respect thereto for final approval by the JSC;

 (iii)    review and provide input on [***]; 

(iv)    facilitating an exchange between the Parties of data, information, material and results relating to the
Development of Co-Funding Products; 
 (v)    discussing [***]; 

(vi)    overseeing, and discussing the [***] in connection with the Co-Funding Products; 

(vii)    [***] for Co-Funding Products conducted under the Global Development Plan(s); and 

  
 27 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (viii)    considering and acting upon such other matters as specifically
assigned to the JDC under this Agreement or by the JSC. 
 2.6    Joint Commercialization Committee. 

(a)    Composition and Purpose. The purpose of the JCC shall be to develop and propose to the JSC the strategy for
the global Commercialization of Co-Funding Products worldwide, to oversee the implementation of the Global Commercialization Plans. The JCC shall be composed of at least [***] of each Party; provided that the total number of representatives may be
changed upon mutual agreement of the Parties (so long as each Party has an equal number of representatives). 

(b)    JCC Responsibilities. In particular, the JCC shall be responsible for: 

(i)    reviewing and advising the JSC on the overall global Commercialization strategy for each Co-Funding Product; 

(ii)    review and provide input on the draft Global Commercialization Plan(s) and related Global Commercialization
Budget(s) and Country/Region Commercialization Plan(s), and related Country/Region Commercialization Budget(s), including the U.S. Commercialization Plan(s) and U.S. Commercialization Budget(s), prepared by the Lead Party, as described in Sections
4.2 and 4.3 and submitting material decisions with respect thereto for final approval by the JSC and the implementation thereof; reviewing and validating latest annual budget estimates for the current calendar year compared to the Global
Commercialization Budget and Country/Region Commercialization Budgets, including the U.S. Commercialization Budgets, and submitting material decisions with respect thereto for final approval by the JSC; 

(iii)    for each Co-Funding Product, [***]; 

(iv)    review and provide input on [***]; 

(v)    review and provide input on [***]; 

(vi)    review and provide guidance on [***]; 

(vii)    review and provide input on [***]; 

(viii)    discussing the [***]; 

(ix)    review and provide input on [***]; 

(x)    review and provide input on [***]; 

(xi)    [***]; 

  
 28 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (xii)    review and provide input on [***]; 

(xiii)    discussing a [***]; and 

(xiv)    considering and acting upon such other matters as specifically assigned to the JCC under this Agreement or by
the JSC. 
 2.7    Joint Finance Committee. The JFC shall be responsible for accounting, financial (including
planning, reporting and controls) and funds flow matters related to the profit and loss sharing relationship between the Parties with respect to Co-Product under this Agreement, and submitting material decisions with respect thereto for final
approval by the JSC, including such specific responsibilities set forth in Sections 3.7(b), 4.3(c), 9.7, and 9.10 and such other responsibilities determined by the JSC or set forth in this Agreement. The JFC also shall respond to inquiries from the
JDC, the JMC and the JCC, as needed. 
 2.8    Joint Manufacturing Committee. Working with the JSC, JDC and JCC,
as appropriate, the Joint Manufacturing Committee shall be responsible for overseeing Manufacturing activities, including reviewing the Manufacturing Plan prepared by the Lead Party and any updates thereto and referring the foregoing for approval by
the JSC and overseeing the specific activities set forth in Sections 8.6 and 8.7 and such other Manufacturing related activities determined by the JSC or set forth in this Agreement, [***]. For process development activities, the Joint Manufacturing
Committee shall consult the appropriate expert functions of both Parties or their Affiliates as appropriate. 

2.9    [See Annex 1.] 

2.10    Resolution of Committee Disputes. 

(a)    Committee Disputes other than the JSC. In the event there is a dispute at the level of the JDC, JFC, JMC or
JCC, the Parties, through such Committee, will seek to resolve the dispute as promptly as possible, but no later than [***] days after a Party has delivered to the other Party a written request to resolve the matter, and in the event that no
resolution is reached at the JDC, JFC, JMC or JCC, as applicable, such matter shall be promptly referred to the JSC. 

(b)    JSC Disputes. Disputes at the JSC shall be resolved as follows: 

(i)    In the event that the JSC, after a period of [***] days from the date a matter is submitted to it for decision
(including if the Parties are unable to agree on a Plan (or amendment thereto), or any other matter that must be resolved by the JSC), is unable to make a decision due to a lack of required unanimity, either Party may require that the matter be
submitted to the Executive Officers for a joint decision by providing written notice to the other Party formally requesting that the dispute be resolved by the Executive Officers and specifying the nature of the dispute with sufficient specificity
to permit adequate consideration by such Executive Officers. 

  
 29 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)    If the dispute is referred to the Executive Officers, then the
Executive Officers shall diligently and in good faith attempt to resolve the referred dispute within [***] days after receiving such written notification or such longer period of time as the Executive Officers may agree in writing. All such referred
disputes shall require a joint decision of both Parties’ Executive Officers. 
 (iii)    If the Executive Officers
cannot resolve such dispute within such [***] days or other agreed period, such dispute will be resolved as follows: 

(A)    [***]; 

(B)    [***]; 

(C)    [***]. 

(D)    [***]. 

2.11    Alliance Management. Section 2.3 of the Collaboration Agreement is hereby incorporated by reference
into this Agreement, applied mutatis mutandis, except that the Alliance Managers shall continue in their role until the expiration or termination of the Term of this Agreement. 

ARTICLE 3 
 DEVELOPMENT
ACTIVITIES FOR CO-FUNDING PRODUCTS 
 3.1    Development of Co-Funding
Products. [See Annex 1.] 
 3.2    Existing Product R&D Programs and Associated Product R&D Plans.
[See Annex 1.] 
 (a)    [See Annex 1.] 

(b)    [See Annex 1.] 

3.3    New Product R&D Programs and Associated Product R&D Plans. [See Annex 1.] 

3.4    [See Annex 1.] 

3.5    Transition of Patent Prosecution Responsibilities. [See Annex 1.] 

3.6    Preparation, Updates and Approval of Global Development Plans. 

  
 30 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (a)    With respect to each Co-Funding Product, the Lead Party in
consultation with the Participating Party shall prepare, and the JDC shall review and present a Global Development Plan for approval by the JSC, and the JSC shall approve a Global Development Plan for such Co-Funding Product, within [***] months
after the Option Exercise Date. [***] the Lead Party shall Develop the Co-Funding Product in accordance with the development plan previously being used by the Party developing such Co-Funding Product prior to the Option Exercise Date. An updated
Global Development Plan for each Co-Funding Product will be prepared by the Lead Party in consultation with the Participating Party, reviewed by the JDC and presented by the JDC for approval by the JSC, and reviewed and approved by the JSC, at least
[***] months prior to the end of each Contract Year. Each Global Development Plan will be reviewed and if necessary updated by the Lead Party (with such update reviewed by the JDC and JSC and approved by the JSC) not less frequently than once every
[***] months. 
 (b)    [See Annex 1.] 

3.7    Global Development Budgets. 

(a)    Approval. Each Global Development Plan for a Co-Funding Product shall include a related Global Development
Budget and each Global Development Budget shall be prepared, updated, reviewed and approved as part of the preparation, update and approval of the Global Development Plan of which such Global Development Budget is a part in accordance with this
Agreement. Amendments and updates to any Global Development Budget shall not be effective without the approval of the JSC. [***]. 

(b)    Changes. If either Party reasonably anticipates that the costs of its conducting, or having a Third Party
conduct, any activity included in a Global Development Budget will exceed the budgeted amount therefor, or if the costs of conducting such activity do exceed the amount set forth in the Global Development Budget, or if additional activities are
required, such Party shall notify the JSC and request a change to the applicable Global Development Budget. The JSC shall in good faith consider all such reasonable requests to change the Global Development Budget. 

(c)    Budgets and Overages. Each Party shall use Commercially Reasonable Efforts to ensure that the actual costs
associated with the performance of activities allocated to it in the Global Development Plan for a Co-Funding Product for a given Contract Year do not exceed [***] of the budgeted costs allocated to such Party for such Contract Year as set forth in
the budget. Costs for the performance of all activities described in the Global Development Plan that exceed the estimated allocated costs therefor as set forth in the budget by up to [***] shall be referred to herein as the “Permitted
Global Development Plan Overage” and such costs shall be included as Development Costs. If either Party reasonably believes that the actual costs in relation to its Development activities in a Contract Year for a Co-Funding Product will
exceed the allocated budget in the Global Development Plan (plus the Permitted Global Development Plan Overage) for all such activities during such Contract Year, such Party may request the JFC to review and for the JSC to approve such activities
and the costs thereof before undertaking such excess cost. [***]. 

  
 31 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 3.8    [See Annex 1.] 

ARTICLE 4 

COMMERCIALIZATION OF CO-FUNDING PRODUCTS 

4.1    Commercialization of Co-Funding Products. Subject to the terms of this Agreement, including
Section 4.5, the Lead Party shall undertake Commercialization activities with respect to Co-Funding Products pursuant to the Global Commercialization Plans and such Commercialization activities shall be under the general direction and oversight
of the JCC and JSC. Except as otherwise agreed to by the Parties or explicitly set forth in this Agreement, the JSC will assign responsibility for conducting all Commercialization activities for a Co-Funding Product to the Lead Party. The Lead Party
shall use Commercially Reasonable Efforts to Commercialize Co-Funding Products in accordance with this Agreement and the applicable Plans, and each Party shall use Commercially Reasonable Efforts to carry out the Commercialization activities
assigned to it in Global Commercialization Plans and Country/Region Commercialization Plans, including the U.S. Commercialization Plans, in a timely manner, and in each case shall conduct all such activities in compliance with Applicable Laws. The
Lead Party shall be responsible for handling collection and receivables and recording and booking sales in each country worldwide [***]. 

4.2    Preparation, Updates and Approval of Global Commercialization Plans. With respect to each Co-Funding
Product, a Global Commercialization Plan shall be prepared by the Lead Party in consultation with the Participating Party, and the JCC shall review and present to the JSC for approval, and the JSC shall approve a Global Commercialization Plan [***]
In each Contract Year following the Contract Year in which the Global Commercialization Plan was first approved, the Global Commercialization Plan shall be updated by the Lead Party in consultation with the Participating Party and reviewed by the
JCC and presented to the JSC for approval and reviewed and approved by the JSC at least [***] months prior to the end of the then current Contract Year. 

4.3    Global Commercialization Budget. 

(a)    Approval. Each Global Commercialization Plan for a Co-Funding Product shall include a related Global
Commercialization Budget (each individually, a “Global Commercialization Budget” and collectively, the “Global Commercialization Budgets”) and each Global Commercialization Budget shall be prepared, updated,
reviewed and approved as part of the preparation, update and approval of the Global Commercialization Plan of which such Global Commercialization Budget is a part in accordance with this Agreement. Amendments and updates to any Global
Commercialization Budget shall not be effective without the approval of the JSC. 

  
 32 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    Changes. If either Party reasonably anticipates that the
costs of its conducting, or having a Third Party conduct, any activity included in a Global Commercialization Budget will exceed the budgeted amount therefor, or if the costs of conducting such activity do exceed the amount set forth in the Global
Commercialization Budget, or if additional activities are required, such Party shall notify the JSC and request a change to the applicable Global Commercialization Budget. The JSC shall in good faith consider all such reasonable requests to change
the Global Commercialization Budget. 
 (c)    Budgets and Overages. Each Party shall use Commercially
Reasonable Efforts to ensure that the actual costs associated with the performance of activities allocated to it in the Global Commercialization Plan for a Co-Funding Product for a given Contract Year do not exceed [***] of the budgeted costs
allocated to such Party for such Contract Year as set forth in the budget. Costs for the performance of all activities described in the Global Commercialization Plan that exceed the estimated allocated costs therefor as set forth in the budget by up
to [***] shall be referred to herein as the “Permitted Global Commercialization Plan Overage” and such costs shall be shared by the Parties in accordance with their respective Co-Funding Percentages and included as Shared Commercial
Expenses. If either Party reasonably believes that the actual costs in relation to its Commercialization activities in a Contract Year for a Co-Funding Product will exceed the allocated budget in the Global Commercialization Plan (plus the Permitted
Global Commercialization Plan Overage) for all such activities during such Contract Year, such Party may request the JFC to review and for the JSC to approve such activities and the costs thereof before undertaking such excess cost. [***]. 

4.4    Country/Region Commercialization Plans. Each Country/Region Commercialization Plan, including each U.S.
Commercialization Plan, and all updates and amendments thereto will be consistent with the Global Commercialization Plan. It is anticipated that each Country/Region Commercialization Plan for a Co-Funding Product, including each U.S.
Commercialization Plan, will be prepared by the Lead Party for the Co-Funding Product in consultation with the Participating Party, reviewed by the JCC and JSC, and approved by the JSC, at least [***]. Such Country/Region Commercialization Plan,
including such U.S. Commercialization Plan, for each subsequent Contract Year shall be updated by the Lead Party in consultation with the JCC, reviewed by the JCC and JSC, and approved by the JSC, at least [***] Each Country/Region Commercialization
Plan, including each U.S. Commercialization Plan, with respect to each Co-Funding Product shall include [***]. 

4.5    Commercialization Efforts; Sharing of Commercial Information. 

(a)    The Lead Party (through its Affiliates where appropriate) shall use Commercially Reasonable Efforts to
Commercialize Co-Funding Products in the Field worldwide in accordance with the Global Commercialization Plans, the Marketing Guidelines and, as applicable, the Country/Region Commercialization Plan(s), including each U.S. Commercialization Plan.
Without limiting the generality of the foregoing, [***] in accordance with Section 4.11, and subject to Section 4.11 (1) the Participating Party shall use Commercially Reasonable Efforts to perform the anticipated total Co-Promotion
effort at the Participating Party 

  
 33 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Commitment Level, and (2) the Lead Party shall use Commercially Reasonable Efforts to perform the anticipated total Co-Promotion effort above the Participating Party Commitment Level, in
each case, with respect to the Co-Funding Products in the Field in accordance with the approved U.S. Commercialization Plan, consistent with the Global Commercialization Plan and in accordance with all Applicable Laws. 

(b)    The Lead Party will provide the Participating Party with full access to material information directly relating to
the Commercialization of each Co-Funding Product in the Field, [***]. Without limiting the foregoing, beginning in the Quarter of the First Commercial Sale (i) in each Major Market Country, the Lead Party will provide the Participating Party
[***], with reports of the activity within its field force in each such Major Market Country and summarizing in reasonable detail other marketing and promotional activities undertaken by the Lead Party, and (ii) with respect to the U.S.,
if the Participating Party exercises its rights to Co-Promote a Co-Funding Product in accordance with Section 4.11, the Participating Party will provide the Lead Party, [***], with reports of the Participating Party’s Co-Promotion
activity within its field force in the United States, in each of (i) and (ii) which will include reasonable data from reports created by a Party for its internal management purposes. 

4.6    Promotional Materials. The Lead Party will be responsible, [***], the Global Commercialization Plan and the
Country/Region Commercialization Plans (as applicable), including the U.S. Commercialization Plans (as applicable), for the creation, preparation, production and reproduction of all Promotional Materials and for filing, as appropriate, all
Promotional Materials with all Regulatory Authorities in the world. Without limiting Section 10.11, the JCC shall review and comment on [***]. 

4.7    Promotional Claims/Compliance. Neither Party nor any of its Affiliates shall make any medical or promotional
claims for any Co-Funding Product other than as permitted by Applicable Laws. When distributing information related to any Co-Funding Product or its use (including information contained in scientific articles,
reference publications and publicly available healthcare economic information), each Party and its Affiliates shall comply with all Applicable Laws and any applicable guidelines established by the pharmaceutical industry in the applicable country.

 4.8    Restriction on Bundling. [***]. 

4.9    Market Exclusivity Extensions. [***]. 

4.10    Post Marketing Approval Obligations. Subject to the provisions of this Agreement, the Lead Party shall
comply with any post-Approval obligations with respect to a Marketing Approval with respect to any Co-Funding Product in any country, imposed by Applicable Law, pursuant to the Approvals or required by a Regulatory Authority. 

  
 34 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 4.11    The Participating Party’s Co-Promotion Option in the
United States. 
 (a)    Exercise of Co-Promote Option. Subject to this Section 4.11, with respect to
the Co-Funding Target and all Co-Funding Products that are Directed to such Co-Funding Target, in the event the Participating Party desires to Co-Promote a Co-Funding Product in the United States, the Participating Party shall notify the Lead Party
of its decision regarding whether to Co-Promote such Co-Funding Product in the United States no later than [***] (such notification, a “Co-Promotion Exercise Notice”). If the Participating Party does not timely deliver to the Lead
Party a Co-Promotion Exercise Notice by the deadline set forth above, as applicable, the Participating Party’s right to Co-Promote such Co-Funding Product in the United States shall immediately and permanently expire. 

(i)    Detailing and Co-Promotion FTE Efforts. The Participating Party shall specify in its Co-Promotion Exercise
Notice the [***]. In no event shall the Participating Party’s Commitment Level in Co-Promoting such Co-Funding Product in the United States [***]. Notwithstanding the Participating Party’s exercise of its option pursuant to
Section 4.11, the Lead Party shall continue to be solely responsible for sales force training, unless agreed otherwise by the JSC. 

(ii)    In the event the Participating Party, either directly or through or its Affiliates, is not commercializing a
product in the United States at the time of the Participating Party’s election to Co-Promote a Co-Funding Product in accordance with this Section 4.11(a), the Participating Party may only exercise
its election to Co-Promote such Co-Funding Product in the event the Participating Party has an existing sales force in the United States at the time of its election to Co-Promote such Co-Funding Product,
[***]. On a Co-Funding Product by Co-Funding Product basis, any costs incurred by the Participating Party [***]. 

(iii)    [***]. 

(b)    Co-Promotion Agreement. The Parties shall enter into a United States Co-Funding Product Co-Promotion
Agreement (“U.S. Co-Promotion Agreement”) [***] that shall set the terms and conditions of Co-Promotion. The actual Co-Promotion activities shall be included in or added to the U.S.
Commercialization Plan for such Co-Funding Product, and in each case in accordance with Section 4.4. 

(c)    Form of Co-Promotion Agreement. [***]. 

ARTICLE 5 
 CLINICAL AND
REGULATORY AFFAIRS 
 5.1    Regulatory Coordination. 

(a)    Subject to the terms of this Agreement, the Lead Party shall determine the appropriate regulatory strategy with
respect to Co-Funding Products, in consultation with the Participating Party under the general direction and oversight of the JDC, JCC, and JSC. The Lead Party shall consult with the Participating Party in the preparation of regulatory strategies
and with respect to all material regulatory actions, communications and Regulatory Filings for Co-Funding Products worldwide. 

  
 35 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    Regulatory Filings. 

(i)    The Lead Party shall be responsible for submitting and maintaining all such Regulatory Filings and shall act as the
point of contact for regulatory communications with each applicable Regulatory Authority with respect to each Co-Funding Product. The Lead Party (or its designee) shall own all such regulatory materials, including all INDs and Approvals with respect
to Co-Funding Products. Without limiting the foregoing, the Lead Party will be responsible for, and will use Commercially Reasonable Efforts in applying for, obtaining and maintaining the applicable Approval or other Registration Filing for each
Co-Funding Product, subject to the oversight of the JSC. The Lead Party shall perform all such activities in accordance with the Plans and all Applicable Laws. 

(ii)    [See Annex 1.] 

(c)    [See Annex 1.] 

(d)    The Parties shall establish procedures to ensure that the Parties exchange on a timely basis all necessary
information to enable each Party and its licensees, as applicable, (i) to comply with its regulatory obligations in connection with the Development, Manufacture and/or Commercialization of Co-Funding Products, including filing updates or
supplements with Regulatory Authorities, pharmacovigilance filings, manufacturing supplements and investigator notifications to and from Regulatory Authorities and (ii) to comply with Applicable Laws in connection with the Development,
Manufacture and/or Commercialization of Co-Funding Products anywhere in the world. The Lead Party shall provide to the Participating Party prompt written notice of any Approval of a Co-Funding Product anywhere in the world. 

(e)    The Lead Party shall provide the Participating Party as promptly as practicable with written notice and copies of
any (i) draft and final Regulatory Filings or other filings with, (ii) submissions [***] to and (iii) material communications with, Regulatory Authorities pertaining to the Development and/or Commercialization of a
Co-Funding Product under the Plans, and shall afford the Participating Party’s representatives an opportunity to review the foregoing filings, submissions and correspondence (including all annual and periodic safety reports for Co-Funding
Products), [***]. 
 5.2    Labeling. For each Co-Funding Product, [***]. 

5.3    Regulatory Events. Each Party shall keep the other Party informed, as soon as possible but no later than the
time period set forth below after notification (or other time period specified below), of any action by, or notification or other information which it receives (directly or indirectly) from, any Regulatory Authority, Third Party or other
Governmental Authority, which: 
 (a)    raises any material concerns regarding the safety or efficacy of any
Co-Funding Product, for which the time period for informing the other Party will be no later than [***] hours; or 

  
 36 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    is reasonably likely to lead to a recall or market withdrawal of
any Co-Funding Product anywhere in the world, for which the time period for informing the other Party will be no later than [***] hours. 
 Information that
shall be disclosed pursuant to this Section 5.3 shall include, the following matters with respect to Co-Funding Products: 

(i)    Governmental Authority inspections or audits of Manufacturing, Development, distribution or other facilities; 

(ii)    receipt of a complete response letter, refusal to file, warning letter or similar communications issued by a
Regulatory Authority; and 
 (iii)    an initiation of any Regulatory Authority or other Governmental Authority
investigation, detention, enforcement action, seizure or injunction. 
 5.4    Recalls and Other Corrective
Actions. Decisions with respect to any recall, market withdrawal or other corrective action related to any Co-Funding Product shall be made by the Lead Party, and the Lead Party shall make any such decision, to the extent reasonably possible, in
consultation with the Participating Party. In any event and without limiting the previous sentence, [***]. 
 ARTICLE 6 

LICENSES 

6.1    Intellia License to Regeneron for Regeneron Co-Funding Products. With respect to Regeneron Co-Funding
Products, Section 6.3 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b), except all references to the IP Term shall be deemed to refer to the IP Term as defined
in this Agreement. Notwithstanding the foregoing, Intellia reserves the rights under the licenses granted under this Section 6.1 to perform the activities designated to it under a Global Development Plan, Global Commercialization Plan,
and U.S. Commercialization Plan, if applicable, and for the supply of Regeneron Co-Funding Products under Section 8.2. 

6.2    Regeneron License to Intellia for Regeneron Co-Funding Products. Regeneron shall grant, and hereby grants,
to Intellia a non-exclusive, worldwide license under the Regeneron Contributed IP solely to the extent necessary for Intellia to perform the activities designated to it under the applicable Global Development Plan, Global Commercialization Plan, and
U.S. Commercialization Plan, if applicable, for such Regeneron Co-Funding Products and for the supply of such Regeneron Co-Funding Products under Section 8.2. Intellia may 

  
 37 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
sublicense the license granted under this Section 6.2 only in accordance with Section 7.2(c) and only as necessary to enable permitted subcontractors to perform such activities
in accordance with Section 7.2(b). 
 6.3    Regeneron License to Intellia for Intellia Co-Funding
Products. Regeneron shall grant, and hereby grants, to Intellia a non-exclusive, worldwide, sublicensable in multiple tiers (in accordance with Section 7.2(c)) license under that portion of the Regeneron Contributed IP that Regeneron
contributed in connection with Intellia Co-Funding Products, to develop, make, have made, use, sell, offer for sale, and import Intellia Co-Funding Products for use in the Field. [See Annex 1.] 

6.4    Unblocking License. [See Annex 1.] 

6.5    Intellia License to Regeneron for Intellia Co-Funding Products. Intellia shall grant, and hereby grants, to
Regeneron a non-exclusive, worldwide license under the Intellia Intellectual Property solely to the extent necessary for Regeneron to perform the activities designated to it under the applicable Global Development Plan, Global Commercialization
Plan, and U.S. Commercialization Plan, if applicable, for such Intellia Co-Funding Product. Regeneron may sublicense the license granted under this Section 6.5 only in accordance with Section 7.2(c) and only as necessary to enable
permitted subcontractors to perform such activities in accordance with Section 7.2(b). 
 6.6    Mutual
License to Materials. Each Party shall grant, and hereby grants, to the other Party a non-exclusive, worldwide license under that portion of the Materials provided pursuant to Section 7.7 for use in accordance with the relevant Plan. 

6.7    Ex-Vivo Field. With respect to Regeneron Co-Funding Targets, Section 6.5 of the Collaboration Agreement
is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

6.8    Restrictions on the Participating Party. [***]. 

6.9    Discussion of Additional License. [***]. 

ARTICLE 7 
 PERFORMANCE
AND PERFORMANCE STANDARDS 
 7.1    Licenses Generally; No Implied License. Except as expressly provided for
herein, nothing in this Agreement grants either Party any right, title or interest in and to the intellectual property rights, materials or Confidential Information of the other Party (either expressly or by implication or estoppel). Except as
expressly provided in this Agreement, neither Party will be deemed by this Agreement to have been granted any license or other rights to the other Party’s Patent Rights or Know-How, either expressly or by implication, estoppel or otherwise.
With respect to Co-Funding Products for which Regeneron is the Lead Party, the last sentence of Section 7.1 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

  
 38 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 7.2    Performance Standards. 

(a)    Affiliates. Each Party may carry out its obligations, and exercise its rights, under this Agreement through
its Affiliates, and in such case, the Party carrying out such activities, or exercising such rights, through its Affiliate absolutely, unconditionally and irrevocably guarantees to the other Party the performance by such Party’s Affiliates in
accordance with this Agreement, including performance of responsibilities, liabilities, covenants, warranties, agreements and undertakings of its Affiliates pursuant to this Agreement. Without limiting the foregoing, neither Party shall cause or
permit any of its Affiliates to commit any act (including any act or omission) which such Party is prohibited hereunder from committing directly. Each Party represents and warrants to the other Party that it has licensed or will license from its
Affiliates the Patent Rights and Know-How Controlled by its Affiliates that are to be licensed (or sublicensed) to the other Party under this Agreement. 

(b)    Subcontracts. Each Party may perform any of its obligations or exercise its rights under this Agreement
through one or more subcontractors; provided that (i) [***]; (ii) the subcontracting Party remains responsible for the work allocated to, and payment to, such subcontractors it selects to the same extent it would if it had done such work itself and
the non-subcontracting Party will have the right to proceed directly against the subcontracting Party without any obligation to first proceed against its subcontractor; (iii) [***]; and (iv) the subcontractor agrees in writing to assign all
inventions and intellectual property developed in the course of performing any such work under this Agreement, to the Party retaining such subcontractor (or to the other Party if such inventions or intellectual property are to be assigned to such
other Party as required under this Agreement) and upon request to sign any documents to confirm or perfect such assignment and to cooperate in the preparation and prosecution of any such inventions. [***]. To the extent any licenses are granted
under any subcontract agreements, such agreements will be subject to Section 7.2(c). 

(c)    Sublicensees. 

(i)    To the extent a license is sublicensable pursuant to the applicable license grant hereunder, or is required in
connection with a permitted subcontracting pursuant to Section 7.2(b), the applicable Party may enter into sublicenses under such licenses granted in this Agreement, but subject to compliance with this Section 7.2(c) and the other
applicable terms and conditions set forth in this Agreement. Any such sublicense agreement must be in writing and shall require the sublicensee of a Party to comply with all applicable obligations of such Party that are relevant to the sublicense
granted, including the confidentiality and non-use obligations set forth in Article 13. [***]. With respect to Co-Funding Products for which Regeneron is the Lead Party, the last sentence of Section 7.2(c)(i) of the Collaboration
Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). The Lead Party shall promptly notify the Participating Party of the grant of each such sublicense. 

  
 39 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)    (A) With respect to any and all Other Co-Funding Agreement
Inventions and Joint Improvements or any other Intellectual Property that is invented and jointly owned by the Parties under this Agreement, subject to the terms and conditions of this Agreement, each Party shall have the right to grant
(sub)licenses (through multiple tiers) thereto for any purposes without the need to seek consent from or account to the other Party (and, for clarity, neither Party shall be required to obtain the consent of the other Party with respect to such
(sub)license anywhere in the world and, to the extent that such consent is required in any country in the world, such consent is hereby granted); provided, that, Regeneron shall only be permitted to grant a (sub)license with respect to the [***].
[See Annex 1.] 
 (B)    Notwithstanding the foregoing Section 7.2(c)(ii)(A), nothing in this
Section 7.2(c)(ii)(B) shall in any way restrict, limit or prohibit or be deemed to restrict, limit or prohibit either Party from soliciting, negotiating, facilitating, executing or undergoing a Change of Control. 

7.3    Third Party Agreements. 

(a)    Intellia will be responsible for delivering all payments under the Intellia Existing Third Party Agreements to the
applicable Third Party counterparty thereto. The amounts of such payments shall be borne by the Parties pursuant to Section 7.5. 

(b)    Following the Effective Date during the Term, Intellia or its Affiliates, in its sole discretion (but subject to
Section 7.4), may enter into new agreements with Third Parties to license technologies or Intellectual Property from such Third Parties, including pursuant to any Third Party Collaboration Agreements (to the extent such technologies or Intellectual
Property, as applicable, were not licensed by Intellia or any of its Affiliates as of the Effective Date) (an “Intellia Platform In-License”). 

(c)    Commencing on the Effective Date and continuing until the expiration of the IP Term [***], if Intellia or its
Affiliates enters into any Intellia Platform In-License during such period that may be useful or necessary in connection with the Development, Manufacture, Commercialization or use of a Co-Funding Product, then Intellia will provide written notice
of such license to the JSC, including a redacted copy of each such Intellia Platform In-License (which may be redacted for information not pertinent to this Agreement to the extent that such redactions do not reasonably impair the JSC’s ability
to evaluate whether it wants to include such Intellia Platform In-License as a New Intellia Platform License under this Agreement), so the JSC (subject to dispute resolution pursuant to Section 2.9) may elect whether to include such license
under this Agreement [***]. If the JSC provides notice within [***] days of receipt of such written notice from Intellia [***] that it does elect to include such Intellectual Property, then (A) the respective Intellia Platform In-License
will be deemed to be a “New Intellia Platform License” hereunder, and (B) with respect to any such New Intellia Platform License, the Patent Rights, Know-How and Materials in-licensed under such New Intellia Platform
License pertaining to the Development, Manufacture and Commercialization of the Co-Funding Target and Co-Funding Products hereunder will be deemed “Controlled” by Intellia under this Agreement. Any Intellia Platform In-License not so
selected by the JSC hereunder within such [***] day period, shall not be deemed a New Intellia Platform License hereunder, [***]. 

  
 40 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (d)    [See Annex 1.] 

(e)    To the extent applicable, the licenses granted to Regeneron and its Affiliates under this Agreement, [***], will
be subject to Regeneron’s and its Affiliates’, and their sublicensees’ compliance with the applicable terms of the applicable Intellia Existing Third Party Agreements [***] and as may be amended or restated from time to time in
accordance with Section 12.3(d), [***] and Intellia shall be permitted to disclose the terms and conditions of this Agreement to such Third Party licensors as and to the extent required for compliance therewith [***] provided that such Third
Party licensors are subject to confidentiality restrictions that are substantially the same as, or at least as restrictive as, the confidentiality obligations in Article 13. 

7.4    Coordination of Third Party Intellectual Property Licensing. 

(a)    During the Term, if either Party (or its Affiliate) desires to obtain a license to Intellectual Property of a Third
Party for use in connection with the Development, Commercialization or Manufacture of [***], then prior to entering into such license, the JSC shall discuss in good faith and coordinate the licensing of such Intellectual Property. [***]. 

(b)    [See Annex 1.] 

7.5    Third Party License Payments. Subject to Section 9.13 and 9.14, all Third Party License Payments made
by a Party in accordance with Section 7.3, Section 7.4, Section 7.12 (if applicable) or the last sentence of Section 9.12 shall be included in the Profit Split and shared by the Parties in accordance
with their respective Co-Funding Percentages [***]. 
 7.6    Records. 

(a)    Records. 

(i)    Section 7.5(a)(i) of the Collaboration Agreement is hereby incorporated by reference into this Agreement in
accordance with Section 2.2(b) and all references in such provisions to the Technology Collaboration and Technology Collaboration Plan shall be deemed to refer to this Agreement and to the applicable Plan, respectively. 

(ii)    [***]. 

(b)    Record Keeping Generally. Section 7.5(b) of the Collaboration Agreement is hereby incorporated by
reference into this Agreement in accordance with Section 2.2(b). 

  
 41 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 7.7    Materials for Development Plans. 

(a)    Contributed Materials. To facilitate the conduct of activities hereunder, a Party shall provide the [***],
collectively, “Materials”). Except as is set forth in the Product R&D Plan with respect to a Regeneron Co-Funding Product or a Party agrees to provide Materials to the other Party as set forth in a Plan, neither Party shall be
obligated to provide any Materials to the other Party. Neither Party shall use the Materials of the other Party except in accordance with a Plan. All such Materials will remain the sole property of the providing Party. The receiving Party will
(i) itself retain control of all such Materials, (ii) use such Materials only in the fulfillment of obligations or exercise of rights under this Agreement, (iii) not use such Materials or deliver the same to, or for the
benefit of, any Third Party, without the providing Party’s prior written consent [***] and (iv) not use such Materials in research or testing involving human subjects, without the providing Party’s prior written [***]. The
Materials supplied under this Section 7.7 are supplied “as is”, and accordingly the receiving Party agrees to use prudence and appropriate caution in the use, handling, storage, transportation and disposition and containment of
all such Materials, as not all of their characteristics may be known. [***]. 
 (b)    Regeneron Mice.
Section 7.7(b) of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

7.8    Debarment. Section 7.8 of the Collaboration Agreement is hereby incorporated by reference into this
Agreement in accordance with Section 2.2(b). 
 7.9    No Use of Non-Controlled IP in Performance of Activities under
this Agreement. Each Party hereby covenants to the other Party that in the course of conducting its activities under this Agreement it will not use in or contribute in the performance of activities under this Agreement, any material,
Confidential Information, Intellectual Property, or trademark that such contributing Party knows (without any duty to inquire) misappropriates the Intellectual Property of a Third Party. The Parties acknowledge and agree that this Section 7.9
is not intended to be, and shall not be deemed to be, a covenant against non-infringement of Intellectual Property. 

7.10    Further Assurances and Transaction Approvals. Section 7.10 of the Collaboration Agreement is hereby
incorporated by reference into this Agreement in accordance with Section 2.2(b). 
 7.11    [See Annex 1.]

 7.12    [See Annex 1.] 

ARTICLE 8 
 CO-FUNDING PRODUCT MANUFACTURING 
 8.1    Non-GMP Manufacture of Co-Funding Products. [See Annex 1.] 
 8.2    Supply for Product R&D
Program or its Equivalent. [See Annex 1.] 

  
 42 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 8.3    Supply Beyond Pre-Clinical. 

(a)    On or before the later to occur of (i) [***] for a Co-Funding Product or (ii) [***], the JMC shall discuss
alternatives for the Manufacture and supply of Co-Funding Products beyond pre-clinical supply, including Initiation of GLP Toxicology Batch and GMP Manufacturing needed to support an IND, in each case, for a Co-Funding Product. 

(b)    [See Annex 1.] 

8.4    [See Annex 1.] 

8.5    Clinical and Commercial Supply. With respect to a Co-Funding Product, the Lead Party will be responsible for
and will use Commercially Reasonable Efforts to adequately and timely Manufacture or have Manufactured the Clinical Supply Requirements and Commercial Supply Requirements of Co-Funding Products worldwide in accordance with the Manufacturing Plan and
in accordance with Applicable Laws, including applicable Good Practices. The Lead Party will be responsible for and will use Commercially Reasonable Efforts to perform the filling, packaging, labeling and testing of the Clinical Supply Requirements
and Commercial Supply Requirements for Co-Funding Products for use under this Agreement in accordance with Applicable Laws, including applicable Good Practices. The Parties through the JMC shall discuss in good faith the Manufacture of Co-Funding Products, and reasonably cooperate with each other in all such supply matters pertaining to the Co-Funding Products under this Article 8. 

8.6    Manufacturing Plans. With respect to a Co-Funding Product, the Lead Party, in consultation with the JMC,
will develop and update as necessary, for each Co-Funding Product, a Manufacturing Plan, which shall be reviewed and approved by the JSC. [***]. Each Manufacturing Plan shall set forth the [***]. The Manufacturing Plan (including each annual update
thereto) for a Co-Funding Product shall be prepared by the Lead Party in consultation with the Participating Party, reviewed by the JMC, presented to the JSC for approval, and reviewed and approved by the JSC at least [***]. The Lead Party shall use
Commercially Reasonable Efforts to perform its responsibilities in accordance with the approved Manufacturing Plans. Upon the Participating Party’s written request, the Lead Party shall provide the Participating Party with complete and accurate
copies of material Manufacturing-related records. 
 8.7    Manufacturing Shortfall. [***] shall provide prompt
written notice to [***] if it reasonably determines that it will not, despite its using Commercially Reasonable Efforts, be able to supply the agreed upon demand forecast for the [***]. Upon such notification, the matter will be referred to the JMC
and JSC to discuss what, if any, corrective actions should be taken with respect to such anticipated shortfall. 

  
 43 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 ARTICLE 9 

PAYMENTS 

9.1    Reimbursement for Past Expenses. [See Annex 1.] 

9.2    Sharing of Profits and Development Costs from Co-Funding Products. Commencing on the Effective Date and
continuing during the Term, on a Co-Funding Product-by-Co-Funding Product basis, the Parties shall share Profits and Development Costs and other costs equally for all Co-Funding Products Directed to a Co-Funding Target as described in Schedule 9.2,
subject to Section 9.3. 
 9.3    Adjustment to the Co-Funding Percentage for the Co-Funding Target by the
Participating Party. 
 (a)    [***]. 

(b)    [***] have been paid and releases have been granted concerning such Covered Claims. 

9.4    Periodic Reports. Intellia and Regeneron shall each prepare and deliver to the other Party the periodic
reports specified below: 
 (a)    Within [***] days following the end of each month for the first [***] of every [***]
commencing with [***] in which the First Commercial Sale of any Co-Funding Product occurs in any country in the world, the Lead Party shall deliver electronically to the Participating Party a monthly detailed
Co-Funding Product Net Sales report, in each case with monthly and year-to-date sales in local currency and in each country in which such Co-Funding Product is sold, such reporting obligation to commence with
the month in which the First Commercial Sale of any Co-Funding Product occurs in any country; 
 (b)    Within [***]
days after the end of each [***], the Lead Party and the Participating Party shall each provide to the other Party a written report (in electronic form) summarizing the material activities undertaken by such Party during such [***] in connection
with each Global Development Plan, together with a statement of Development Costs incurred by such Party during such [***], which statement shall detail those amounts to be included in the Development Payment Report for such [***]; 

(c)    Within [***] days following the end of each [***] commencing with the [***] in which the First Commercial Sale of
any Co-Funding Product occurs in any country in the world, the Lead Party shall deliver electronically to the Participating Party a written report setting forth, on a country-by-country basis for such [***], for each country, (i) the Co-Funding
Product Net Sales of each Co-Funding Product in local currency and in United States Dollars, (ii) Co-Funding Product quantities sold and (iii) gross Co-Funding Product sales and an accounting of the deductions from gross sales
permitted by the definition of Co-Funding Product Net Sales; 

  
 44 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (d)    Within [***] days following the end of each Quarter, each Party
that has incurred any Other Shared Expenses, Shared Commercial Expenses or Cost of Goods Sold in that [***] shall deliver electronically to the other Party a written report setting forth in reasonable detail the Other Shared Expenses, Shared
Commercial Expenses and/or Cost of Goods Sold incurred by such Party in such [***] in the aggregate on a worldwide basis and also on a Major Market Country-by-Major Market Country basis and on a Co-Funding Product-by-Co-Funding Product basis, in local currency and in United States Dollars, including whether any such expenses are also
included in the reports delivered pursuant to clause (e) below; 
 (e)    Within [***] days following the end of
each Quarter, the Lead Party shall provide to the Participating Party, in electronic form, a Development Payment Report in respect of such [***], combining the information reported by each Party pursuant to this Section 9.4(b) and showing its
calculations in accordance with Schedule 9.2 of the amount of any payments to be made by the Parties hereunder for such [***] as contemplated by this Section 9.4 [***] and, if applicable, providing for the netting of such payments; and 

(f)    Within [***] days following the end of each Quarter, the Lead Party shall deliver electronically to the
Participating Party a Profit Payment Report in respect of such [***], combining the information reported by each Party pursuant to this Section 9.4(c)-(d)_and showing its calculations in accordance with Schedule 9.2 of the amount of
any payments to be made by the Parties hereunder for such [***] as contemplated by this Section 9.4 [***] and, if applicable, providing for the netting of such payments. 

9.5    Adjustments to FTE Rates. Notwithstanding anything herein to the contrary, upon the request of either Party,
such request not to be delivered more than once per Contract Year, the Parties shall meet to review the accuracy of an applicable FTE rate in any country (e.g., Field Force FTE Rate, Development FTE Rate, etc.). The Parties agree to share reasonable
supporting documents and materials in connection with an assessment of the applicable FTE rate and to determine in good faith whether to adjust the rate(s) in any country. 

9.6    Funds Flow. The Parties shall make [***] Development True-Up and [***] Profit True-Up payments as set forth
in Schedule 9.2. If the Lead Party is the Party owing [***] Development True-Up or [***] Profit True-Up payment(s) based on the calculations in the applicable Development Payment Report or Profit Payment Report, it shall, subject to
Section 9.10, make such payment to the Participating Party within [***] days after its delivery to the Participating Party of such Development Payment Report or Profit Payment Report, as applicable and receipt of an invoice therefor from
the Participating Party. If the Participating Party is the Party owing the [***] Development True-Up or [***] Profit True-Up payment(s) based on the calculations in the applicable Development Payment Report or Profit Payment Report, it shall,
subject to Section 9.10, make such payment to the Lead Party within [***] days after its receipt of such Development Payment Report or Profit Payment Report, as applicable, from the Lead Party and receipt of an invoice therefor from the
Lead Party. If agreed between the Parties, the Parties may also net the collective payment(s) due under the Development Payment Report and Profit Payment Report. In the event that the Third Party Licenses entered

  
 45 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
in compliance with this Agreement reasonably require the payment of royalties or other amounts payable thereunder (to the extent attributable to the Manufacture, Development and/or
Commercialization of Co-Funding Products) on a schedule other than the schedule set forth in this Agreement for [***] Development True-Up or [***] Profit True-Up
payment(s), the Parties shall discuss in good faith an appropriate schedule upon which the Party that is not party to such Third Party License shall make such payment to the other Party or its designee, and the Parties shall adjust the amounts
payable for the next [***] Development True-Up or [***] Profit True-Up payment(s) accordingly to credit such paying Party for its
pre-payment of any amounts under the Third Party Licenses. 
 9.7    Invoices
and Documentation. The JFC shall propose and the JSC shall approve the form of any necessary documentation relating to any Development Costs or Profit Split payments hereunder so as to afford the Parties appropriate accounting treatment in
relation to any of the transactions or payments contemplated hereunder. Unless otherwise agreed by the JSC, the financial data in the reports will include calculations in local currency and United States Dollars. 

9.8    Payment Method and Currency. Section 9.9 of the Collaboration Agreement is hereby incorporated by
reference into this Agreement. 
 9.9    Taxes. Section 9.10 of the Collaboration Agreement is hereby
incorporated by reference into this Agreement. 
 9.10    Resolution of Payment Disputes. In the event there is a
dispute relating to any payment obligations or reports hereunder, the Party with the dispute shall have its representative on the JFC provide the other Party’s representative on the JFC with written notice setting forth in reasonable detail the
nature and factual basis for such good faith dispute and the Parties, through the JFC, will seek to resolve the dispute as promptly as possible, but no later than ten (10) days after such written notice is received. If the JFC is unable to
resolve such payment dispute within such period then the matter shall be referred to the JSC. The Parties agree that if there is a dispute regarding any payment amount, only the disputed amount shall be withheld from the payment, and the undisputed
amount shall be paid within the applicable timeframes. 
 9.11    Late Fee. Section 9.12 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 9.12    Effect of Intellia Option
Exercise. If a Co-Funding Product constitutes a Regeneron Co-Funding Product, then no milestone payments or royalties shall be due or payable from Regeneron to Intellia under Article 9 of the Collaboration Agreement with respect to such
Regeneron Co-Funding Product [***]. For clarity, Third Party License Payments (including pursuant to the Intellia Existing Third Party Agreements) shall be included in the Profit Split and shared by the Parties in accordance with their respective
Co-Funding Percentages subject to the other terms and conditions of this Agreement that relate to their inclusion and allocation thereof. 

  
 46 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 9.13    [See Annex 1.] 

9.14    [See Annex 1.] 

ARTICLE 10 
 INTELLECTUAL
PROPERTY 
 10.1    Newly Created Intellectual Property. 

(a)    Ownership of Newly Created Intellectual Property. Inventorship of Intellectual Property invented through the
performance of activities under this Agreement shall be determined in accordance with United States patent laws (regardless of where the applicable activities occurred) and ownership of such Intellectual Property shall follow inventorship.
Notwithstanding the previous sentence, all right, title and interest in any [***], Regeneron Materials Improvements, Intellia Materials Improvements, Co-Funding Product Inventions and [***], in each case, shall be determined in accordance with the
following terms and conditions: 
 (i)    the Parties shall jointly own all [***]; 

(ii)    Intellia shall solely own all Intellia Materials Improvements and Intellia Co-Funding Product Inventions [***];
and 
 (iii)    Regeneron shall solely own all Regeneron Materials Improvements and Regeneron Co-Funding Product
Inventions, provided that if at any time any given Target that was previously a Regeneron Co-Funding Target is no longer a Regeneron Co-Funding Target hereunder, then in such case, Regeneron shall assign to Intellia an equal undivided ownership
interest in the Regeneron Co-Funding Product Inventions solely related to such Target [***]. 
 (b)    Applicability
of Non-Coding Elements to Targets Other than Regeneron Co-Funding Targets. [***]. 
 (c)    Treatment.
All Intellia Materials Improvements shall be treated as Intellia Patent Rights or Intellia Know-How, as applicable, for purposes of this Article 10. All Regeneron Materials Improvements shall be treated as Regeneron Co-Funding Product Inventions for
purposes of this Article 10. 
 (d)    Invention Assignment; Assistance. Section 10.1(d) of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 (e)    Joint Ownership of Other
Co-Funding Agreement Inventions. The Parties shall each own an equal, undivided interest in, and, subject to the other applicable provisions of this Agreement (including Sections 6.1, 6.2, 6.3, 6.5, 10.1(b), 12.6(b), 16.8(b) and 16.11), each
Party shall otherwise enjoy an equal undivided right to exploit any and all [***] including the right to use, practice and otherwise exploit for research, development, manufacturing, 

  
 47 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
commercialization and other purposes (including to grant licenses or other similar rights under) the [***], without the need to seek consent from or account to the other Party (and, for clarity,
neither Party shall be required to obtain the consent of the other Party with respect to the exploitation thereof anywhere in the world and, to the extent that such consent is required in any country in the world, such consent is hereby granted).
The foregoing joint ownership rights shall not be construed as granting, conveying or creating any license or other rights to any of the other Party’s other intellectual property, unless otherwise expressly set forth in this Agreement. Subject
to any licenses granted under this Agreement and subject to the other applicable provisions of this Agreement (including Sections 6.1, 6.2, 6.3, 6.5, 10.1(b), 12.6(b), 16.8(b) and 16.11) each Party shall grant and hereby grants its consent to the
other Party to exploit, (sub)license, assign [***] where such consent is required under Applicable Law, and further shall confirm the foregoing in writing at the other Party’s reasonable request. [***]. 

(f)    Other Intellectual Property. Section 10.1(f) of the Collaboration Agreement is hereby incorporated by
reference into this Agreement. 
 (g)    Employees and Consultants. Section 10.1(g) of the Collaboration
Agreement is hereby incorporated by reference into this Agreement. 
 (h)    Disclosure. Each Party shall
promptly disclose to the other Party all Intellectual Property that (i) is invented by such Party, its employees, agents and consultants pursuant to this Agreement and (ii) that is [***]. 

10.2    Prosecution and Maintenance of Patent Rights. 

(a)    Intellia Patent Rights. Intellia shall use Commercially Reasonable Efforts to prepare, file, prosecute and
maintain the Intellia Patent Rights [***] (and as between the Parties, in the name of Intellia). Intellia shall be solely responsible for all fees and costs incurred for the preparation, filing, prosecution and maintenance of such Intellia Patent
Rights, [***]. 
 (b)    Intellia Co-Funding Product Inventions, Other Co-Funding Agreement Inventions and Joint
Improvements. Intellia shall, through counsel it selects and, for Major Market Countries, who has been approved by Regeneron (such approval not be unreasonably withheld, conditioned or delayed), use Commercially Reasonable Efforts to prepare,
file, prosecute and maintain Patents and Patent Applications within [***] in the countries mutually agreed upon by the Parties. [***], all such Patents and Patent Applications shall be in the name of Intellia and for [***], all such Patents and
Patent Applications shall be jointly in the names of both Intellia and Regeneron and Intellia shall bear the costs thereof, [***]. For clarity, subject to Section 10.2(e), Regeneron shall not prepare, file, prosecute or maintain Patents or
Patent Applications that contain any claims that claim only Intellia Co-Funding Product Inventions. 

(c)    Regeneron Co-Funding Product Inventions. Regeneron shall use Commercially Reasonable Efforts to prepare,
file, prosecute and maintain Patents and Patent Applications within Regeneron Co-Funding Product Inventions. All such Patents and Patent 

  
 48 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Applications shall be in the name of Regeneron [***]. For clarity, subject to Section 10.2(e), Intellia shall not prepare, file, prosecute or maintain Patents or Patent Applications that
contain any claims that claim only Regeneron Co-Funding Product Inventions. 
 (d)    Consultation Rights. 

(i)    Each Party shall confer with and keep the other Party reasonably informed regarding the status of such Party’s
activities under Section 10.2(a), 10.2(b) or 10.2(c), as applicable (the Party with primary responsibility under each such Section, the “Responsible Party”, and the other Party, the “Consultation Party”). The
Responsible Party shall have the following obligations with respect to the filing, prosecution and maintenance thereof [***] the Responsible Party shall consult with the Consultation Party a reasonable time prior to taking or failing to take any
substantive action (including making any filings) with respect to such Patent Applications or Patents under Section 10.2(a), 10.2(b) or 10.2(c), as applicable, including any action that would materially affect the scope or validity of
rights under any Patent Applications or Patents (such as substantially narrowing or canceling any claim without reserving the right to file a continuing or divisional Patent Application, abandoning any Patent or not filing or perfecting the filing
of any Patent Application in any country) and the Responsible Party shall consider in good faith and discuss all reasonable comments thereto from the Consultation Party. 

(ii)    If either Party desires to file a patent application that discloses the Confidential Information of the other
Party (including Confidential Information that is treated by this Agreement as the Confidential Information of both Parties), within a reasonable period of time prior to the anticipated filing date, a notice that specifies the Confidential
Information to be disclosed within such patent application shall be provided to the other Party and, upon the request of the other Party, the filing Party shall be obliged at the other Party’s discretion to either (A) remove the
Confidential Information belonging solely to the other Party [***] from such patent application or (B) provide the other Party reasonably sufficient time [***] to file a Patent Application claiming or otherwise covering such Confidential
Information (including Confidential Information that is treated by this Agreement as the Confidential Information of both Parties), as applicable (unless any disclosure resulting from such filing under this clause (B) is prohibited by
any Third Party obligations of such other Party, in which case this clause (B) shall not be available and only clause (A) shall apply). Confidential Information of Regeneron includes the Regeneron Materials unless subject to
the exceptions set forth in Section 13.2. Confidential Information of Intellia includes the Intellia Materials unless subject to the exceptions set forth in Section 13.2. 

(e)    Step-In Rights. 

(i)    In the event that the Responsible Party desires not to file or to abandon any Patent Right or Patent Application
that would otherwise be subject to Section 10.2(a), 10.2(b) or 10.2(c), as applicable, and which results in a material loss of Patent Rights, the Responsible Party shall provide reasonable prior written notice to the Consultation Party of such
intention to not to file or to abandon (which notice shall, in any event, be given no later than [***] days prior to the next deadline for any action that may be taken with respect to such Patent or Patent Application with the applicable patent
office). 

  
 49 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)    With respect to any Intellia Patent Rights [***] that Intellia
(as the Responsible Party) desires not to file or to abandon which results in a material loss of Patent Rights, Regeneron (as the Consultation Party) shall have the right, but not the obligation, at its expense, to assume responsibility for the
filing, prosecution and maintenance of such Patents and Patent Applications within the Intellia Patents Rights in Intellia’s (or the applicable Affiliate’s or Third Party’s) name, unless, with respect to any such Patent Applications
that are unpublished, Intellia notifies Regeneron that Intellia would prefer to maintain the subject matter of such Patent Application as a trade secret. 

(iii)    With respect to any Patent or Patent Application within [***] Improvements that Intellia (as the Responsible
Party) desires not to file or to abandon which results in a material loss of Patent Rights, Regeneron (as the Consultation Party) shall have the right, but not the obligation, at its expense, to prepare, file, prosecute and maintain such Patents and
Patent Applications within [***] in the names of both Parties. 
 (iv)    With respect to any Patent or Patent
Application within [***] that Intellia (as the Responsible Party) desires not to file or to abandon which results in a material loss of Patent Rights, Regeneron (as the Consultation Party) shall have the right, but not the obligation, at its
expense, to prepare, file, prosecute and maintain such Patents and Patent Applications within [***]. 
 (v)    With
respect to any Patent or Patent Application within [***] that Regeneron (as the Responsible Party) desires not to file or to abandon which results in a material loss of Patent Rights, Intellia (as the Consultation Party) shall have the right, but
not the obligation, at its expense, to prepare, file, prosecute and maintain such Patents and Patent Applications within [***]. 

(f)    Regeneron Contributed IP. As between the Parties, Regeneron shall have the sole and exclusive right, in its
discretion and at its expense, to prepare, file, prosecute and maintain Patents and Patent Applications within the Regeneron Contributed IP and Intellia shall have no right to do so. For clarity, any such costs and expenses shall be borne solely by
Regeneron and shall not be subject to sharing by the Parties in accordance with their respective Co-Funding Percentages and shall not be treated as Other Shared Expenses. 

(g)    Cooperation. Section 10.2(g) of the Collaboration Agreement is hereby incorporated by reference into
this Agreement. 
 (h)    Cooperative Research and Technology Enhancement Act. Section 10.2(h) of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 

  
 50 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 10.3    Administrative Patent Proceedings. 

(a)    Proceedings. Each Party will notify the other within [***] days after receipt by such Party of information
concerning the request for, or filing or declaration of, any reissue, post-grant review, inter partes review, derivation proceeding, supplemental examination, interference, opposition, reexamination or other administrative proceeding relating
to (i) any Intellia Patent Rights or (ii) any Patent or Patent Application [***]. 

(b)    Product Infringement. If any proceeding under Section 10.3(a) involves Patents or Patent Applications
involved in a Product Infringement under Section 10.4, then notwithstanding the provisions of Section 10.3(a), any decisions on whether to initiate or how to respond to such a proceeding, as applicable, and the course of
action in such proceeding, shall be made by the Party controlling such Product Infringement action pursuant to Section 10.4 in consultation with the other Party [***]. 

(c)    Cost. All Out-of-Pocket Costs incurred in connection with any proceeding under Section 10.3(a) shall
be borne solely by [***]. 
 (d)    Regeneron Contributed IP and Regeneron Materials Improvements. As between
the Parties, Regeneron shall have the sole and exclusive right, in its discretion and at its expense, to handle any reissue, post-grant review, inter partes review, derivation proceeding, supplemental examination, interference, opposition,
reexamination or other administrative proceeding relating to (i) Patents and Patent Applications within the Regeneron Contributed IP and (ii) Patents and Patent Applications claiming or otherwise covering Regeneron Materials
Improvements. For clarity, any such costs and expenses shall be borne solely by Regeneron and shall not be subject to sharing by the Parties in accordance with their respective Co-Funding Percentages and shall not be treated as Other Shared
Expenses. 
 10.4    Third Party Infringement Suits. 

(a)    Product Infringement. In the event that either Party or any of its Affiliates becomes aware of an actual,
anticipated, or suspected infringement or misappropriation by a Third Party of (i) [***], or (ii) [***] (collectively (i) and (ii), “Product Infringement”), the Party that became aware of the Product Infringement
shall promptly notify the other Party in writing of this actual or suspected infringement and shall provide such other Party with all available evidence in such Party’s possession (and that is not subject to a binding contractual
confidentiality obligation to a Third Party) supporting such actual or suspected infringement. 
 (b)    Lead
Litigation Party. The Parties will consult and cooperate fully in an effort to determine a mutually agreeable course of action with respect to any Product Infringement; provided, that: 

(i)    [***]; 

(ii)    [***]; 

  
 51 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (iii)    [***]; 

(iv)    [***]; and 

(v)    [***]. 
 The Party
initiating the litigations shall be referred to as the “Lead Litigation Party”. The Lead Litigation Party cannot require the non-Lead Litigation Party to join in the suit, provided, however
that [***]. 
 (c)    Costs. All Out-of-Pocket Costs incurred in the connection with the enforcement of a
Product Infringement shall be borne [***]. 
 (d)    Recoveries. The amount of any recovery from any Product
Infringement suit shall first be used to pay each of the Party’s reasonable costs, including attorneys’ fees, relating to such legal proceedings and the balance of any such recovery shall be retained by the Lead Litigation Party; provided,
however, that with respect to any amounts of such recovery from any such Product Infringement suit (other than those amounts used to pay a Party’s reasonable costs) that have been awarded (as reimbursement for lost sales or lost royalties) of
Co-Funding Products, regardless of which Party is the Lead Litigation Party, such amounts shall be included in the calculation of Profit Split in accordance with Section 9.2. 

(e)    Assistance. In the event either Party initiates a proceeding pursuant to this Section 10.4, without
any effect as to who is the Lead Litigation Party pursuant to the terms of Section 10.4(b), the other Party shall provide all assistance reasonably requested by the Lead Litigation Party [***]. 

(f)    Settlements; Admissions. Section 10.4(f) of the Collaboration Agreement is hereby incorporated by
reference into this Agreement. 
 (g)    Step-In Rights. Section 10.4(g) of the Collaboration Agreement is
hereby incorporated by reference into this Agreement. 
 (h)    Biosimilar Applications. Section 10.4(h) of
the Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 (i)    Regeneron Contributed
IP and Regeneron Materials Improvements. As between the Parties, Regeneron shall have the sole and exclusive right, in its discretion and at its expense, to handle enforcement relating to the Regeneron Contributed IP and Regeneron Materials
Improvements. 

  
 52 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 10.5    BPCIA and Biosimilar Applications. 

(a)    BPCIA Listings. 

(i)    With respect to Regeneron Co-Funding Products, Regeneron will have sole decision-making authority with respect to
the determination of which Intellia Patent Rights or Patent Rights Controlled by Regeneron or its Affiliates to submit to a Third Party that files a Biosimilar Application, or any other act of patent information exchange or listing as required by
the BPCIA or other similar measure in any other country worldwide (provided that with respect to Intellia Background Patent Rights, if such Patent Rights cover one or more products of Intellia or its (sub)licensees, then any such determination shall
discussed in good faith by the Parties with respect to such Patent Rights); provided, that to the extent permitted by Applicable Law, Regeneron shall confer in good faith with Intellia regarding which, if any, such Intellia Patent Rights are listed
pursuant to 42 U.S.C. § 262(l)(3)(A) (or any successor legislation) (or other similar measure in any other country worldwide), or otherwise included in any litigation with such a Third Party applicant. 

(ii)    With respect to Intellia Co-Funding Products, Intellia will have sole decision-making authority with respect to
the determination of which Intellia Patent Rights to submit to a Third Party that files a Biosimilar Application, or any other act of patent information exchange or listing as required by the BPCIA or other similar measure in any other country
worldwide; provided, that to the extent permitted by Applicable Law, Intellia shall confer in good faith with Regeneron regarding which, if any, such Intellia Patent Rights are listed pursuant to 42 U.S.C. § 262(l)(3)(A) (or any successor
legislation) (or other similar measure in any other country worldwide), or otherwise included in any litigation with such a Third Party applicant. 

(b)    Biosimilar Applications. Notwithstanding anything to the contrary herein, if either Party receives a copy
of a Biosimilar Application referencing a Co-Funding Product or otherwise becomes aware that such a Biosimilar Application has been submitted to a Regulatory Authority for marketing approval (such as in an instance described in 42 U.S.C.
§262(l)(9)(C)), such Party shall within [***] notify the other Party. The owner of the relevant Patent Rights shall then seek permission to view the application and related confidential information from the filer of the Biosimilar Application
if necessary under 42 U.S.C. §262(l)(1)(B)(iii). If either Party receives any equivalent or similar communication or notice in the United States or any other jurisdiction, either Party shall within [***] notify and provide the other Party
copies of such communication to the extent permitted by Applicable Laws. Promptly after receiving notice of a Biosimilar Application referencing a Co-Funding Product or any equivalent or similar communication or notice in the United States or any
other jurisdiction referencing a Co-Funding Product, the Parties shall enter into an appropriate joint defense agreement. Regeneron shall have the right to be the Lead Litigation Party with respect to a Regeneron Co-Funding Product and Intellia
shall have the right to be the Lead Litigation Party with respect to an Intellia Co-Funding Product. A Party that is not the Lead Litigation Party in a litigation shall consent to being joined in a litigation
or being named as the plaintiff in a litigation if such being joined or 

  
 53 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
named as a plaintiff is necessary to confer standing to bring the litigation or is otherwise necessary for the pendency of the litigation, and in such instance the joined Party shall provide
reasonable cooperation and assistance to the Lead Litigation Party, and all Out-of-Pocket Costs incurred by the joined Party in connection therewith shall be shared by the Parties in accordance with their respective Co-Funding Percentages and
treated as Other Shared Expenses. 
 (c)    Coordination. With regard to issues related to potential Biosimilar
Applications referencing a Co-Funding Product, the Parties shall conduct and maintain ongoing and regular communications between their legal/intellectual property departments. 

10.6    Extensions and Other Protections. The Lead Party shall have the sole right to apply for supplementary
protection certificates, patent term extensions, patent term restorations or any other exclusivity, including as may be available under the provisions of the Drug Price Competition and Patent Term Restoration Act of 1984 (or comparable laws outside
the United States of America), in respect of a Co-Funding Product. At the Lead Party’s reasonable request, the other Party will provide reasonable assistance to the Lead Party in connection with any such applications. [***]. 

10.7    Patent Marking. Each Party shall comply with the patent marking statutes in each country in which a
Co-Funding Product or Terminated Co-Funding Products, as applicable, is made, offered for sale, sold or imported by such Party, its Affiliates or sublicensees. 

10.8    Third Party Claims Related to Technology Collaboration, Regeneron Target Evaluation Program, Intellia Target
Evaluation Program or Product R&D Program. If either Party or its Affiliates shall learn of a Third Party claim, assertion or certification that the activities under this Agreement infringe or otherwise violate the intellectual property
rights of any Third Party, then such Party shall promptly notify the other Party in writing of this claim, assertion or certification. As soon as reasonably practical after the receipt of such notice, the Parties shall [***]. 

10.9    Infringement of Third Party Patent Rights or Third Party Know-How. If any Co-Funding Product manufactured,
used or sold by a Party, its Affiliates or sublicensees becomes the subject of a Third Party’s claim or assertion of infringement of a Patent Right or misappropriation of Know-How, the Party first having notice of the claim or assertion shall
promptly notify the other Party. Regeneron shall have the sole right, but not the obligation, to defend any such Third Party claim or assertion of infringement of a Regeneron Co-Funding Product. Intellia shall have the sole right, but not the
obligation, to defend any such Third Party claim or assertion of infringement of an Intellia Co-Funding Product. The non-defending Party shall provide reasonable cooperation and assistance to the defending Party. Subject to Section 14.1, all Out-of-Pocket Costs incurred by the defending Party in connection with a defense against a Third Party claim or assertion pursuant to this Section 10.9 and by the non-defending Party in connection with
providing the assistance set forth in the previous sentence [***]. 

  
 54 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 10.10    Product Trademarks. The Lead Party shall exclusively own
and be responsible for, filing, prosecuting, protecting and maintaining the Product Trademarks, including all enforcement and defense thereof. All Out-of-Pocket Costs incurred in the filing, prosecution and maintenance, enforcement and defense of
Product Trademarks pursuant to this Section 10.10 shall be shared by the Parties in accordance with their respective Co-Funding Percentages and treated as Other Shared Expenses. The Participating Party shall provide all assistance reasonably
requested by the Lead Party in connection with the maintenance, enforcement and defense of the Product Trademarks. 

10.11    Use of Corporate Names. The Lead Party shall use Commercially Reasonable Efforts to include the
Participating Party’s name with [***] on materials related to the Product (including package inserts, packaging, trade packaging, internet pages, social media, samples and all Promotional Materials used or distributed in connection with the
Product), unless to do so would be prohibited under Applicable Law; provided, in the case of multi-product materials that refer to the Product as well as other (bio)pharmaceutical products [***]. Each Party grants to the other Party (and its
Affiliates) the right, free of charge, to use [***]. 
 10.12    Third Party Rights. 

(a)    Notwithstanding the foregoing provisions of this Article 10, the Parties acknowledge and agree that each
Party’s rights and obligations with respect to any Patent Rights under this Article 10 will be subject to the terms and conditions of the Intellia Existing Third Party Agreements [***] and as may be amended or restated from time to time in
accordance with Section 12.3(d) [***]. 
 (b)    [See Annex 1.] 

(c)    This Section 10.12 shall not apply to, and expressly excludes, the Patent Rights licensed under any Third
Party Collaboration Agreement. 
 ARTICLE 11 

BOOKS, RECORDS AND INSPECTIONS; AUDITS AND ADJUSTMENTS 

11.1    Books and Records. Section 11.1 of the Collaboration Agreement is hereby incorporated by reference
into this Agreement in accordance with Section 2.2(b). Each Party shall keep its books of record and account to the extent related to this Agreement in a readily available and organized form to allow an independent auditor to verify the
accuracy of all financial, accounting and numerical information provided in a reasonably efficient manner. To the extent an audited Party is reasonably determined to not be in compliance with the previous sentence, such audited Party shall be
responsible for any additional fees charged by the independent auditor to the auditing Party as a result of additional time spent by the independent auditor assembling or organizing such information. 

  
 55 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 11.2    Audits and Adjustments. Section 11.2 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 11.3    GAAP.
Section 11.3 of the Collaboration Agreement is hereby incorporated by reference into this Agreement 
 ARTICLE 12 

REPRESENTATIONS, WARRANTIES AND COVENANTS 

12.1    Joint Representations and Warranties. Each Party hereto represents and warrants to the other Party, as of
the Effective Date, as follows: (a) it is duly organized, validly existing, and in good standing under the laws of its jurisdiction of incorporation; (b) it has full corporate power and authority to execute, deliver, and perform
this Agreement, and has taken all corporate action necessary to enter into, deliver, and perform this Agreement; (c) the execution and performance by it of its obligations hereunder will not constitute a breach of, or conflict with, its
organizational documents nor any other material agreement or arrangement, whether written or oral, by which it is bound or requirement of Applicable Laws; (d) this Agreement is its legal, valid and binding obligation, enforceable in
accordance with the terms and conditions hereof (subject to Applicable Laws of bankruptcy and moratorium); (e) such Party is not prohibited by the terms of any agreement to which it is a party from granting the licenses expressly to the other Party
hereunder; (f) no broker, finder or investment banker is entitled to any brokerage, finder’s or other fee in connection with this Agreement or the transactions contemplated hereby based on arrangements made by it or on its behalf;
and (g) it has obtained all necessary consents, approvals and authorizations of all Governmental Authorities and other Persons required to be obtained by it as of the Effective Date, as applicable, in connection with the execution,
delivery and performance of this Agreement. 
 12.2    Additional Representations and Warranties of the Parties.

 (a)    By Intellia. [See Annex 1.] 

(b)    By Regeneron. [See Annex 1.] 

12.3    Covenants. 

(a)    Each Party hereby covenants to the other Party as follows: (i) it will not during the Term grant any right or
license to any Third Party which would be in conflict with the rights granted to the other Party under this Agreement, and (ii) neither Party will use the Patent Rights, Know-How, materials, or Confidential Information of the other Party
outside the scope of the licenses and rights granted to it under this Agreement. 
 (b)    Intellia (on behalf of
itself and its Affiliates) hereby further covenants to Regeneron that it (and they) shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance
or 

  
 56 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
otherwise) any rights to any Intellia Know-How or Intellia Patent Rights, in any manner that would conflict with, or would adversely interfere with, the grant of the rights or licenses granted to
Regeneron hereunder. 
 (c)    Regeneron (on behalf of itself and its Affiliates) hereby further covenants to Intellia
that it (and they) shall not assign, transfer, convey or otherwise grant to any Person or otherwise encumber (including through lien, charge, security interest, mortgage, encumbrance or otherwise) any rights to any Regeneron Know-How or Regeneron
Patent Rights, in any manner that would conflict with, or would adversely interfere with, the grant of the rights or licenses granted to Intellia hereunder. 

(d)    [See Annex 1.] 

12.4    Compliance with Laws. Section 12.5 of the Collaboration Agreement is hereby incorporated by reference
into this Agreement. 
 12.5    Disclaimer of Warranties. EXCEPT AS OTHERWISE SPECIFICALLY AND EXPRESSLY PROVIDED
IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR WARRANTIES, EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, CONCERNING THE SUCCESS OR POTENTIAL SUCCESS OF ANY ACTIVITIES PERFORMED UNDER ANY PLAN OR THE DEVELOPMENT, COMMERCIALIZATION,
MARKETING OR SALE OF ANY CO-FUNDING PRODUCT. EXCEPT AS EXPRESSLY SET FORTH HEREIN, EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF NON-INFRINGEMENT, MERCHANTABILITY AND FITNESS FOR A
PARTICULAR PURPOSE. 
 12.6    Exclusivity. The Parties hereby agree as follows: 

(a)    Exception to Intellia Liver Exclusivity. For clarity, nothing in Section 12.7(a) of the Collaboration
Agreement shall restrict or limit or otherwise be deemed to restrict or limit Intellia’s rights under this Agreement to research, develop, manufacture, commercialize or otherwise exploit Intellia Co-Funding Products as a Lead Party in
accordance with this Agreement or Intellia’s rights under this Agreement to act as a Participating Party with respect to Regeneron Co-Funding Products. 

(b)    Target Exclusivity. Except in accordance with this Agreement in accordance with an applicable Plan, neither
Party or its Affiliates will, on its or their own, or by assisting or working with or through any Third Party (or otherwise granting any licenses or other rights to any Third Party to) [***]. Nothing in this Section 12.6(b) shall be
deemed to restrict either Party or its Affiliates from [***]. 

  
 57 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (c)    Change of Control of a Party. Notwithstanding anything in
this Agreement to the contrary, in the event of a Change of Control of a Party, [***] (each, an “Existing Permitted Change of Control CP”). [***]. 

(d)    Other Acquisitions by a Party. Notwithstanding Section 12.6(b), in the event that a Party or its
Affiliates acquire a Third Party or a portion of the business of a Third Party (whether by merger, stock purchase, purchase of assets or other means of acquiring ownership) (such Party, the “Acquiring Party” and such acquisition, a
“Third Party Acquisition”) that is, immediately prior to such acquisition, conducting a research, development or commercialization program that, if conducted by such Party at such time, would be a breach of such Party’s
exclusivity obligation in Section 12.6(b) (a “Competing Program”), the Acquiring Party shall give the other Party express written notice thereof within [***] Business Days after the closing of such Third Party
Acquisition and furthermore the Acquiring Party shall in its sole discretion do one of the following within [***] days after the closing of such Third Party Acquisition: 

(i)    [***]; 

(ii)    [***]; or 

(iii)    [***]. 

(iv)    [***]. 

ARTICLE 13 

CONFIDENTIALITY 

13.1    Confidential Information. 

(a)    Each Party and its Affiliates (in such capacity, collectively, the “Receiving Party”) shall keep
confidential, and other than as provided herein, shall not disclose, directly or indirectly, any proprietary or confidential information, including any proprietary data, inventions, documents, ideas, information, discoveries, or materials,
Controlled by the other Party or its Affiliates (in such capacity, collectively, the “Disclosing Party”), whether in tangible or intangible form, including Regeneron Contributed IP and Intellia Know-How, that is disclosed pursuant
to this Agreement (the “Confidential Information”). 
 (b)    Each Party and its Affiliates shall use
the Confidential Information of the other Party and its Affiliates solely for the purpose of exercising its rights and performing its obligations hereunder. 

(c)    Each Party covenants that neither it nor any of its respective Affiliates shall disclose any Confidential
Information of the other Party to any Third Party except (i) to its directors, officers, employees, agents, consultants and subcontractors to the extent necessary to 

  
 58 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
perform such Party’s obligations, or exercise such Party’s rights, hereunder, provided such directors, officers, employees, agents, consultants, subcontractors or other Persons are
subject to confidentiality obligations applicable to such Confidential Information no less strict than those set forth herein, (ii) as approved by the Disclosing Party hereunder in writing, (iii) as set forth elsewhere in this
Agreement, including to subcontractors and sublicensees in accordance with Section 7.2, (iv) to file or prosecute Patent Rights in accordance with this Agreement, (v) to prosecute or defend litigation as permitted by this
Agreement, (vi) to any Governmental Authority or other Regulatory Authority in order to gain or maintain approval to conduct clinical trials or to market Co-Funding Products, but such disclosure may be only to the extent reasonably
necessary to obtain such approvals (subject to the applicable provisions of Article 3, Article 4, Article 5 and Article 8 as and to the extent applicable), or (vii) as required by Applicable Law, valid order of a court of competent
jurisdictions, or other judicial or administrative proceedings of any Governmental Authority requires to be disclosed, provided that in the case of (v), (vi) or (vii) the Receiving Party gives the Disclosing Party reasonable advance
notice (if practical) of such required disclosure in sufficient time to enable the Disclosing Party to seek confidential treatment for such information, and provided further that the Receiving Party provides all reasonable cooperation to assist the
Disclosing Party to protect such information and limits the disclosure to that information which is required by Applicable Law to be disclosed, and also provided that, such information shall still be treated as Confidential Information for all
purposes other than satisfaction of such disclosure requirement. 
 (d)    Other Co-Funding Agreement Inventions,
Co-Funding Product Inventions to the extent jointly owned by the Parties as provided in Section 10.1(a), and Joint Improvements shall be Confidential Information of both Parties; provided that the Other Co-Funding Agreement Inventions, and
Joint Improvements may be utilized as provided in (c) above, as well as, the following: (i) used by either Party (or their respective subcontractors, licensees or sublicensees) but not disclosed to Third Parties except as
other Confidential Information may be disclosed by the Receiving Party (a) as expressly permitted herein (including through the publication procedures set forth in Section 13.4) or (b) with the prior written
consent of the other Party; (ii) disclosed under commercially reasonable confidentiality terms and solely to the extent reasonably necessary to any potential or actual investor, advisor, lender, investment banker, financing partner, or
acquirer; and (iii) disclosed under confidentiality obligations at least as restrictive as, or substantially the same as, those set forth herein (except with respect to the duration of such obligations, which shall not be less than [***]
years from the date that the agreement under which such information is disclosed), to any actual or prospective subcontractor, licensee or sublicensee. Notwithstanding the foregoing or anything to the contrary contained herein, (A) (I)
Regeneron Materials Improvements, Know-How within the Regeneron Contributed Technology and Know-How within the Regeneron Co-Funding Product Inventions to the extent solely owned by Regeneron and (II) any other Confidential Information to
the extent related to Regeneron Co-Funding Products or Regeneron Co-Funding Targets, shall be the Confidential Information of Regeneron, and (B)(I) Intellia Know-How [***], (II) Intellia Materials Improvements and Know-How within the Intellia
Co-Funding Product Inventions to the extent solely owned by Intellia and (III) any other Confidential Information to the extent related to Intellia Co-Funding Products or Intellia Co-Funding Targets, shall be the Confidential Information of Intellia. 

  
 59 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 13.2    Exceptions. Section 13.2 of the Collaboration
Agreement is hereby incorporated by reference into this Agreement. 
 13.3    Injunctive Relief.
Section 13.3 of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

13.4    Publications. 

(a)    Joint Improvements and Other Co-Funding Agreement Inventions. Subject to the prior written consent of the
JSC and subject further to Sections 13.4(b) and 13.4(c), either Party may issue publications in scientific journals and make scientific presentations regarding Joint Improvements or Other Co-Funding Agreement Inventions with the order and inclusion
of Intellia and Regeneron authors to be agreed upon in accordance with International Committee of Medical Journal Editors (ICJME) Standards or other mutually agreed upon applicable standards and in compliance with any applicable rules or policies of
the publisher of such publication. 
 (b)    Co-Funding Products, Co-Funding Targets and Co-Funding Product
Inventions. Subject to Section 13.4(c), Regeneron shall have the sole right to issue and control all publications in scientific journals and make scientific presentations regarding Regeneron Co-Funding Products, Regeneron Co-Funding Targets
and the Regeneron Co-Funding Product Inventions that are solely owned by Regeneron, and to extent Intellia contributes to such publication, the order and inclusion of Regeneron and Intellia authors to be agreed upon in accordance with International
Committee of Medical Journal Editors (ICJME) Standards or other mutually agreed upon applicable standards and in compliance with any applicable rules or policies of the publisher of such publication.. Subject to Section 13.4(c), Intellia
shall have the sole right to issue and control all publications in scientific journals and make scientific presentations regarding Intellia Co-Funding Products, Intellia Co-Funding Targets and the Intellia Co-Funding Product Inventions that are
solely owned by Intellia, and to extent Regeneron contributes to such publication, the order and inclusion of Intellia and Regeneron authors to be agreed upon in accordance with International Committee of Medical Journal Editors (ICJME) Standards or
other mutually agreed upon applicable standards and in compliance with any applicable rules or policies of the publisher of such publication. 

(c)    Review Rights. If the JSC approves a publication under Section 13.4(a), Regeneron intends to make a
publication under the first sentence of Section 13.4(b) or Intellia intends to make a publication under the second sentence of Section 13.4(b), the publishing Party shall provide the non-publishing Party an advance copy of
any such proposed publication prior to submission for publication or disclosure. The non-publishing Party shall have a reasonable opportunity to (i) recommend any changes to prevent disclosure of its Confidential Information
(including any joint Confidential Information) and (ii) file a Patent Application related to such 

  
 60 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Confidential Information, if any. The publishing Party shall remove any such Confidential Information, and shall not make any such publication if the non-publishing Party requests a delay of
up to [***] days to enable it to file Patent Applications until expiration of such [***] day period. 

13.5    Disclosures Concerning this Agreement. 

(a)    Press Releases. The Parties do not intend to issue a press release announcing the execution of this
Agreement. Excluding the first sentence, the remainder of Section 13.5(a) of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

(b)    Agreement Terms. Except as required by a Governmental Authority or Applicable Law (including the rules and
regulations of any stock exchange or trading market on which a Party’s (or its parent entity’s) securities are or will be traded), or in connection with the enforcement of this Agreement, neither Party (or their respective Affiliates)
shall disclose to any Third Party, under any circumstances, any terms of this [***] that have not been previously disclosed publicly in accordance with this Article 13 without the prior written consent of the other Party, which consent shall not be
unreasonably conditioned, withheld or delayed; except for disclosures thereof pursuant to Section 7.3(e) of this Agreement or (i) to potential or actual investors, advisors, lenders, investment bankers, financing partners,
acquirers, subcontractors, licensees or sublicensees that are bound by obligations of confidentiality and nonuse substantially equivalent in scope to those included herein with a term of at least [***] years (but of shorter duration if customary in
connection with any disclosure to a potential or actual investor, advisor, lender, investment banker or financing partner) or (ii) to Persons that are identified in Section 13.1(c)(i) who are subject to the confidentiality
obligations specified therein; provided that, in the event of any such disclosure to a Third Party who is a potential or actual investor, advisor, lender, financing partner, acquirer, licensee or sublicensee (A) this Agreement shall only
be initially disclosed in the Redacted Agreement form to such Third Party and its advisors and (B) after negotiations with any such Third Party have progressed so that the Disclosing Party reasonably and in good faith believes it will
execute a definitive agreement with such Third Party within [***] Business Days, this Agreement may be disclosed in an unredacted form to such Third Party and its advisors as and to the extent relevant to such Third Party [***]. 

(c)    Communications General. Any mechanisms and procedures established by the JSC pursuant to
Section 13.5(c) of the Collaboration Agreement to ensure coordinated timely corporate communications relating to the Collaboration Agreement shall also apply to this Agreement, including the Co-Funding Products. 

(d)    Publicly Traded Company. Each Party acknowledges that the other Party, as a publicly traded company, is
legally obligated to make timely disclosures of all material events relating to its business. Therefore, the Parties acknowledge that either or both Parties may be obligated to file a copy of this Agreement with the United States Securities and
Exchange Commission or its equivalent (the “SEC”). The Parties agree that the form of the 

  
 61 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
redacted version of this Agreement (the “Redacted Agreement”), which shall be mutually agreed by the Parties in good faith within [***] Business Days of the Effective Date, may
be used as its filing (or submission) of this Agreement to the SEC, and the Parties shall cooperate with one another and use reasonable efforts to obtain confidential treatment of confidential information (including any information that constitutes
a trade secret or a sensitive commercial term), including with respect to any comments received from the SEC with respect to the proposed redactions. The Parties further agree that, following the initial filing (or submission) of the Redacted
Agreement, the filing Party will (i) promptly deliver to the non-filing Party any written correspondence received by the filing Party or its representatives from the SEC with respect to such confidential treatment request and promptly advise
the non-filing Party of any other communications between the filing Party or its representatives with the SEC with respect to such confidential treatment request, allowing a reasonable time for the non-filing Party to review and comment;
(ii) upon the written request of the non-filing Party, request an appropriate extension of the term of the confidential treatment period; and (iii) if the SEC requests any changes to the redactions set forth in the Redacted
Agreement, to the extent reasonably practicable, not agree to any changes to the Redacted Agreement without first discussing such changes with the non-filing Party and taking the non-filing Party’s comments into consideration when deciding
whether to agree to such changes. In addition, each Party will provide the other Party with an advance copy of any securities filings in which the Agreement is discussed or disclosed, in each case only to the extent describing this
Agreement or referencing the other Party, allowing a reasonable time (but in no event less than [***] Business Days) for the other Party to review and comment, and will reasonably consider and, to the extent permitted by a Governmental Authority, or
Applicable Law (including the rules and regulations of any stock exchange or trading market on which a Party’s (or its parent entity’s) securities are or will be traded), incorporate the other Party’s timely comments thereon; [***].

 ARTICLE 14 

INDEMNITY 

14.1    Indemnity and Insurance. 

(a)    Intellia’s Indemnification Obligations. Intellia will indemnify and hold harmless Regeneron, its
Affiliates and their respective officers, directors, employees and agents (“Regeneron Indemnitees”) from and against all loss, liabilities, damages, penalties, fines and expenses, including reasonable attorneys’ fees and costs
(collectively, “Damages”), incurred by any Regeneron Indemnitee as a result of a Third Party’s claim, action, suit, settlement, or proceeding (each, a “Claim”) against a Regeneron Indemnitee that arises out of
or results from: 
 (i)    the gross negligence, recklessness, willful misconduct, or intentional wrongful acts or
omissions of Intellia or any other Intellia Indemnitee(s) in its performance under the Plans or other activity under this Agreement, including in connection with the Development, Manufacture or Commercialization of any Co-Funding Product in the
Field; or 

  
 62 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)    breach by Intellia of this Agreement (including the inaccuracy
of any representation or warranty made by Intellia in this Agreement); 
 in each case, except to the extent such Claim is subject
to Regeneron’s indemnification obligations under Section 14.1(b)(i) or (ii) below. 

(b)    Regeneron’s Indemnification Obligations. Regeneron will indemnify and hold harmless Intellia, its
Affiliates and their respective officers, directors, employees and agents (“Intellia Indemnitees”) from and against all Damages incurred by any Intellia Indemnitee as a result of a Claim against an Intellia Indemnitee that arises
out of or results from: 
 (i)    the gross negligence, recklessness, willful misconduct, or intentional wrongful acts
or omissions of any Regeneron or any other Regeneron Indemnitee(s) in its performance under the Plans or other activity under this Agreement, including in connection with the Development, Manufacture or Commercialization of any Co-Funding Product in
the Field; or 
 (ii)    breach by Regeneron of this Agreement (including the inaccuracy of any representation or
warranty made by Regeneron in this Agreement); 
 in each case, except to the extent such Claim is subject to Intellia’s
indemnification obligations under Section 14.1(a)(i) or (ii) above. 
 (c)    Product Liability. In
the event of any Third Party product liability Claim alleging that the Development, Manufacture or Commercialization of any Co-Funding Product in the Field causes damages for which, and to the extent to which, neither Party is entitled to
indemnification hereunder, during the Term such Damages shall be shared by the Parties in accordance with their respective Co-Funding Percentages and treated as Other Shared Expenses. Regeneron shall have the sole right, but not the obligation, to
defend any such Third Party product liability claim of a Regeneron Co-Funding Product. Intellia shall have the sole right, but not the obligation, to defend any such Third Party product liability claim of an Intellia
Co-Funding Product. The non-defending Party shall provide reasonable cooperation and assistance to the defending Party. 

14.2    Indemnity Procedure. 

(a)    Notification. The Party entitled to indemnification under this Article 14 (an “Indemnified
Party”) shall notify the Party potentially responsible for such indemnification (the “Indemnifying Party”) within [***] Business Days of becoming aware of any Claim asserted or threatened in writing against the Indemnified
Party which could give rise to a right of indemnification under this Agreement; provided, however, that the failure to give such notice shall not relieve the Indemnifying Party of its obligations hereunder except to the extent that such failure
materially prejudices the Indemnifying Party. 

  
 63 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    Control of Defense. If the Indemnifying Party elects in
writing to the Indemnified Party that it will assume control of the defense of such Claim, the Indemnifying Party shall have the right to defend, at its sole cost and expense, such Claim by all appropriate proceedings, which proceedings shall be
prosecuted diligently by the Indemnifying Party to a final conclusion or settled at the discretion of the Indemnifying Party; provided, however, that the Indemnifying Party may not enter into any compromise or settlement unless (i) such
compromise or settlement includes as an unconditional term thereof, the giving by each claimant or plaintiff to the Indemnified Party of a release from all liability in respect of such claim; and (ii) the Indemnified Party consents to
such compromise or settlement, which consent shall not be conditioned, withheld or delayed unless such compromise or settlement involves (A) any admission of legal wrongdoing by the Indemnified Party, (B) any payment by the
Indemnified Party that is not indemnified hereunder or (C) the imposition of any equitable relief against the Indemnified Party. If the Indemnifying Party does not elect to assume control of the defense of such Claim within [***] days of
its receipt of notice thereof, or if the Indemnifying Party elects in writing to the Indemnified Party to cease maintaining control of the defense of such Claim, the Indemnified Party shall have the right, at the expense of the Indemnifying Party,
upon at least [***] Business Days’ prior written notice to the Indemnifying Party of its intent to do so, to undertake the defense of such Claim for the account of the Indemnifying Party (with counsel reasonably selected by the Indemnified
Party and approved by the Indemnifying Party, such approval not unreasonably conditioned, withheld or delayed), provided, that the Indemnified Party shall keep the Indemnifying Party apprised of all material developments with respect to such Claim
and promptly provide the Indemnifying Party with copies of all correspondence and documents exchanged by the Indemnified Party and the opposing party(ies) to such Claim. The Indemnified Party may not compromise or settle such Claim without the prior
written consent of the Indemnifying Party, such consent not to be unreasonably conditioned, withheld or delayed. 

(c)    Indemnified Party’s Participation. The Indemnified Party shall cooperate with the Indemnifying Party
in, and may participate in, but not control, any defense or settlement of any Claim controlled by the Indemnifying Party pursuant to this Section 14.2 and shall bear its own costs and expenses with respect to such participation; provided,
however, that the Indemnifying Party shall bear such costs and expenses if counsel for the Indemnifying Party shall have reasonably determined that such counsel may not properly represent both the Indemnifying Party and the Indemnified Party (and
the Out-of-Pocket Costs of the Indemnified Party shall be shared by the Parties in accordance with their respective Co-Funding Percentages and treated as Other Shared Expenses if the Claim is covered by Section 10.9 or
Section 14.1(c)). 
 (d)    Defense Procedures For Damages that are Other Shared Expenses. The
indemnification procedures in this Section 14.2 shall apply to Claims for which each Party indemnifies the other Party for its Co-Funding Percentage subject to Section 9.3(b) of all Damages under the terms of
Section 10.9 and Section 14.1(c); provided that Regeneron shall be deemed to be the Indemnifying Party if the Claim in Section 10.9 or Section 14.1(c) relates to a Regeneron Co-Funding Product and
Intellia shall be deemed to be the Indemnifying Party if the Claim in Section 10.9 or Section 14.1(c) relates to an Intellia Co-Funding Product. 

  
 64 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 14.3    Insurance. During the Term and for a minimum period of
[***] years thereafter and for an otherwise longer period as may be required by Applicable Law, each of Regeneron and Intellia will (i) use Commercially Reasonable Efforts to procure and maintain appropriate commercial general liability and
product liability insurance in amounts appropriate for the industry and considering the activities being conducted or (ii) with respect to Regeneron as of the Effective Date, or Intellia as such time as Intellia and its Affiliates have annual
revenue in excess of [***] (including after any Change of Control of Intellia), procure and maintain adequate insurance by means of self-insurance in such amounts and on such terms as are consistent with normal business practices of large
pharmaceutical companies in the life sciences industry. Such insurance shall insure against liability arising from this Agreement on the part of Regeneron or Intellia, respectively, or any of their respective Affiliates, due to injury, disability or
death of any person or persons, or property damage arising from activities performed in connection with this Agreement. It is understood that such insurance shall not be construed to create a limit of either Party’s liability with respect to
its indemnification obligations under Section 14.1 or otherwise. Any insurance proceeds received by a Party in connection with any Damages shall be retained by such Party and shall not reduce any obligation of the other Party. 

ARTICLE 15 
 FORCE
MAJEURE 
 Article 15 of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

ARTICLE 16 
 TERM AND
TERMINATION3 
 16.1    Term. The
“Term” of this Agreement shall begin on the Effective Date and will expire with respect to all Co-Funding Products Directed to such Co-Funding Target at such time as neither the Lead Party nor
any of its Affiliates, nor any of their respective sublicensees, is Developing, Commercializing and Manufacturing (for purposes of Development or Commercialization) any Co-Funding Product in the Field Directed
to such Co-Funding Target anywhere in the world under this Agreement (and such cessation of Development, Manufacturing and Commercialization activities is acknowledged by the Lead Party in writing to be
permanent), unless this Agreement is earlier terminated in its entirety in accordance with this Article 16, in which event the Term shall end on the effective date of such termination. 

16.2    Termination for Insolvency. Section 16.2 of the Collaboration Agreement is hereby incorporated
by reference into this Agreement. 
  
  

	3 	 NTD: May be subject to further consideration by the parties as the draft progresses. In the final document, the
termination scenarios will be included in the sub-annexes depending on the category of Co-Funding Target. 

  
 65 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 16.3    Termination of Co-Funding Target for which a Party is the Lead
Party for Convenience. At any time, upon one hundred eighty (180) days advanced written notice, with respect to all Co-Funding Products Directed to such Co-Funding Target, the Lead Party may terminate this Agreement with respect to the
Co-Funding Target and all Co-Funding Products hereunder; provided, that, the Lead Party’s obligation to use Commercially Reasonably Efforts to develop and commercialize Co-Funding Products with respect to a given Co-Funding Target and such
Co-Funding Products shall continue during the one hundred eighty (180)-day period following its delivery of such a notice of termination with respect to such terminated Co-Funding Target in accordance with this Agreement. 

16.4    Termination of Co-Funding Target by the Participating Party for Convenience. 

(a)    The Participating Party may terminate this Agreement, (i) at any time upon one hundred eighty
(180) days advanced written notice, (ii) within the first three (3) months after the Effective Date, pursuant to Section 3.2(b), (iii) within three (3) months of the approval of a Global
Development Plan by the JSC that exceeds the previously-approved Global Development Budget for any Contract Year by more than [***]; or (iv) within three (3) months of the approval of a Global Commercialization Plan by the
JSC that exceeds the previously-approved Global Commercialization Budget for any Contract Year by more than [***]. 

(b)    With respect to termination under Section 16.4(a)(i) or Section 16.4(a)(ii), the Participating
Party shall continue to be responsible for its share (applicable Co-Funding Percentage) of all Development Costs and Shared Commercial Expenses incurred in connection with the Co-Funding Product in accordance with the Global Development Budget set
forth in the last Global Development Plan approved by the JSC and in accordance with the Global Commercialization Budget set forth in the last Global Commercialization Plan approved by the JSC and the Country/Region Commercialization Budget set
forth in the last Country/Region Commercialization Plan approved by the JSC, including the U.S. Commercialization Budget set forth in the last U.S. Commercialization Plan, to the extent applicable, in each case prior to the Participating
Party’s notice of termination up until the effective date of termination in accordance with this Section 16.4. 

(c)    With respect to termination under Section 16.4(a)(iii) or Section 16.4(a)(iv), the Participating
Party shall continue to be responsible for its share (applicable Co-Funding Percentage) of all Development Costs and Shared Commercial Expenses incurred in connection with the Co-Funding Product in accordance with the previously-approved Global
Development Budget and in accordance with the previously-approved Global Commercialization Budget and the previously-approved Country/Region Commercialization Budget, including the previously approved U.S. Commercialization Budget, to the extent
applicable, in each case prior to the Participating Party’s notice of termination up until the effective date of termination in accordance with this Section 16.4. [***]. 

  
 66 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 16.5    Breach of the Agreement. 

(a)    Either Party may terminate this Agreement in accordance with the remainder of this Section 16.5, its entirety
if, as applicable, the other Party commits a material breach of this Agreement, in a manner that fundamentally frustrates the value or essential characteristics of the transactions contemplated by this Agreement. 

(b)    In the event that one Party (the “Alleging Party”) believes that the other Party (the
“Alleged Party”) has committed a material breach, the Alleging Party shall provide written notice (“Breach Notice”) to the Alleged Party describing in an appropriate detail the nature of such material breach. 

(c)    The Alleged Party shall have ninety (90) days from its receipt of the Breach Notice to cure such material
breach; provided that if such breach is not curable within the foregoing cure period, then such cure period will be extended for a period of up to sixty (60) additional days (for a total cure period of one hundred fifty
(150) days) if the Alleged Party prepares and provides to the Alleging Party a reasonable written plan for curing such breach and uses Commercially Reasonable Efforts to cure such breach in accordance with such written plan. In the event
such breach is not cured within such ninety (90) or one hundred fifty (150) day period, as applicable, this Agreement or portion thereof, as applicable, may be terminated immediately by the Alleging Party. 

(d)    In the event of a good faith dispute as to the existence or materiality of a breach specified in such notice,
including any good faith dispute as to payments due under this Agreement, and the Alleged Party provides the Alleging Party notice of such dispute within such ninety (90) day period, the cure period will be tolled from the date the Alleged
Party notifies the Alleging Party of such good faith dispute and through the diligent resolution of such dispute in accordance with the applicable provisions of this Agreement (provided that if such dispute relates to payment, the cure period will
only apply with respect to payment of disputed amounts, and not with respect to undisputed amounts). It is understood and agreed that during the pendency of such dispute, all of the terms and conditions of this Agreement will remain in effect and
the Parties will continue to perform all of their respective obligations, and retain their respective rights, hereunder. Termination will become effective, if at all, following a final and conclusive determination pursuant to 17.1(c) of the
Collaboration Agreement (which is incorporated into this Agreement in accordance with Section 17.1) that the Alleged Party committed such material breach and failed to cure the same during the applicable cure period. 

16.6    Termination for IP Challenge. With respect to Co-Funding Products, Section 16.5 of the Collaboration
Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) and all references to Regeneron Target or Regeneron Product therein shall be deemed to refer to the Co-Funding Target and Co-Funding
Product(s) respectively. 
 16.7    Termination for Suspension of Development or Commercialization. If during the
period after the Effective Date, the Lead Party elects to permanently discontinue all Development, Commercialization and Manufacturing (for purposes of Development or 

  
 67 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Commercialization) of all Co-Funding Products Directed to the Co-Funding Target it shall provide written notice to the Participating Party which will automatically be treated as the Lead
Party’s submission of written notice pursuant to Section 16.3 with respect to the Co-Funding Target. 

16.8    Effects of Termination of the Agreement where Regeneron is the Lead Party, except if the Agreement is
Terminated by Intellia pursuant to Section 16.4. 
 (a)    If this Agreement is terminated by either Party
with respect to a Co-Funding Target for which Regeneron is the Lead Party for any reason other than by Intellia pursuant to Section 16.4 then the following provisions of this Section 16.8(a) will apply, subject to
Section 16.8(b): 
 (i)    This Agreement shall terminate in its entirety with respect to such Terminated Co-Funding Target and Terminated Co-Funding Products, including the licenses granted to the Parties under Section 6.1, Section 6.2 and
Section 6.6 and the exclusivity under Section 12.6(b). 
 (ii)    Sections 16.7(c)-(l) of the
Collaboration Agreement are hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) (including all provisions in the Collaboration Agreement that are incorporated by reference into such provisions), except that
(A) references to the Terminated Regeneron Target in such provisions shall be deemed to refer to the Terminated Co-Funding Target and (B) Regeneron’s interest in and to the Converted CFP Inventions shall be included
within the Collaboration Reversion IP thereunder. Intellia may request a transition services agreement or other like agreement to effect such transfer. Within ninety (90) days after Regeneron receives such request, the Parties will use
Commercially Reasonable Efforts to enter into such agreement on commercially reasonable terms to effectuate Sections 16.7(c)-(l) of the Collaboration Agreement, and to the extent Regeneron is Manufacturing the Terminated Co-Funding Product at the
time of termination, requiring Regeneron to use Commercially Reasonable efforts to perform a manufacturing technology transfer to Intellia and providing that Intellia will pay Regeneron for Regeneron’s fully-burdened FTEs and Out-of-Pocket
Costs associated with performing a manufacturing technology transfer. 
 (iii)    Regeneron shall assign to Intellia
all right, title and interest in the Intellia Material Improvements within Co-Funding Product Inventions that solely relates to the Terminated Co-Funding Products. 

(b)    If this Agreement is terminated by Regeneron pursuant to Section 16.5 (Breach), then,
(i) this Agreement shall terminate in its entirety with respect to such Terminated Co-Funding Target, and Terminated Co-Funding Products, including the licenses granted to the Parties under Section 6.1,
Section 6.2 and Section 6.6 and the exclusivity under Section 12.6(b), and (ii) Regeneron may elect (which election shall be made in writing by Regeneron no later than thirty (30) days of
such determination thereof and no later than the effective date of 

  
 68 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
termination of this Agreement) that the Collaboration Agreement (and all the terms and conditions therein) shall be deemed to apply to such Terminated Co-Funding Target and all Terminated
Co-Funding Products that are Directed to such Terminated Co-Funding Target, and upon such election, the Terminated Co-Funding Target shall become a Regeneron Target and all associated Terminated Co-Funding Products shall be deemed to be Regeneron
Products (provided that if Intellia disputes whether such material breach has occurred and notifies Regeneron thereof in writing within sixty (60) days after receipt of Regeneron’s notice, Regeneron shall not have the right to exercise its
remedies under this Section 16.8(b) until such dispute is resolved pursuant to Section 17.1(c) of the Collaboration Agreement (which is incorporated into this Agreement in accordance with Section 17.1), provided
that the scope of such dispute resolution shall be limited to determination of whether a material breach has occurred solely for purposes of Regeneron being able to exercise its rights under this Section 16.8(b) and for no other
purposes). It is understood and agreed by the Parties that Regeneron may only Develop, Manufacture or Commercialize CPs (including Terminated Co-Funding Products) Directed to such Terminated Co-Funding Target by electing this option. If Regeneron
exercises its rights under this Section 16.8(b), Regeneron shall not be entitled to seek any monetary damages against Intellia under a breach of contract or other claim to the extent that such damages arise from or are a result of the
material breach giving rise to Regeneron’s termination right with respect to such Terminated Co-Funding Target (provided that, for clarity, Regeneron shall still be entitled to bring an indemnification claim pursuant to Section 14.1
or seek equitable remedies). 
 16.9    Effects of Termination of the Agreement where Regeneron is the Lead Party if
the Agreement is Terminated by Intellia pursuant to Section 16.4. Without limiting any other legal or equitable remedies that either Party may have, if this Agreement with respect to a Co-Funding Target for which Regeneron is the Lead Party
is terminated by Intellia pursuant to Section 16.4, then this Agreement shall terminate in its entirety with respect to such Terminated Co-Funding Target and Terminated Co-Funding Products, including the licenses granted to the Parties
under Section 6.1, Section 6.2 and Section 6.6 and the exclusivity under Section 12.6(b), and the Collaboration Agreement (and all the terms and conditions therein) shall be deemed to apply to such
Terminated Co-Funding Target and all Terminated Co-Funding Products that are Directed to such Terminated Target, and such Terminated Co-Funding Target shall be considered a Regeneron Target and all Terminated Co-Funding Products shall be deemed to
be Regeneron Products. 
 16.10    Effects of Termination of the Agreement where Intellia is the Lead Party, except
if the Agreement is Terminated by Intellia pursuant to Section 16.3 or Section 16.7 or the Agreement is Terminated by Regeneron pursuant to Section 16.4. If this Agreement with respect to a Co-Funding Target for which
Intellia is the Lead Party is terminated by either Party for any reason other than by Intellia pursuant to Section 16.3 or Section 16.7 or by Regeneron pursuant to Section 16.4 then the provisions of this
Section 16.10 will apply: 
 (a)    This Agreement shall terminate in its entirety, including the licenses
granted under Section 6.3, Section 6.5, and Section 6.6 and the exclusivity under Section 12.6(b). 

  
 69 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    Section 16.12(a) through 16.12(c) shall apply. 

(c)    Intellia shall assign to Regeneron all right, title and interest in the Regeneron Material Improvements within
Co-Funding Product Inventions that solely relates to the Terminated Co-Funding Products, and such Regeneron Material Improvements shall be deemed to be Regeneron Contributed IP for purposes of Section 16.12(c). 

16.11    Effects of Termination of the Agreement where Intellia is the Lead Party if this Agreement is Terminated by
Intellia pursuant to Section 16.3 or Section 16.7. With respect to Intellia Co-Funding Targets and Intellia Co-Funding Products, without limiting any other legal or equitable remedies that either Party may have, if this Agreement is
terminated by Intellia pursuant to Section 16.3 or Section 16.7, then the provisions of this Section 16.11 will apply: 

(a)    This Agreement shall terminate in its entirety, including the licenses granted under Section 6.3,
Section 6.5, and Section 6.6 and the exclusivity under Section 12.6(b), and the Collaboration Agreement (and all the terms and conditions therein) shall be deemed to apply to such Terminated Target and all
Terminated Co-Funding Products, and such Terminated Target shall be deemed to be a Regeneron Target and the Terminated Co-Funding Products shall be deemed to be Regeneron Products and
Section 16.7(d)-(l) of the Collaboration Agreement shall apply mutatis mutandis so that Regeneron may assume development and commercialization of Terminated Co-Funding Products as Regeneron
Products thereunder. Regeneron may request a transition services agreement or other like agreement to effect such transfer. Within [***] days after Intellia receiving such request, the Parties will use Commercially Reasonable Efforts to enter into
such agreement on commercially reasonable terms to effectuate Sections 16.7(d)-(l) of the Collaboration Agreement mutatis mutandis, and to the extent Intellia is Manufacturing the Terminated Co-Funding Product at the time of termination,
requiring Intellia to use Commercially Reasonable efforts to perform a manufacturing technology transfer to Regeneron and providing that Regeneron will pay Intellia for Intellia’s fully-burdened FTEs and Out-of-Pocket Costs associated with
performing a manufacturing technology transfer. 
 (b)    Intellia shall assign to Regeneron all right, title and
interest in the Regeneron Material Improvements within Co-Funding Product Inventions that solely relates to the Terminated Co-Funding Products. 

16.12    Effects of Termination of the Agreement where Intellia is the Lead Party if this Agreement is Terminated by
Regeneron pursuant to Section 16.4. With respect to Intellia Co-Funding Targets and Intellia Co-Funding Products, without limiting any other legal or equitable remedies that either Party may have, if this Agreement is terminated by Regeneron
pursuant to Section 16.4, then the provisions of this Section 16.12 will apply: 
 (a)    This Agreement shall
terminate in its entirety with respect to such Terminated Co-Funding Target and all Terminated Co-Funding Products Directed to such Terminated Target, including the licenses granted under Section 6.3, Section 6.5, and
Section 6.6 and the exclusivity under Section 12.6(b). 

  
 70 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    If Regeneron has paid at least [***] in Development Costs for
such Terminated Co-Funding Products, all such Terminated Co-Funding Products shall be subject to the payment by Intellia to Regeneron of royalties on Net Sales of such Terminated Co-Funding Products at the rate set forth in the table below based on
the stage of the most advanced Terminated Co-Funding Product Directed to the applicable Terminated Co-Funding Target and Regeneron’s Co-Funding Percentage, in each case, as of the effective date of termination with respect to such Terminated
Co-Funding Target and Section 16.7(c)(v) of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) (including all provisions in the Collaboration Agreement that are
incorporated by reference into such provisions), except that references to the Reversion Product in such provisions shall be deemed to refer to the Terminated Co-Funding Product and the proviso in the last sentence of Section 16.7(c)(v) of
the Collaboration Agreement shall also apply in the event that no employee or agent of Regeneron is an inventor, either sole or joint, on at least one Patent licensed to Intellia with a Valid Claim that covers the Terminated Co-Funding Product, but
in no event shall the royalties be less than the royalties in the table below in the column under the heading “Royalty Rate if Regeneron’s Co-Funding Percentage is [***]. 

 

									
	 Stage
	  	Royalty Rate if
Regeneron’s Co-
Funding Percentage
is [***]	 	  	Royalty Rate if
Regeneron’s Co-
Funding Percentage
is [***]	 
	 The Lead Party has commenced [***]
	  	 	[***	] 	  	 	[***	] 
	 The first patient has been dosed in a [***]
	  	 	[***	] 	  	 	[***	] 
	 The first patient has been dosed in a [***]
	  	 	[***	] 	  	 	[***	] 
	 Anytime following the presentation of [***] to the JDC [***]
	  	 	[***	] 	  	 	[***	] 

 (c)    Effective upon the effective date of termination, Regeneron shall grant, and
hereby grants, to Intellia a perpetual, irrevocable, worldwide, sublicensable through multiple tiers (in accordance with Section 7.2(c) of the Collaboration Agreement applied mutatis mutandis), non-exclusive license under the Regeneron
Contributed IP that as of the date of notice of termination has been actually incorporated into or is otherwise necessary for the use or manufacture of any Terminated Co-Funding Product to use, practice and otherwise exploit such Regeneron
Contributed IP to research, develop, make, have made, use, sell, offer for sale and import Terminated Co-Funding Products for any and all uses in the Field. 

(d)    Intellia shall assign to Regeneron all right, title and interest in the Regeneron Material Improvements within
Co-Funding Product Inventions that solely relates to the Terminated Co-Funding Products, and such Regeneron Material Improvements shall be deemed to be Regeneron Contributed IP for purposes of Section 16.12(c). 

  
 71 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 16.13    Participating Party’s Remedies in lieu of
Termination. 
 (a)    In the event that the Participating Party notifies the Lead Party in writing that Lead Party
has materially breached this Agreement such that the Participating Party would have a right of termination pursuant to Section 16.5 as a result of such material breach (including the application of Section 16.5(b)) (provided that if
the Lead Party disputes whether such material breach has occurred and notifies the Participating Party thereof in writing within sixty (60) days after receipt of the Participating Party’s notice, the Participating Party shall not
have the right to exercise its remedies under this Section 16.13 until such dispute is resolved pursuant to Section 17.1(b) of the Collaboration Agreement (which is incorporated into this Agreement in accordance with
Section 17.1), provided that the scope of such dispute resolution shall be limited to determination of whether a material breach has occurred solely for purposes of the Participating Party being able to exercise its rights under this
Section 16.14 and for no other purposes), then, in lieu of the Participating Party exercising such termination right pursuant to Section 16.5, the Participating Party may elect to enter into a new agreement using the form of
this agreement with the relevant provisions for the Co-Funding Product (which election shall be made in writing by the Participating Party no later than thirty (30) days of such determination thereof); provided, however, that if the
Participating Party so elects to enter into a new agreement, then with respect to such Co-Funding Target for which the Lead Party has materially breached this Agreement and for all CPs that are Directed to such Co-Funding Target, such Co-Funding
Target and such CPs Directed thereto shall become upon written notice delivered to such breaching Lead Party, (i) in the case where Intellia is the breaching Lead Party, a Regeneron Co-Funding Target and Regeneron Co-Funding Products or
(ii) in the case where Regeneron is the breaching Lead Party, Intellia Co-Funding Target and Intellia Co-Funding Products, as applicable, and it shall be treated as if the breaching Lead Party had terminated this Agreement pursuant to
Section 16.3 and Section 16.11 or Section 16.8(a) (as applicable) shall apply mutatis mutandis and the Participating Party making such election to so enter into a new agreement shall from and after such
date be the Lead Party and the breaching Lead Party shall thereafter be the Participating Party with respect to such Co-Funding Target and all CPs Directed to such Co-Funding Target. In connection with such changing roles of the Lead Party and
Participating Party in the new agreement, the Parties agree that over a reasonable period of time, not to exceed [***] months to transfer all rights, obligations, commitments and operations between the Parties to reflect the change in the Lead
Party. The former Lead Party shall, as promptly as reasonably practicable, transfer all Patent prosecution and maintenance responsibilities for Co-Funding Product Inventions to the former Participating Party, including transferring all files related
to the prosecution and maintenance of such Patents to the former Participating Party and at the request of the former Participating Party, make appropriate personnel available to the former Participating Party to answer such reasonable questions as
the former Participating Party may have in connection with the prosecution and maintenance of such Patents. In connection with such transfer, either Party may request that the other Party enter into a transition services agreement or other like
agreement to effect such transfer. Within ninety (90) days after receiving such request, the Parties will use Commercially Reasonable Efforts to enter into such agreement to effect such transfer on commercially reasonable terms,
including, if requested by the former Participating Party, and to the extent the former Lead Party is Manufacturing the Co-Funding Product at the time of changing of the roles of the Parties, 

  
 72 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
requiring the former Lead Party to use Commercially Reasonable efforts to perform a manufacturing technology transfer to the former Participating Party and providing that the former Participating
Party will pay the former Lead Party for the former Lead Party’s fully-burdened FTEs and Out-of-Pocket Costs associated with performing a manufacturing technology transfer. 

(b)    Solely if clause (a) above applies, the Participating Party making such election to continue in accordance
therewith shall not be entitled to seek any monetary damages against the breaching Lead Party under a breach of contract or other claim to the extent that such damages arise from or are a result of the material breach giving rise to such
Participating Party’s termination right (provided that, for clarity, such Participating Party shall still be entitled to bring an indemnification claim pursuant to Section 14.1 or seek equitable remedies). 

16.14    Change of Control of the Participating Party. In the event of a Change of Control of the Participating
Party during the Term, the Participating Party shall deliver to the Lead Party written notice of the closing of such transaction within ten (10) days following such closing. If, as of the closing of such Change of Control of the Participating Party,
the Lead Party or any of its Affiliates is in litigation that is material to the Lead Party or its Affiliate, or has initiated or received notice of a claim, action, suit, or proceeding, or has sent or received a demand letter, that is reasonably
likely to result in litigation that is material to the Lead Party or its Affiliate, with the Third Party or its Affiliate (other than a Party or a Party’s Affiliates immediately prior to the closing of such Change of Control) involved in such
Change of Control of the Participating Party (the “Subject Litigation”), then [***]: 
 [***]. 

For clarity, if, as of the closing of such Change of Control of the Participating Party, there is no [***]. 

16.15    Survival of Obligations. Expiration or termination of this Agreement shall not relieve the Parties of any
obligation accruing prior to such expiration or termination. Any expiration or termination of this Agreement shall be without prejudice to the rights of either Party against the other accrued or accruing under this Agreement prior to expiration or
termination. Except for the following provisions (which shall survive expiration or termination of this Agreement), upon expiration or termination of this Agreement, the rights granted to the Parties hereunder and obligations of the Parties
hereunder shall terminate, and this Agreement shall cease to be of further force or effect: (I) Section 2.2(a), Section 2.2(b), Sections 5.3 and 5.4 (until the Development and Commercialization of the Co-Funding Products
have been transferred to the Party that will continue to be responsible for such Development and Commercialization after termination of this Agreement), Section 7.1, Section 7.2(a), Section 7.2(c),
Section 7.6 (for the period set forth therein), Section 7.7, Section 7.12(a) (only with respect to the incorporation of Section 7.12 of the Collaboration Agreement), Section 9.4 and
Section 9.6 (with respect to the final Quarter of the Term), Section 9.8, Section 9.9, Section 9.10, Section 9.11, Section 10.1, Section 13.1,
Section 13.2, Section 13.3, [Section 16.8, Section 16.9, 

  
 73 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Section 16.10, Section 16.11, Section 16.12,]4 Section 16.15, and Section 16.16; (II) Sections
10.2, 10.3, 10.4, 10.6, 10.7, 10.8, and 10.9 solely with respect to Intellectual Property covered by this Agreement that is jointly owned by the Parties pursuant to the terms of this Agreement; and (III) Article 1 (to the extent
necessary to give effect to the other surviving provisions), Article 11, Article 14, Article 15, and Article 17. In addition, the other applicable provisions of Article 9 will survive such expiration or termination of this Agreement to the extent
required to make final reimbursements, reconciliations or other payments incurred or accrued prior to the date of termination or expiration or after such termination or expiration with respect to Section 16.7 (including any milestone
payments and royalties that become due as a result of Section 16.7(i)). For any surviving provisions requiring action or decision by a Committee or an Executive Officer, each Party will appoint representatives to act as its Committee
members or Executive Officer, as applicable. 
 16.16    Return of Confidential Information. Confidential
Information disclosed by the Disclosing Party, including permitted copies, shall remain the property of the Disclosing Party. Upon the expiration or termination of this Agreement, and [***], the Receiving Party shall promptly return to the
Disclosing Party or, at the Disclosing Party’s request, destroy, all documents or other tangible materials representing the Disclosing Party’s Confidential Information (or any designated portion thereof) pertaining to the expired or
terminated subject matter and, if expressly requested in writing by the Disclosing Party, provide the Disclosing Party with written certification of such destruction within [***] days; provided, that one (1) copy may be maintained in the
confidential files of the Receiving Party for the purpose of complying with the terms of this Agreement; further provided that the Receiving Party may retain the Disclosing Party’s Confidential Information that is necessary or useful for the
practice of any license from the Disclosing Party to the Receiving Party that survives expiration or termination, as applicable. [***]. 

ARTICLE 17 

MISCELLANEOUS 

17.1    Governing Law; Dispute Resolution; Submission to Jurisdiction. Section 17.1 of the Collaboration
Agreement is hereby incorporated by reference into this Agreement, except that the reference in Section 17.1(b) of the Collaboration Agreement to Section 16.9 shall be deemed to refer to Section 16.14 of this
Agreement. For clarity, Section 17.1(b) of the Collaboration Agreement shall apply to unresolved Financial Disputes. 

17.2    Waiver. Section 17.2 of the Collaboration Agreement is hereby incorporated by reference into this
Agreement. 
 17.3    Notices. Section 17.3 (including Schedule 17.3) of the Collaboration Agreement is
hereby incorporated by reference into this Agreement. 
  
  

	4 	 NTD: To be updated in each Co-Co Agreement, as applicable.

  
 74 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 17.4    Entire Agreement. The first sentence of Section 17.4
of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 17.5    Amendments.
Section 17.5 of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

17.6    Interpretation. Section 17.6 of the Collaboration Agreement is hereby incorporated by reference
into this Agreement. 
 17.7    Construction. Section 17.7 of the Collaboration Agreement is hereby incorporated
by reference into this Agreement. 
 17.8    Severability. Section 17.8 of the Collaboration Agreement is
hereby incorporated by reference into this Agreement. 
 17.9    Assignment. Section 17.9 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 17.10    Successors and
Assigns. Section 17.10 of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

17.11    Counterparts. Section 17.11 of the Collaboration Agreement is hereby incorporated by reference into
this Agreement. 
 17.12    Third Party Beneficiaries. Section 17.12 of the Collaboration Agreement is hereby
incorporated by reference into this Agreement. 
 17.13    Relationship of the Parties. Section 17.13 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 17.14    Limitation of
Damages. Section 17.14 of the Collaboration Agreement is hereby incorporated by reference into this Agreement. 

17.15    Injunctive or Other Equity Relief. Section 17.15 of the Collaboration Agreement is hereby
incorporated by reference into this Agreement. 
 17.16    Non-Exclusive Remedies. Section 17.16 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement. 
 [Remainder of page intentionally left blank; signature
page follows] 

  
 75 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 IN WITNESS WHEREOF, Regeneron and Intellia have caused this Agreement to be executed by their
duly authorized representatives as of the day and year first above written. 
  

			
	REGENERON PHARMACEUTICALS, INC.
		
	By	 	
                     
                                         
           

		 	Name:
		 	Title:
	
	INTELLIA THERAPEUTICS, INC.
		
	By	 	  

		 	Name:
		 	Title:

  
 [Signature Page to
[                    ] Co-Development and Co-Promotion Agreement] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 Schedule 1.18 

Co-Funding Target 

  
 Schedule 1.18 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 Schedule 1.102 

Manufacturing Cost 
 Manufacturing Cost as used in this
Agreement shall be determined as provided in this Schedule 1.102. 
 “Manufacturing Cost” means the [***]. 

 

	(a)	 “Direct Costs” equals the sum of the following: 

 

	 	(i)	 [***]. 

  

	 	(ii)	 [***]. 

  

	 	(iii)	 [***]. 

  

	 	(iv)	 [***]. 

  

	 	(v)	 [***]. 

  

	(b)	 “Indirect Costs” equals the sum of the following: 

 

	 	(i)	 [***]. 

  

	 	(ii)	 [***]. 

[***]. 

  
 Schedule 1.102 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 Schedule 9.2 

Aggregate [***] True-Up 

General Provisions: 
 [***] 

At the end of each applicable [***], with respect to any Co-Funding Product, the Lead Party will calculate the [***]
Development True-Up and/or [***] Profit True-Up (each, as defined below) for such Co-Funding Product pursuant to Section 9.2
and Section 9.4 which are the net payment(s) that each Party shall be required to make to the other Party as described in this Schedule 9.2. 

The “Aggregate [***] True-Up” is the sum of (i) the [***] Development True-Up for Co-Funding Product A, (ii) the [***] True-Up for Co-Funding Product B, (iii) the [***]
True-Up for Co-Funding Product A, and (iv) the [***] Profit True-Up for Co-Funding
Product B. For the purposes of this example, the Aggregate [***] True-Up assumed that there were two Co-Funding Products Directed to a
Co-Funding Target. For Clarity, the Aggregate [***] True-Up will include a Quarterly Development True-Up and a Quarterly Profit True-Up for each Co-Funding Product. In the event that under and in accordance with the terms of a supply agreement between the Parties, a Participating Party has incurred
Commercial Supply Costs for a Co-Funding Product, the Participating Party will be reimbursed for such costs outside of this Quarterly True-Up and in accordance with the
terms of a supply agreement between the Parties for such Co-Funding Product. 
 In the event that the Aggregate
[***] True-Up is an amount greater than zero, such amount shall be payable by the Participating Party to the Lead Party. If the amount of the Aggregate [***] True-up is
less than zero, then the absolute value of such amount will be payable by the Lead Party to Participating Party. Any payment due to a Party shall be made in accordance with the terms set forth in Article 9. 

Definitions: 
 As used in this Agreement, the following
terms shall have the following meanings: 
 “Total Development Costs” means the aggregate of Development Costs incurred by both Regeneron
and Intellia for a Co-Funding Product. 
 “[***] Development
True-Up” means, in the event that there are Total Development Costs for a Co-Funding Product for a [***], the Development Costs incurred by the Lead Party for a
Co-Funding Product minus the product of (i) Total Development Costs and (ii) the applicable Lead Party Co-Funding Percentage for such Quarter. 

  
 Schedule 9.2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 “Profits” in a [***] means for a particular
Co-Funding Product the Co-Funding Product Net Sales recorded by the Lead Party worldwide in the Quarter less the sum of (a) Cost of Goods incurred by the Lead Party
world-wide in the Quarter, (b) Shared Commercial Expenses incurred by both Parties in the [***], and (c) Other Shared Expenses incurred by both Parties in the [***]. 

“Lead Party [***] Expenses” is the sum of the amounts in (a), (b) and (c) in the definition of Profits that are incurred by the
Lead Party in a [***] for a Co-Funding Product. 
 “Participating Party [***] Expenses” shall be
the sum of the amounts in (a), (b) and (c) in the definition of Profits that are incurred by the Participating Party in a [***] for a Co-Funding Product. 

“Profit Split” for a Co-Funding Product means the product of (i) Profits in a [***] worldwide,
(ii) the Participating Party Co-Funding Percentage, and (iii) -1. 

“[***] Profit True-Up” for a Co-Funding Product means
(i) the Profit Split minus (ii) Participating Party Quarterly Expenses. 
 Examples 

In all of the examples below, it is assumed that the Participating Party Co-Funding Percentage is [***] for a given
Co-Funding Product: 
  

	 	•	 	 [***] Development True-Up for
Co-Funding Product A Example: 

  

													
	 	  	Aggregate	 	  	Lead Party	 	  	Participating
Party	 
	 Development Costs
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 Total Development Costs
	  	 	[***	] 	  				  			

 [***] Development True-Up = [***] 

[***] 
 In this example, [***] would be included in the
Aggregate [***] True-Up for Co-Funding Product A. 

  
 Schedule 9.2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

	 	•	 	 [***] Development True-Up for
Co-Funding Product B Example: 

  

													
	 	  	Aggregate	 	  	Lead Party	 	  	Participating
Party	 
	 Development Costs
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 Total Development Costs
	  	 	[***	] 	  				  			
				
	[***] Development True-Up = [***]	  				  				  			
				
	[***]	  				  				  			

 In this example, [***] would be included in the Aggregate [***] True-Up for Co-Funding Product B. 
  

	 	•	 	 [***] Profit True-Up Examples: 

 

	 	•	 	 Co-Funding Product A: Calculation of the Profit Split in a
Quarter: 

  

													
	 	  	Aggregate	 	  	Lead Party	 	  	Participating
Party	 
	 Co-Funding Product Net Sales
	  	 	[***	] 	  	 	[***	] 	  			
				
	 (-) Cost of Goods Sold
	  	 	[***	] 	  	 	[***	] 	  			
				
	 (-) Shared Commercial Expenses
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 (-) Other Shared Expenses
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 Profits
	  	 	[***	] 	  				  			
				
	Profit Split = [***].	  				  				  			
				
	[***] Profit True-Up = [***]	  				  				  			
	[***]	  				  				  			

 In this example, [***] would be included in the Aggregate [***] True-Up for Co-Funding Product A. 

  
 Schedule 9.2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

	 	•	 	 Co-Funding Product B Example: Calculation of the Profit Split in a
Quarter in which there are no Co-Funding Product Net Sales: 

  

													
	 	  	Aggregate	 	  	Lead Party	 	  	Participating
Party	 
	 Co-Funding Product Net Sales
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 (-) Cost of Goods Sold
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 (-) Shared Commercial Expenses
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 (-) Other Shared Expenses
	  	 	[***	] 	  	 	[***	] 	  	 	[***	] 
				
	 Profits
	  	 	[***	] 	  				  			
				
	Profit Split = [***].	  				  				  			
				
	Quarterly Profit True-Up = [***]	  				  				  			
	[***]	  				  				  			

 In this example, [***] would be included in the Aggregate [***] True-Up for Co-Funding Product B. 
  

	 	•	 	 Aggregate [***] True-Up Example: 

 

			
	[***] Development True-Up for Co-Funding Product A	  	[***]
	[***] Development True-Up for Co-Funding Product B	  	[***]
	[***] Profit True-Up for Co-Funding Product A	  	[***]
	[***] Profit True-Up for Co-Funding Product B [***]	  	[***]
		
	Aggregate [***] True-Up	  	[***]

 In this example, [***] would be payable by the Lead Party to the Participating Party in accordance with the terms of Article 9
and this Schedule 9.2. 
 Combination Products. 
 In the
event a Co-Funding Product is a Combination Product [***]. 
 In the event a
Co-Funding Product is a Combination Product [***]. 

  
 Schedule 9.2 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 ANNEX 1 

Provisions Specific to Categories of Products 

This Annex is divided into four (4) sub-annexes. The Sections set forth in
sub-annex (A), (B), (C) or (D) shall be inserted into the corresponding Sections of this Agreement prior to execution for the applicable Co-Funding Target,
depending on whether the Co-Funding Target is: 
 (A) Regeneron
Co-Funding Target where a Regeneron Target is the Co-Funding Target; 

(B) Regeneron Co-Funding Target where an Intellia Liver Target is the
Co-Funding Target; 
 (C) Intellia Co-Funding Target;
or 
 (D) TTR. 
 For clarity, for
each Co-Funding Target, only one of the four (4) above sub-annexes shall apply. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 SUB-ANNEX 1(A): 

Regeneron Co-Funding Target where a Regeneron Target is the
Co-Funding Target 
 1.17 “Co-Funding
Product” shall mean each Regeneron Co-Funding Product that is Directed to the Co-Funding Target. 

1.27 “Converted CFP Inventions” means the Co-Funding Product Inventions which become
Other Co-Funding Product Inventions by operation of Section 10.1(a)(iii) upon termination of this Agreement. 

1.38 
 4.
    [Intentionally Omitted] 
 1.44 “Exercised Option” shall mean the Intellia Option, exercised by
Intellia under Section 5.2(c) of the Collaboration Agreement, in accordance with the Collaboration Agreement, for the Target set forth on Schedule 1.44 of this Agreement. 

1.89 “IP Term” shall mean that period, during the Term, commencing on the Effective Date and continuing for [***] to such Co-Funding Target. 
 1.94 “Lead Party” shall mean Regeneron. 

1.115 “Participating Party” shall mean Intellia. 

2.2(b)    There are instances where certain provisions of this Agreement only apply to Regeneron Co-Funding Products and not to Intellia Co-Funding Products and where such provisions were already set forth in the Collaboration Agreement with respect to Regeneron Products.
In such cases, this Agreement incorporates by reference the applicable terms of the Collaboration Agreement, except that references to Regeneron Products in the applicable terms of the Collaboration Agreement shall be deemed to refer to Regeneron Co-Funding Products and references to the Collaboration Agreement in the applicable terms of the Collaboration Agreement shall be deemed to refer to this Agreement. 

2.4(b)(viii)    [Intentionally Omitted] 

2.9    [Intentionally Omitted] 

3.1    Development of Co-Funding Products. Subject to the terms of this
Agreement, the Lead Party shall undertake, and in accordance with Section 3.2 with respect to a Regeneron Co-Funding Product, the Parties shall jointly undertake Development activities with respect to Co-Funding Products unless otherwise mutually agreed to in the Global Development Plan, and such Development activities shall be under the general direction and oversight of the JDC and JSC. [***]. Except as set
forth in Section 3.2 with respect to a Regeneron Co-Funding Product 

  
 SUB-ANNEX 1 (A) — 1

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
or otherwise agreed to by the Parties in writing or explicitly set forth in this Agreement, the JSC will assign responsibility for conducting all Development activities for a Co-Funding Product to the Lead Party. For clarity, with respect to a given Regeneron Product that constitutes a Co-Funding Product under this Agreement, the diligence
obligations of Regeneron to develop and commercialize such Regeneron Product in Sections 4.4(d) and 6.1(a) of the Collaboration Agreement shall be superseded (from and after the Effective Date of this Agreement) by Regeneron’s diligence
obligations as a Lead Party for such Co-Funding Product under this Agreement, [***]. 

3.2    Existing Product R&D Programs and Associated Product R&D Plans. 

(a)    With respect to a Co-Funding Product that constituted a Regeneron Product
immediately prior the Effective Date of this Agreement, if a Product R&D Program and an associated Product R&D Plan existed immediately prior to Option Exercise Date for a Regeneron Product that becomes a Regeneron Co-Funding Product on account of Intellia’s exercise of the Exercised Option, to the extent applicable, such Product R&D Program and associated Product R&D Plan shall be incorporated and made a part of
the Global Development Plan for the relevant Regeneron Co-Funding Product and Section 4.3(b), 4.4(a), 4.4(d), 4.4(e) and 4.6(b) of the Collaboration Agreement are hereby incorporated by reference into
this Agreement in accordance with Section 2.2(b). [***]. 
 (b)    The Participating Party may terminate this
Agreement with respect to the Co-Funding Target and all Co-Funding Products Directed to such Co-Funding Target any time within
three (3) months after the Effective Date. In such three (3) month period, the Participating Party shall have the right to review the Global Development Plan and Global Development Budget prepared pursuant to Sections 3.6 and 3.7, and may
terminate this Agreement in accordance with Section 16.4(a)(ii). Upon such termination, the Regeneron Option exercised in conjunction with this Agreement shall no longer constitute one of the Regeneron Options exercised by Regeneron under
Section 5.1 of the Collaboration Agreement. For clarity, each Party shall be responsible for the costs incurred under this Agreement through the date of termination in accordance with their respective
Co-Funding Percentages. 
 3.3    [Intentionally Omitted] 

3.4    [Intentionally Omitted] 

3.5    [Intentionally Omitted] 

3.6(b)    [Intentionally Omitted] 

3.8    Intellia Technical Support Related to the Development of Regeneron
Co-Funding Products. With respect to Regeneron Co-Funding Products, Section 6.1(b) of the Collaboration Agreement is hereby incorporated by reference into this
Agreement in accordance with Section 2.2(b). Costs incurred by Intellia in the conduct of activities conducted pursuant to this Section 3.8 shall be shared by the Parties in accordance with their respective
Co-Funding Percentages and treated as Other Shared Expenses. 

  
 SUB-ANNEX 1 (A) — 2

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 5.1(b)(ii)    Regeneron shall be responsible for all communications with
Regulatory Authorities in connection with Regeneron Co-Funding Products, with Intellia’s support and input (which may include preparation by Intellia of [***]), which support and input shall be provided
by Intellia upon reasonable request by Regeneron; provided, that, in connection with such support prior to commencing such support, [***]. Costs incurred by Intellia in the conduct of the assistance contemplated by the previous sentence shall
constitute Development Costs and shall be shared by the Parties in accordance with their respective Co-Funding Percentages. 

5.1(c)    [Intentionally Omitted] 

6.3     [Intentionally Omitted] 

6.4    In the event that either (a) the use, practice or exercise by Regeneron (or any of its Affiliates or
sublicensees) of any Intellia Intellectual Property in accordance with the licenses expressly granted to Regeneron in accordance with this Agreement or (b) the research, development, making, having made, use, sale, offering for sale, or
import by Regeneron (or any of its Affiliates or sublicensees) of a Regeneron Co-Funding Product [***] for use in the Field, pursuant to, and in accordance with, this Agreement, would infringe or misappropriate any Patent Right which is first
Controlled by Intellia or its Affiliates after the IP Term and which is not covered by the license grant in Section 6.1, Intellia shall grant, and hereby grants, to Regeneron a non-exclusive, royalty-free, worldwide, sublicensable in
multiple tiers (in accordance with Section 7.2(c) license under such Patent Right solely as necessary to (i) use, practice and exercise the Intellia Intellectual Property in accordance with the licenses expressly granted to
Regeneron in accordance with this Agreement and (ii) research, develop, make, have made, use, sale, offer for sale, and import Regeneron Co-Funding Products for use in the Field in accordance with this Agreement, and solely for such
purpose. The foregoing license under this Section 6.4 shall automatically terminate on a Regeneron Co-Funding Target-by-Regeneron Co-Funding Target basis (and with respect to all Regeneron Co-Funding Products Directed to such Co-Funding
Target) simultaneous with the termination of the license under Section 6.1 with respect to such Regeneron Co-Funding Product. [***]. 

7.2(c)(ii)    [***]. 

7.3(d)      [***]. 

7.4(b)    With respect to the Regeneron Co-Funding Products, the second sentence
of Section 7.4(a) and Section 7.4(b) of the Collaboration Agreement are hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) and any payments made by Regeneron in accordance Section 7.4(a) of the
Collaboration Agreement shall be considered Third Party License Payments and shall be treated in accordance with Section 7.5. 

  
 SUB-ANNEX 1 (A) — 3

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 7.11    Ongoing Technology Update and Transfer Obligations. With
respect to the Co-Funding Products, Section 7.11 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). Costs incurred by Intellia in the
performance of activities conducted pursuant to clause (c) of Section 7.11 of the Collaboration Agreement shall be shared by the Parties in accordance with their respective Co-Funding Percentages and treated as Other Shared Expenses. 

7.12    [Intentionally Omitted] 

8.1    Non-GMP Manufacture of Co-Funding Products. With respect to the
Regeneron Co-Funding Products, Section 8.1 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

8.2    Section 8.2 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance
with Section 2.2(b). [***]. 
 8.3(b)    With respect to a Regeneron
Co-Funding Product, the second and third sentences of Section 8.3 of the Collaboration Agreement are hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

8.4    Manufacturing Process Technology Transfer. With respect to the Regeneron
Co-Funding Products, [***]. 
 9.1    Reimbursement for Past Expenses.
Within [***] after the Effective Date of this Agreement, the Party that exercised the Exercised Option, as applicable, shall pay to the other Party an amount equal to [***]. 

9.13    Effect of Amendment of the UC Technology License. [***]. 

9.14    Treatment of Certain Payments for Sharing of Profits and Development Costs for Regeneron Co-Funding Products. With respect to Regeneron Co-Funding Products [***]. 

10.12(b)    In the event that Regeneron is not fully able to enjoy any rights granted Regeneron under this Article 10 as a
result of the provisions of this Section 10.12, then Intellia shall use diligent efforts to afford and allow Regeneron to exercise and enjoy such rights to the maximum extent possible under the applicable Third Party agreement (but Intellia
shall not be required to amend or otherwise modify any such agreement, or make any payments to such Third Party), [***]. 

12.2    Additional Representations, Warranties and Covenants of the Parties. 

(a)    [Intentionally Omitted] 

(b)     

  
 SUB-ANNEX 1 (A) — 4

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (i)    Except as set forth on Schedule 12.2(b)(i), Regeneron
additionally hereby represents and warrants to Intellia, as modified by any exceptions to such representations and warranties applied mutatis mutandis to the subject matter of the Intellia Option as set forth in the Option Package for the Co-Funding Target and Co-Funding Products, that as of the Option Exercise Date: 

(1)    There are no claims, judgments or settlements against or owed by Regeneron (or any of its Affiliates) and no
pending or, to Regeneron’s knowledge, threatened (in writing) claims or litigation, in each case, to which Regeneron (or its Affiliates,) is a party or threatened (in writing) party relating to the Regeneron Contributed IP or otherwise
challenging Regeneron’s ownership or control of the Regeneron Contributed IP, in each case, with respect to the foregoing, solely with respect to the Co-Funding Products (such Regeneron Contributed IP,
the “CFP Regeneron Contributed IP”); 
 (2)    Schedule 12.2(b)(i)(2)(A) sets forth a true, correct and
complete list of Patent Rights within the CFP Regeneron Contributed IP existing as of the Option Exercise Date, in each case, with respect to the foregoing, solely with respect to the Co-Funding Products (the
“CFP Regeneron Patent Rights”). To the knowledge of the individuals listed on Schedule 12.2(b)(i)(2)(B) (without any duty to inquire), the CFP Regeneron Patent Rights exist and are not invalid or unenforceable, in whole or in part;

 (3)    Regeneron solely owns all CFP Regeneron Contributed IP; and Regeneron Controls all of the CFP Regeneron
Patent Rights; 
 (4)    Schedule 12.2(b)(i)(4) sets forth a true, correct and complete list of all agreements pursuant
to which Regeneron has in-licensed, or otherwise obtained rights to, CFP Regeneron Contributed IP (the “Regeneron Agreements”); 

(5)    Regeneron is not aware of any claim made in writing against it asserting the invalidity, misuse,
unregisterability, unenforceability or non-infringement of any of the CFP Regeneron Patent Rights; 

(6)    Neither Regeneron nor any of its Affiliates is or has been a party to any agreement with the U.S. federal
government or an agency thereof pursuant to which the U.S. federal government or such agency provided funding for the development of the CFP Regeneron Contributed IP; 

(7)    Neither Regeneron nor any of its Affiliates has received any written notification from a Third Party that the use
of any CFP Regeneron Contributed IP infringes or misappropriates the Patent Rights or Know-How owned or controlled by such Third Party; 

  
 SUB-ANNEX 1 (A) — 5

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (8)    The CFP Regeneron Contributed IP is not subject to any liens or
encumbrances or other grants in favor of any Third Party that conflicts with the rights or licenses granted to Intellia under this Agreement; 

(9)    To the knowledge of the individuals listed on Schedule 12.2(b)(i)(9) [***], the conception, discovery,
development or reduction to practice of CFP Regeneron Contributed IP has not constituted or involved misappropriation of Intellectual Property or rights of any Person; and 

(10)    Regeneron has a right and license to use the Patent Rights that are licensed to Regeneron (directly or
indirectly) under each of the Regeneron Agreements on a worldwide basis, and Regeneron is granting a sublicense to such Patent Rights to Intellia for use on a worldwide basis, in each case, with respect to the foregoing, solely with respect to the Co-Funding Products. 
 (ii)    With respect to each of the Regeneron Agreements (as
may be amended from time to time), Regeneron hereby represents and warrants as of the Effective Date, and covenants during the Term, to Intellia that: 

(1)    Sections 12.4(a)(i) and (ii) of the Collaboration Agreement (as applied mutatis mutandis) are hereby
incorporated by reference into this Agreement in accordance with Section 2.2(b), in each case, with respect to the foregoing, solely with respect to the Co-Funding Products; and 

(2)    Regeneron shall fulfill all of its material obligations, including its payment obligations, under the Regeneron
Agreements, with respect to the Co-Funding Products. 
 12.3(d)    
Covenants. 
 (i)    With respect to the Regeneron Co-Funding Products
under this Agreement, [***]. 
 (ii)    Section 12.4 of the Collaboration Agreement is hereby incorporated by reference
into this Agreement in accordance with Section 2.2(b). 

  
 SUB-ANNEX 1 (A) — 6

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 SUB-ANNEX 1(B): 

Regeneron Co-Funding Target where an Intellia Liver Target is the
Co-Funding Target 

1.17    “Co-Funding Product” shall mean each Regeneron Co-Funding Product that is Directed to the Co-Funding Target. 

1.27    “Converted CFP Inventions” means the Co-Funding Product
Inventions which become Other Co-Funding Product Inventions by operation of Section 10.1(a)(iii) upon termination of this Agreement. 

1.38     

4.    [Intentionally Omitted] 

1.44    “Exercised Option” shall mean the Regeneron Option exercised by Regeneron under
Section 5.1(e) of the Collaboration Agreement, in each case, in accordance with the Collaboration Agreement, for the Target set forth on Schedule 1.44 of this Agreement. 

1.89    “IP Term” shall mean that period, during the Term, commencing on the Effective Date and
continuing for [***] such Co-Funding Target. 
 1.94    “Lead
Party” shall mean Regeneron. 
 1.115    “Participating Party” shall mean Intellia. 

2.2(b)    There are instances where certain provisions of this Agreement only apply to Regeneron Co-Funding Products and not to Intellia Co-Funding Products and where such provisions were already set forth in the Collaboration Agreement with respect to Regeneron Products.
In such cases, this Agreement incorporates by reference the applicable terms of the Collaboration Agreement, except that references to Regeneron Products in the applicable terms of the Collaboration Agreement shall be deemed to refer to Regeneron Co-Funding Products and references to the Collaboration Agreement in the applicable terms of the Collaboration Agreement shall be deemed to refer to this Agreement. 

2.4(b)(viii)    [Intentionally Omitted] 

2.9    [Intentionally Omitted] 

3.1    Development of Co-Funding Products. Subject to the terms of this
Agreement, the Lead Party shall undertake, and in accordance with Section 3.2 with respect to a Regeneron Co-Funding Product the Parties shall jointly undertake, Development activities with respect to Co-Funding Products unless otherwise mutually agreed to in the Global Development Plan, and such Development activities shall be under the general direction and oversight of the JDC and JSC. [***]. Except as set
forth in Section 3.2 with respect to a Regeneron Co-Funding Product 

  
 SUB-ANNEX 1 (B) — 1

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
or otherwise agreed to by the Parties in writing or explicitly set forth in this Agreement, the JSC will assign responsibility for conducting all Development activities for a Co-Funding Product to the Lead Party. For clarity, with respect to a given Regeneron Product that constitutes a Co-Funding Product under this Agreement, the diligence
obligations of Regeneron to develop and commercialize such Regeneron Product in Sections 4.4(d) and 6.1(a) of the Collaboration Agreement shall be superseded (from and after the Effective Date of this Agreement) by Regeneron’s diligence
obligations as a Lead Party for such Co-Funding Product under this Agreement, [***]. 

3.2    Existing Product R&D Programs and Associated Product R&D Plans. 

(a)    [Intentionally Omitted] 

(b)    The Participating Party may terminate this Agreement with respect to the
Co-Funding Target and all Co-Funding Products Directed to such Co-Funding Target any time within three (3) months after the
Effective Date. In such three (3) month period, the Participating Party shall have the right to review the Global Development Plan and Global Development Budget prepared pursuant to Sections 3.6 and 3.7, and may terminate this Agreement in
accordance with Section 16.4(a)(ii). Upon such termination, the Regeneron Option exercised in conjunction with this Agreement shall no longer constitute one of the Regeneron Options exercised by Regeneron under Section 5.1 of the
Collaboration Agreement. For clarity, each Party shall be responsible for the costs incurred under this Agreement through the date of termination in accordance with their respective Co-Funding Percentages.

 3.3    New Product R&D Programs and Associated Product R&D Plans. In the event Regeneron exercises the
Exercised Option to an Intellia Liver Target and Regeneron is the Lead Party for such Target, upon Regeneron’s written request, Intellia shall perform certain activities for Regeneron under the Global Development Plan for such Regeneron Co-Funding Product, if Intellia has agreed to perform similar types of activities for Regeneron under a Product R&D Program and an associated Product R&D Plan for a Regeneron Product under the Collaboration
Agreement (e.g., guide RNA and repair template design, optimization, and in vitro validation; in vitro functional assays; and development of non-viral systems for liver delivery; and the generation of CRISPR-Cas Materials and nanoparticle formulations for in-vivo proof of concept studies). [***].  

3.4    Transition of Research and Development Activities for Regeneron
Co-Funding Products that were formerly Intellia Liver Products. If the Co-Funding Target constitutes an Intellia Liver Target for which Regeneron is the Lead Party,
Intellia shall, as promptly as reasonably practicable, [***]. The costs incurred by Intellia in the conduct of transition activities conducted pursuant to this Section 3.4 in accordance with the plan and cost estimate provided by Intellia
pursuant to the previous sentence shall be treated as Development Costs and shared by the Parties in accordance with their respective Co-Funding Percentages. 

  
 SUB-ANNEX 1 (B) — 2

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 3.5    Transition of Patent Prosecution Responsibilities. After
Regeneron’s exercise of the Exercised Option for an Intellia Liver Product Directed to an Intellia Liver Target for which Regeneron is designated as the Lead Party, Intellia shall, as promptly as reasonably practicable, transfer all Patent
prosecution and maintenance responsibilities for Intellia Liver Product Inventions to Regeneron, including transferring all files related to the prosecution and maintenance of such Patents to Regeneron and at the request of Regeneron, make
appropriate personnel available to Regeneron to answer such reasonable questions as Regeneron may have in connection with the prosecution and maintenance of such Patents. 

3.6(b)    [Intentionally Omitted] 

3.8    Intellia Technical Support Related to the Development of Regeneron
Co-Funding Products. With respect to Regeneron Co-Funding Products, Section 6.1(b) of the Collaboration Agreement is hereby incorporated by reference into this
Agreement in accordance with Section 2.2(b). Costs incurred by Intellia in the conduct of activities conducted pursuant to this Section 3.8 shared by the Parties in accordance with their respective
Co-Funding Percentages and shall be treated as Other Shared Expenses. 
 5.1(b)(ii) Regeneron shall
be responsible for all communications with Regulatory Authorities in connection with Regeneron Co-Funding Products, with Intellia’s support and input (which may include preparation by Intellia of [***]),
which support and input shall be provided by Intellia upon reasonable request by Regeneron; provided that, in connection with such support prior to commencing such support, [***]. Costs incurred by Intellia in the conduct of the assistance
contemplated by the previous sentence shall constitute Development Costs and shall be shared by the Parties in accordance with their respective Co-Funding Percentages. 

5.1(c)    With respect to Regeneron Co-Funding Products that were formerly
Intellia Liver Products, Intellia shall license, transfer, provide a letter of reference with respect to, or take other action necessary to make available the relevant Registration Filings and Approvals to and for the benefit of Regeneron, or
otherwise to allow Regeneron to Develop and Commercialize Regeneron Co-Funding Products as set forth in this Agreement. 

6.3     [Intentionally Omitted] 

6.4    In the event that either (a) the use, practice or exercise by Regeneron (or any of its Affiliates or
sublicensees) of any Intellia Intellectual Property in accordance with the licenses expressly granted to Regeneron in accordance with this Agreement or (b) the research, development, making, having made, use, sale, offering for sale, or
import by Regeneron (or any of its Affiliates or sublicensees) of a Regeneron Co-Funding Product [***] for use in the Field, pursuant to, and in accordance with, this Agreement, would infringe or misappropriate any Patent Right which is first
Controlled by Intellia or its Affiliates after the IP Term and which is not covered by the license grant in Section 6.1, Intellia shall grant, and hereby grants, to Regeneron a non-exclusive, royalty-free, worldwide, sublicensable in
multiple tiers (in accordance with Section 7.2(c)) license under such Patent Right solely as necessary to (i) use, 

  
 SUB-ANNEX 1 (B) — 3

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
practice and exercise the Intellia Intellectual Property in accordance with the licenses expressly granted to Regeneron in accordance with this Agreement and (ii) research, develop, make,
have made, use, sale, offer for sale, and import Regeneron Co-Funding Products for use in the Field in accordance with this Agreement, and solely for such purpose. The foregoing license under this Section 6.4 shall automatically
terminate on a Regeneron Co-Funding Target-by-Regeneron Co-Funding Target basis (and with respect to all Regeneron Co-Funding Products Directed to such Co-Funding Target) simultaneous with the termination of
the license under Section 6.1 with respect to such Regeneron Co-Funding Product. [***]. 

7.2(c)(ii)    [***]. 

7.3(d)      [***]. 

7.4(b)    With respect to Regeneron Co-Funding Products, the second sentence of
Section 7.4(a) and Section 7.4(b) of the Collaboration Agreement are hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) and any payments made by Regeneron in accordance Section 7.4(a) of the
Collaboration Agreement shall be considered Third Party License Payments. 
 7.11    Ongoing Technology Update and
Transfer Obligations. With respect to Regeneron Co-Funding Products, Section 7.11 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with
Section 2.2(b). Costs incurred by Intellia in the performance of activities conducted pursuant to clause (c) of Section 7.11 of the Collaboration Agreement shall be shared by the Parties in accordance with their respective Co-Funding Percentages and treated as Other Shared Expenses. 
 7.12    [Intentionally
Omitted] 
 8.1    Non-GMP Manufacture of
Co-Funding Products. With respect to Regeneron Co-Funding Products, Section 8.1 of the Collaboration Agreement is hereby incorporated by reference into this
Agreement in accordance with Section 2.2(b). 
 8.2    With respect to a Regeneron
Co-Funding Product that is Directed to a Co-Funding Target that was an Intellia Liver Target to which Regeneron exercised the Exercised Option (for which there is no
Product R&D Program), Intellia shall manufacture (or have manufactured) the quantities of Co-Funding Products (including its components) that are necessary to perform the
pre-clinical activities under the Global Development Plan and Section 8.2 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b),
except that the references to the Product R&D Program shall be deemed to refer to the Global Development Plan. [***]. 

8.3(b)    With respect to a Regeneron Co-Funding Product, the second and third
sentences of Section 8.3 of the Collaboration Agreement are hereby incorporated by reference into this Agreement in accordance with Section 2.2(b). 

  
 SUB-ANNEX 1 (B) — 4

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 8.4    Manufacturing Process Technology Transfer. With respect to
Regeneron Co-Funding Products, [***]. 
 9.1    Reimbursement for Past
Expenses. Within [***] days after the Effective Date of this Agreement, the Party that exercised the Exercised Option, as applicable, shall pay to the other Party an amount equal to [***]. 

9.13    Effect of Amendment of the UC Technology License. [***]: 

(a)    [***]; or 

(b)    [***]. 

9.14    Treatment of Certain Payments for Sharing of Profits and Development Costs for Regeneron Co-Funding Products. 
 (a)    With respect to Regeneron Co-Funding Products, [***] the following amounts: 
 (i)     [***]; and 

(ii)     [***]. 

(b)    [***]. 

10.12(b)    In the event that Regeneron is not fully able to enjoy any rights granted Regeneron under this Article 10 as a
result of the provisions of this Section 10.11, then Intellia shall use diligent efforts to afford and allow Regeneron to exercise and enjoy such rights to the maximum extent possible under the applicable Third Party agreement (but Intellia
shall not be required to amend or otherwise modify any such agreement, or make any payments to such Third Party), [***]. 

12.2    Additional Representations, Warranties and Covenants of the Parties. 

(a)    Except as set forth on Schedule 12.2(a)(1), Intellia additionally hereby represents and warrants to Regeneron, as
modified by any exceptions to such representations and warranties applied mutatis mutandis to the subject matter of the Regeneron Option as set forth in the Option Package for the Co-Funding Target and Co-Funding Products, that as of the Option Exercise Date: 
 (i)    There are no
claims, judgments or settlements against or owed by Intellia (or any of its Affiliates) and no pending or, to Intellia’s knowledge, threatened (in writing) claims or litigation, in each case, to which Intellia (or its Affiliates, or, to its or
their knowledge, any of the counterparties to the Option Exercise Intellia Existing Third Party Agreements) is a party or threatened (in writing) party relating to the Intellia Intellectual Property or otherwise challenging Intellia’s ownership
or control of the Intellia Intellectual Property (such Intellia Intellectual Property, the “CFP Intellia IP”); 

  
 SUB-ANNEX 1 (B) — 5

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)    Schedule 12.2(a)(1)(ii)(A) sets forth a true, correct and
complete list of Patent Rights within the CFP Intellia IP existing as of the Option Exercise Date, (the “CFP Intellia Patent Rights”). To the knowledge of the individuals listed on Schedule 12.2(a)(1)(ii)(B) [***], the CFP Intellia
Patent Rights exist and are not invalid or unenforceable, in whole or in part; 
 (iii)    Intellia solely owns all CFP
Intellia IP, except for such CFP Intellia IP that Intellia Controls pursuant to the Option Exercise Intellia Existing Third Party Agreements, and Intellia Controls all of the CFP Intellia Patent Rights; 

(iv)    Schedule 12.2(a)(1)(iv) sets forth a true, correct and complete list of all agreements with Third Parties
pursuant to which Intellia has in-licensed, or otherwise obtained rights to, any Intellectual Property related to activities hereunder, including CRISPR-Cas, Targets,
delivery technologies and CPs (the “Option Exercise Intellia Existing Third Party Agreements”); 

(v)    Intellia is not aware of any claim made in writing against it asserting the invalidity, misuse, unregisterability,
unenforceability or non-infringement of any of the CFP Intellia Patent Rights; 

(vi)    Neither Intellia nor any of its Affiliates is or has been a party to any agreement with the U.S. federal
government or an agency thereof pursuant to which the U.S. federal government or such agency provided funding for the development of the CFP Intellia IP; 

(vii)    Neither Intellia nor any of its Affiliates has received any written notification from a Third Party that the use
of any CFP Intellia IP infringes or misappropriates the Patent Rights or Know-How owned or controlled by such Third Party; 

(viii)    The CFP Intellia IP is not subject to any liens or encumbrances or other grants in favor of any Third Party
that conflicts with the rights or licenses granted to Regeneron under this Agreement; 
 (ix)    To the knowledge of
the individuals listed on Schedule 12.2(a)(1)(ix) (without any duty to inquire), the conception, discovery, development or reduction to practice of CFP Intellia IP has not constituted or involved misappropriation of Intellectual Property or rights
of any Person; and 
 (x)    Intellia has a right and license to use the Patent Rights that are licensed to Intellia
(directly or indirectly) under Option Exercise Intellia Existing Third Party Agreements on a worldwide basis, and Intellia is granting a sublicense to such Patent Rights to Regeneron for use on a worldwide basis, in each case, with respect to the
foregoing, solely with respect to the Co-Funding Products hereunder; 

  
 SUB-ANNEX 1 (B) — 6

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (b)    [Intentionally Omitted] 

12.3(d)     Covenants. 

(i)    With respect to the Regeneron Co-Funding Products under this Agreement,
[***]. 
 (ii)    Section 12.4 of the Collaboration Agreement is hereby incorporated by reference into this Agreement
in accordance with Section 2.2(b), except that any references to the Intellia Existing Third Party Agreements shall be deemed to refer to the Option Exercise Intellia Existing Third Party Agreements. 

  
 SUB-ANNEX 1 (B) — 7

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 SUB-ANNEX 1(C): 

Intellia Co-Funding Target 

1.17    “Co-Funding Product” shall mean each Intellia Co-Funding Product that is Directed to the Co-Funding Target. 

1.27    [Intentionally Omitted] 

1.38     
  

	 	4.	 [Intentionally Omitted] 

1.44    “Exercised Option” shall mean the Intellia Option exercised by Intellia under Section 5.2(c)
of the Collaboration Agreement, in accordance with the Collaboration Agreement, for the Target set forth on Schedule 1.44 of this Agreement. 

1.89    [Intentionally Omitted] 

1.94    “Lead Party” shall mean Intellia. 

1.115    “Participating Party” shall mean Regeneron. 

2.2(b)    [Intentionally Omitted] 

2.4(b)(viii)    [***]; 

2.9    [***]. 

3.1    Development of Co-Funding Products. Subject to the terms of this
Agreement, the Lead Party shall undertake, Development activities with respect to Co-Funding Products unless otherwise mutually agreed to in the Global Development Plan, and such Development activities shall
be under the general direction and oversight of the JDC and JSC. [***]. Except as otherwise agreed to by the Parties in writing or explicitly set forth in this Agreement, the JSC will assign responsibility for conducting all Development activities
for a Co-Funding Product to the Lead Party. 
 3.2    Existing Product
R&D Programs and Associated Product R&D Plans. 
 (a)    [Intentionally Omitted] 

(b)    The Participating Party may terminate this Agreement with respect to the
Co-Funding Target and all Co-Funding Products Directed to such Co-Funding Target any time within three (3) months after the
Effective Date. In such three (3) month period, the Participating Party shall have the right to review the Global Development Plan and Global 

  
 SUB-ANNEX 1(C) — 1

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 
Development Budget prepared pursuant to Sections 3.6 and 3.7, and may terminate this Agreement in accordance with Section 16.4(a)(ii). Upon such termination, the Intellia Option
exercised in conjunction with this Agreement shall no longer constitute one of the Intellia Options exercised by Intellia under Section 5.2 of the Collaboration Agreement. For clarity, each Party shall be responsible for the costs incurred
under this Agreement through the date of termination in accordance with their respective Co-Funding Percentages. 

3.3    [Intentionally Omitted] 

3.4    [Intentionally Omitted] 

3.5    [Intentionally Omitted] 

3.6(b)    [Intentionally Omitted] 

3.8    [Intentionally Omitted] 

5.1(b)(ii)    [Intentionally Omitted] 

5.1(c)    [Intentionally Omitted] 

6.3    [***]. 

6.4    Subject to the terms and conditions of this Agreement (including Section 6.1 and Section 12.6),
Regeneron shall grant, and hereby grants, to Intellia a non-exclusive, worldwide, sublicensable through multiple tiers (in accordance with Section 7.2(c), provided that such sublicense shall not require the prior written consent of
Regeneron), royalty-free and fully paid-up (subject to Section 7.12) license under Patents Rights and Know-How Controlled by Regeneron solely to the extent necessary (and with respect to any Patent Rights, on a claim-by-claim basis) to
use, practice and otherwise exploit the applicable Regeneron Contributed Technology [***] for the research, development, making, having made, using, selling, offering for sale and importing of Intellia Co-Funding Products. 

7.2(c)(ii)    [Intentionally Omitted]. 

7.3(d)    To the extent that any milestones or royalties under a New Intellia Platform License are attributable to one or
more Co-Funding Products (as opposed to amounts attributable to other products or activities) [***]. 

7.4(b)    [Intentionally Omitted] 

7.11    Ongoing Technology Update and Transfer Obligations. Without limiting the last sentence of Section 6.3,
[***]. Costs incurred by Regeneron in the performance of activities conducted pursuant to clause (b)(ii) of this Section 7.11 shall be shared by the Parties in accordance with their respective Co-Funding
Percentages and treated as Other Shared Expenses. 

  
 SUB-ANNEX 1(C) — 2

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 7.12    Regeneron Contributed IP. With respect to Co-Funding Products for which Intellia has a license to Regeneron Contributed IP pursuant to Section 6.3: 

(a)    Section 7.12 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance
with Section 2.2(b) and any payments made by Intellia to Regeneron in accordance with Section 7.12 of the Collaboration Agreement shall be considered Third Party License Payments hereunder and treated in accordance with Section 7.5 of
this Agreement. 
 (b)    In the event that any Regeneron Contributed IP (or other Intellectual Property licensed by
Regeneron to Intellia hereunder) [***] with respect to the Co-Funding Products hereunder, (1) Regeneron will provide prompt written notice thereof to Intellia, and (2) unless Regeneron is already
undertaking such efforts for itself and Intellia, Regeneron will provide reasonable assistance to Intellia in Intellia’s efforts to obtain rights to such Intellectual Property Rights consistent with the rights (including scope) granted by
Regeneron to Intellia under this Agreement pertaining to the Co-Funding Products hereunder. 

8.1    Non-GMP Manufacture of Intellia
Co-Funding Products. With respect to Intellia Co-Funding Products, Intellia will be responsible for the non-GMP Manufacture
and supply of Intellia Co-Funding Products to support the research and pre-clinical development of Intellia Co-Funding Products.

 8.2    Intellia shall manufacture (or have manufactured) the quantities of
Co-Funding Products (including its components) that are necessary to perform the pre-clinical activities under the Global Development Plan and the first sentence of
Section 8.2 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b), except that the references to the Product R&D Program shall be deemed to refer to the Global
Development Plan (or the Option Package for such Co-Funding Product prior to approval of such Global Development Plan). [***]. 

8.3(b)    [Intentionally Omitted] 

8.4    [Intentionally Omitted] 

9.1    Reimbursement for Past Expenses. Within [***] days after the Effective Date of this Agreement, Regeneron
shall pay to Intellia an amount equal to [***]. 
 9.13    Effect of Amendment of the UC Technology License.
[***]. 
 9.14    Treatment of Certain Payments for Sharing of Profits and Development Costs for Intellia Co-Funding Products. 
 (a)    With respect to Intellia Co-Funding Products, [***] the following amounts: 
 (i)     [***]; and 

  
 SUB-ANNEX 1(C) — 3

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (ii)     [***]. 

(b)    [***]. 

10.12(b)    [Intentionally Omitted] 

12.2    Additional Representations, Warranties and Covenants of the Parties. 

(a)     (i) Except as set forth on Schedule 12.2(a)(i), Intellia additionally hereby represents and warrants to Regeneron,
as modified by any exceptions to such representations and warranties applied mutatis mutandis to the subject matter of the Regeneron Option as set forth in the Option Package for the Co-Funding Target
and Co-Funding Products, that as of the Option Exercise Date: 
 (1)    There
are no claims, judgments or settlements against or owed by Intellia (or any of its Affiliates) and no pending or, to Intellia’s knowledge, threatened (in writing) claims or litigation, in each case, to which Intellia (or its Affiliates, or, to
its or their knowledge, any of the counterparties to the Option Exercise Intellia Existing Third Party Agreements) is a party or threatened (in writing) party relating to the Intellia Intellectual Property or otherwise challenging Intellia’s
ownership or control of the Intellia Intellectual Property (such Intellia Intellectual Property, the “CFP Intellia IP”); 

(2)    Schedule 12.2(a)(i)(2)(A) sets forth a true, correct and complete list of Patent Rights within the CFP Intellia IP
existing as of the Option Exercise Date, (the “CFP Intellia Patent Rights”). To the knowledge of the individuals listed on Schedule 12.2(a)(1)(ii)(B) [***], the CFP Intellia Patent Rights exist and are not invalid or unenforceable,
in whole or in part; 
 (3)    Intellia solely owns all CFP Intellia IP, except for such CFP Intellia IP that Intellia
Controls pursuant to the Option Exercise Intellia Existing Third Party Agreements; and Intellia Controls all of the CFP Intellia Patent Rights; 

(4)    Schedule 12.2(a)(i)(4) sets forth a true, correct and complete list of all agreements with Third Parties pursuant
to which Intellia has in-licensed, or otherwise obtained rights to, any Intellectual Property related to activities hereunder, including CRISPR-Cas, Targets, delivery
technologies and CPs (the “Option Exercise Intellia Existing Third Party Agreements”); 

(5)    Intellia is not aware of any claim made in writing against it asserting the invalidity, misuse, unregisterability,
unenforceability or non-infringement of any of the CFP Intellia Patent Rights; 

  
 SUB-ANNEX 1(C) — 4

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 (6)    Neither Intellia nor any of its Affiliates is or has been a party
to any agreement with the U.S. federal government or an agency thereof pursuant to which the U.S. federal government or such agency provided funding for the development of the CFP Intellia IP; 

(7)    Neither Intellia nor any of its Affiliates has received any written notification from a Third Party that the use
of any CFP Intellia IP infringes or misappropriates the Patent Rights or Know-How owned or controlled by such Third Party; 

(8)    The CFP Intellia IP is not subject to any liens or encumbrances or other grants in favor of any Third Party that
conflicts with the rights or licenses granted to Regeneron under this Agreement; 
 (9)    To the knowledge of the
individuals listed on Schedule 12.2(a)(i)(9) [***], the conception, discovery, development or reduction to practice of CFP Intellia IP has not constituted or involved misappropriation of Intellectual Property or rights of any Person; and 

(10)    Intellia has a right and license to use the Patent Rights that are licensed to Intellia (directly or indirectly)
under the Option Exercise Intellia Existing Third Party Agreements on a worldwide basis. 
 (ii)    With respect to the
agreements set forth on Schedule 12.2(a)(1)(iv) (as may be amended from time to time (the “Intellia Agreements”), Intellia hereby represents and warrants as of the Effective Date, and covenants during the Term, to Regeneron that:

 (1)    Sections 12.4(a)(i) and (ii) of the Collaboration Agreement (as applied mutatis mutandis) are
hereby incorporated by reference into this Agreement in accordance with Section 2.2(b), in each case, with respect to the foregoing, solely with respect to the Co-Funding Products except that any
references to the Intellia Existing Third Party Agreements shall be deemed to refer to the Option Exercise Intellia Existing Third Party Agreements. [***]; and 

(2)    Intellia shall fulfill all of its material obligations, including its payment obligations, under the Option
Exercise Intellia Existing Third Party Agreements, with respect to the Co-Funding Products under this Agreement. 

12.3(d)     [Intentionally Omitted] 

  
 SUB-ANNEX 1(C) — 5

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 SUB-ANNEX 1(D): 

TTR 

1.17    “Co-Funding Product” shall mean each Co-Funding Product that is Directed to the Initial Co/Co Target. 

1.27    [Intentionally Omitted] 

1.38 
  

	 	4.	 [***]. 

1.44    “Exercised Option” shall mean the Regeneron Option exercised by Regeneron under
Section 5.1(e) of the Collaboration Agreement in accordance with the Collaboration Agreement, for the Initial Co/Co Target, as such term is defined in the Collaboration Agreement. 

1.89    [Intentionally Omitted] 

1.94    “Lead Party” shall mean Intellia. 

1.115    “Participating Party” shall mean Regeneron. 

2.2(b)    [Intentionally Omitted] 

2.4(b)(viii)    [***]; 

2.9    [***]. 

3.1    Development of Co-Funding Products. Subject to the terms of this
Agreement, the Lead Party shall undertake, Development activities with respect to Co-Funding Products unless otherwise mutually agreed to in the Global Development Plan, and such Development activities shall
be under the general direction and oversight of the JDC and JSC. [***]. Except as otherwise agreed to by the Parties in writing or explicitly set forth in this Agreement, the JSC will assign responsibility for conducting all Development activities
for a Co-Funding Product to the Lead Party. 
 3.2    [Intentionally Omitted]

 3.3    [Intentionally Omitted] 

3.4    [Intentionally Omitted] 

3.5    [Intentionally Omitted] 

  
 SUB-ANNEX 1(D) — 1

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 3.6(b)    Schedule 5.1(e)(iii) of the Collaboration Agreement shall be
deemed to be the initial Global Development Plan for the Initial Co/Co Target until updated by Intellia and reviewed and approved by the JSC. 

3.8    [Intentionally Omitted] 

5.1(b)(ii)    [Intentionally Omitted] 

5.1(c)    [Intentionally Omitted] 

6.3    [***]. 

6.4    Subject to the terms and conditions of this Agreement (including Section 6.1 and Section 12.6),
Regeneron shall grant, and hereby grants, to Intellia a non-exclusive, worldwide, sublicensable through multiple tiers (in accordance with Section 7.2(c)), provided that such sublicense shall not require the prior written consent of
Regeneron), royalty-free and fully paid-up (subject to Section 7.12) license under Patents Rights and Know-How Controlled by Regeneron solely to the extent necessary (and with respect to any Patent Rights, on a claim-by-claim basis) to
use, practice and otherwise exploit the applicable Regeneron Contributed Technology [***] for the research, development, making, having made, using, selling, offering for sale and importing of Intellia Co-Funding Products. 

7.2(c)(ii)    [Intentionally Omitted]. 

7.3(d)     [***]. 

7.4(b)    [Intentionally Omitted] 

7.11    Ongoing Technology Update and Transfer Obligations. Without limiting the last sentence of Section 6.3,
[***]. Costs incurred by Regeneron in the performance of activities conducted pursuant to clause (b)(ii) of this Section 7.11 [***]. 

7.12    Regeneron Contributed IP. With respect to Co-Funding Products for
which Intellia has a license to Regeneron Contributed IP pursuant to Section 6.3: 
 (a)    Section 7.12 of the
Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b) and [***]. 

(b)    In the event that any Regeneron Contributed IP (or other Intellectual Property licensed by Regeneron to Intellia
hereunder) is [***] with respect to the Co-Funding Products hereunder, (1) Regeneron will provide prompt written notice thereof to Intellia, and (2) unless Regeneron is already undertaking such
efforts for itself and Intellia, Regeneron will provide reasonable assistance to Intellia in Intellia’s efforts to obtain rights to such Intellectual Property Rights consistent with the rights (including scope) granted by Regeneron to Intellia
under this Agreement pertaining to the Co-Funding Products hereunder. 

  
 SUB-ANNEX 1(D) — 2

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

 8.1    Non-GMP Manufacture of Co-Funding Products. With respect to Intellia Co-Funding Products, Intellia will be responsible for the non-GMP Manufacture and
supply of Intellia Co-Funding Products to support the research and pre-clinical development of Intellia Co-Funding Products. 

8.2    Intellia shall manufacture (or have manufactured) the quantities of
Co-Funding Products (including its components) that are necessary to perform the pre-clinical activities under the Global Development Plan and the first sentence of
Section 8.2 of the Collaboration Agreement is hereby incorporated by reference into this Agreement in accordance with Section 2.2(b), except that the references to the Product R&D Program shall be deemed to refer to the Global
Development Plan. [***]. 
 8.3(b)    [Intentionally Omitted] 

8.4    [Intentionally Omitted] 

9.1    Reimbursement for Past Expenses. [***]. The Lead Party provided to the Participating Party invoices totaling
[***] to be paid by the Participating Party [***]. 
 9.13    Effect of Amendment of the UC Technology License.
[***]. Payments under this Agreement, and as between the Parties [***]. 

9.14    Treatment of Certain Payments for Sharing of Profits and Development Costs for
Co-Funding Products. With respect to Intellia Co-Funding Products, in the event that Intellia (or its Affiliate or sublicensee) is required to make any upfront,
annual or other license fees, milestone or royalty payments to a Third Party as a result of a license (or other right) granted to Intellia (or its Affiliate or sublicensee) by such Third Party under such Third Party’s Intellectual Property or
otherwise in connection with any settlement with such Third Party [***]. 
 12.2    Additional Representations,
Warranties and Covenants of the Parties. 
 (a)    [Intentionally Omitted] 

(b) 

(i)    With respect to the Intellia Co-Funding Products under this Agreement,
[***]. 
 (ii)    Intellia shall fulfill all of its material obligations, including its payment obligations, under the
Intellia Existing Third Party Agreements, with respect to the Intellia Co-Funding Products under this Agreement. 

12.3(d)    [Intentionally Omitted] 

  
 SUB-ANNEX 1(D) — 3

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE
VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. 
  

  
 SUB-ANNEX 1(D) — 4Exhibit

 

EMPLOYMENT AGREEMENT
This Employment Agreement (this “Agreement”), dated March 22, 2019 (the “Effective Date”) is made by and between Cardtronics USA, Inc., a Delaware corporation (together with any successor thereof, the “Company”), and Paul Wilmore (“Executive”).
WITNESSETH:
WHEREAS, the Company desires to employ Executive on the terms and conditions, and for the consideration hereinafter set forth, and Executive desires to be employed by the Company on such terms and conditions and for such consideration.
NOW, THEREFORE, for and in consideration of the mutual promises, covenants and obligations contained herein, the sufficiency of which is hereby acknowledged by the parties, the Company and Executive agree as follows: 
ARTICLE I 
DEFINITIONS
In addition to the terms otherwise defined herein, for purposes of this Agreement the following capitalized words shall have the following meanings:
1.1    “Affiliate” shall mean any other Person that owns or controls, is owned or controlled by, or is under common ownership or control with, such particular Person.  Without limiting the scope of the preceding sentence, the Parent Company shall be deemed to be an Affiliate of the Company for all purposes of this Agreement.
1.2    “Average Annual Bonus” shall mean the Executive’s Annual Bonus paid (or payable) at target. 
1.3    “Beneficial Owner” shall have the meaning set forth in Rule 13d-3 under the U.S. Securities Exchange Act of 1934, as amended from time to time (the “Exchange Act”).
1.4    “Board” shall mean the Board of Directors of the Parent Company.
1.5    “Cause” shall mean a reasonable and good faith determination by the Board that Executive has (a) engaged in gross negligence, gross incompetence or willful misconduct in the performance of Executive’s duties with respect to the Company or any of its Affiliates, (b) refused without proper legal reason to perform Executive’s duties and responsibilities to the Company or any of its Affiliates, (c) materially breached any material provision of this Agreement or any written agreement or corporate policy or code of conduct established by the Company or any of its Affiliates, (d) willfully engaged in conduct that is materially injurious to the Company or any of its Affiliates, (e) breached restrictive covenants in this Agreement or any other agreement between the Executive and the Company or any of its Affiliates, (f) committed an act of theft, fraud, embezzlement, misappropriation or willful breach of a fiduciary duty to the Company or any of its Affiliates, or (g) been convicted of (or pleaded no contest to) a crime involving fraud, dishonesty or moral turpitude or any felony (or a crime of similar import in a foreign jurisdiction); provided that any assertion by the Company of a termination of employment for “Cause” shall not be effective unless the Company has provided written Notice of Breach to Executive.   
1.6    “Change in Control” shall mean and shall be deemed to have occurred if any event set forth in any one of the following paragraphs shall have occurred:
		
	(a)
	the consummation of a merger of, or other business combination by, the Parent Company with or involving another entity; a reorganization, reincorporation, amalgamation, scheme of arrangement or consolidation involving the Parent Company; or the sale of all or substantially all of the Parent Company’s or the Company’s Assets to another entity (any of which, a “Corporate Transaction”); unless, following such Corporate Transaction, (a) the holders of equity securities of the Parent Company immediately prior to such transaction beneficially own, directly or indirectly, immediately after such transaction, equity securities of the resulting or surviving parent entity, the transferee entity or any new direct or indirect parent entity of the Parent Company resulting from or surviving any such transaction (such entity, the “Successor Entity”) entitled to 70% or more 

Initial ____________

of the votes then eligible to be cast in the election of directors generally (or comparable governing body) of the Successor Entity in substantially the same proportion that they owned the equity securities of the Parent Company immediately prior to such transaction or (b) at least a majority of the members of the board of directors (or comparable governing body) of the Successor Entity immediately following the Corporate Transaction were Incumbent Directors (defined below) at the time of the execution of the initial agreement providing for such Corporate Transaction; 
		
	(b)
	upon the dissolution or liquidation of the Parent Company, other than a liquidation or dissolution into any entity in which the holders of equity securities of the Parent Company immediately prior to such liquidation or dissolution beneficially own, directly or indirectly, immediately after such liquidation or dissolution equity securities of the entity into which the Parent Company was liquidated or dissolved entitled to 70% or more of the votes then eligible to be cast in the election of directors generally (or comparable governing body) of such entity, in substantially the same proportion that they owned the equity securities of the Parent Company immediately prior to such liquidation or dissolution;

		
	(c)
	when any person or entity, including a “group” as contemplated by Section 13(d)(3) of the Exchange Act, but excluding any employee benefit plan sponsored by the Parent Company (or any related trust thereto), acquires or gains ownership or control (including, without limitation, power to vote) of more than 30% of the combined voting power of the outstanding equity securities of the Parent Company, other than any entity in which the holders of equity securities of the Parent Company immediately prior to such acquisition beneficially own, directly or indirectly, immediately after such acquisition, equity securities of the acquiring entity entitled to 70% or more of the votes then eligible to be cast in the election of directors generally (or comparable governing body) of the acquiring entity, in substantially the same proportion that they owned the equity securities of the Parent Company immediately prior to such acquisition or any employee benefit plan sponsored by any such entity (or any related trust thereto); or

		
	(d)
	during any period of twelve consecutive months the following individuals (the “Incumbent Directors”) cease for any reason to constitute a majority of the number of directors then serving on the Board: individuals who, on the Effective Date, constitute the Board and any new director whose appointment or election by the Board or nomination for election by the Company’s shareholders was approved or recommended by a vote of at least a majority of the directors then still in office who either were directors on the Effective Date or whose appointment, election or nomination for election was previously so approved or recommended (other than such new director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent or proxy solicitation, relating to the election of directors of the Company by or on behalf of a Person other than the Board).

1.7    “Code” shall mean the Internal Revenue Code of 1986, as amended.
1.8    “Company’s Assets” shall mean the assets (of any kind) owned by the Parent Company, including, without limitation, the securities of the Parent Company’s Subsidiaries and any of the assets owned by the Parent Company’s Subsidiaries.
1.9    “Date of Termination” shall mean the date of Executive’s Separation From Service set forth in the Notice of Termination or the date of death, as applicable.
1.10    “Entity” shall mean any corporation, partnership, association, joint-stock company, limitedliability company, trust, unincorporated organization or other business entity.
1.11    “Good Reason” shall mean the occurrence of any of the following events:
		
	(a)
	a diminution in Executive’s Base Salary of 5% or more, unless such reduction is part of an initiative that applies to and affects all similarly situated executive officers of the Company substantially the same and proportionately; 

		
	(b)
	a material diminution in Executive’s authority, duties, or responsibilities (including, in connection with a Change in Control or other Corporate Transaction, Executive being assigned to any position (including offices and reporting requirements), authority, duties or responsibilities that are not at or with the Parent Company, engaged in the business of the successor to the Parent Company or the corporation or other Entity surviving 

2
Initial ____________

or resulting from such Corporate Transaction), including, without limitation, Executive’s ceasing to be an officer of a publicly traded company;
		
	(c)
	in connection with a Change in Control or other Corporate Transaction, the involuntary relocation of the geographic location of Executive’s principal place of employment by more than 50 miles from its then current location;

		
	(d)
	a material breach by the Company of this Agreement, other than an isolated, insubstantial and inadvertent failure to comply with this Agreement not occurring in bad faith.

Notwithstanding the foregoing provisions of this Section 1.11 or any other provision in this Agreement to the contrary, any assertion by Executive of a termination of employment for “Good Reason” shall not be effective unless all of the following conditions are satisfied: (i) the condition described in Section 1.11(a), (b), (c), or (d) giving rise to Executive’s termination of employment must have arisen without Executive’s written consent; (ii) Executive must provide written Notice of Breach to the Company of such condition in accordance with Section 10.1 within 90 days of the initial existence of the condition specified in the Notice of Breach; and (iii) the condition specified in the Notice of Breach must remain uncorrected for 30 days after receipt of the Notice of Breach by the Company.  Any Notice of Breach shall be deemed void if the Company cures the matter giving rise to Good Reason under this Section 1.11 within 30 days of the receipt of the Notice of Breach. 
1.12    “Impaired” or “Impairment” means:
		
	(a)
	the Executive being eligible for the Company’s (or its Affiliate’s) long-term disability benefits, if any are available to Executive; or

		
	(b)
	the Executive being unable to perform Executive’s duties or fulfill Executive’s obligations under this Agreement by reason of any medically determinable physical or mental impairment that can be expected to result in death or can be expected to last for a continuous period of not less than 180 days, as determined by the Company and certified in writing by a competent medical physician selected solely by the Company in the event of any alleged mental impairment and, in the event of any alleged physical impairment by the Company with the Executive having the right to approve such selection (however, if the Executive fails to approve the Company’s first two selections within ten days of being notified of each such selection, the Company will have the right thereafter to designate any licensed medical physician on staff with either the Baylor College of Medicine or Methodist Hospital, each located in Houston, Texas).

1.13    “Notice of Breach” shall mean a written notice delivered to the other party within the time period required under the definition of “Cause” or “Good Reason,” as applicable, that (a) indicates, as applicable, the specific provision in this Agreement that the party contends the other party has breached or the specific clause of the definition of “Cause” or “Good Reason” that the party alleges to exist, and (b) to the extent applicable, sets forth in reasonable detail the facts and circumstances Executive or the Company, as applicable, claims provide the basis for such breach or other condition.
1.14    “Notice of Termination” shall mean a written notice delivered to the other party indicating the specific termination provision in this Agreement relied upon for termination of Executive’s employment and the Date of Termination and shall set forth in reasonable detail the facts and circumstances claimed to provide a basis for termination of Executive’s employment under the provision so indicated and shall include a Notice of Breach, but only at the time and to the extent such Notice of Breach becomes a Notice of Termination under Section 3.3.    
1.15    “Parent Company” shall mean Cardtronics plc, a public limited company organized under English law, or any successor thereof, including any Entity into which Cardtronics plc is merged, consolidated or amalgamated, including, without limitation, any Entity otherwise resulting from a Corporate Transaction.  
1.16    “Person” shall mean (a) an individual or Entity and (b) for purposes of the definition of “Change in Control” and related provisions shall have the meaning provided in Section 3(a)(9) of the Exchange Act, as modified and used in Sections 13(d) and 14(d) thereof, except that such term shall not include (i) the Parent Company or any of its Subsidiaries, (ii) a trustee or other fiduciary holding securities under a Benefit Plan of the Parent Company or any of its Affiliated companies, (iii) an underwriter temporarily holding securities pursuant to an offering by the Parent Company of such securities, or (iv) an Entity owned, directly or indirectly, by the shareholders of the Parent Company in substantially the same proportion as their ownership of shares of the Parent Company.
1.17    “Section 409A Payment Date” shall have the meaning set forth in Section 7.2(b).

3
Initial ____________

1.18    “Subsidiary” shall mean any direct or indirect majority-owned subsidiary of the Parent Company or any majority-owned subsidiary thereof, or any other Entity in which the Parent Company owns, directly or indirectly, a significant financial interest provided that the Chief Executive Officer of the Parent Company designates such Entity to be a Subsidiary for the purposes of this Agreement.
ARTICLE II     
EMPLOYMENT AND DUTIES
2.1    Employment; Commencement Date.  Executive is commencing employment with the Company pursuant to this Agreement on May 1, 2019 (the “Commencement Date”) and, from and after such date, the Company agrees to employ Executive, and Executive agrees to be employed by the Company, pursuant to the terms of this Agreement and continuing for the period of time set forth in Article III, subject to the terms and conditions of this Agreement.
2.2    Positions. From and after the Commencement Date, the Company shall employ Executive in the position of Chief Marketing Officer of the Company or in such other position or positions as the parties mutually may agree, and Executive shall report to the Chief Executive Officer of the Company.
2.3    Duties and Services. Executive agrees to serve in the position(s) referred to in Section 2.2 and to perform diligently and to the best of Executive’s abilities the duties and services appertaining to such position(s) as well as such additional duties and services appropriate to such position(s) as may be assigned, from time to time, by the Company. Executive’s employment shall also be subject to the policies maintained and established by the Company and its Affiliates that are of general applicability to the Company’s executive employees, as such policies may be amended from time to time.
2.4    Other Interests. Executive agrees, during the period of Executive’s employment by the Company, to devote substantially all of Executive’s business time, energy and best efforts to the business and affairs of the Company and its Affiliates. Notwithstanding the foregoing, the parties acknowledge and agree that Executive may (a) engage in and manage Executive’s passive personal investments, (b) engage in charitable and civic activities, (c) at the sole discretion of the Board, serve on the boards of other for- and non-profit Entities, and (d) engage in de minimis other activities such as non-commercial speeches; provided, however, that such activities shall be permitted solely if such activities do not conflict with the business and affairs of the Company or interfere with Executive’s performance of Executive’s duties hereunder or any restrictive covenant in favor of the Company or its Affiliate, in each case, as determined by the Company.  
2.5    Duty of Loyalty. Executive acknowledges and agrees that Executive owes a fiduciary duty of loyalty, fidelity and allegiance to act in the best interests of the Company and to do no act that would materially injure the business, interests or reputation of the Company or any of its Affiliates. In keeping with these duties, Executive shall make full disclosure to the Company of all business opportunities pertaining to the Company’s business and shall not appropriate for Executive’s own benefit business opportunities concerning the subject matter of the fiduciary relationship.
ARTICLE III     
TERM AND TERMINATION OF EMPLOYMENT
3.1    Term. Subject to the remaining terms of this Article III, this Agreement shall be for an initial term that begins on the Commencement Date and continues in effect through the fourth anniversary of the Commencement Date (the “Initial Term”) and, unless terminated sooner as herein provided, shall continue on a year‐to‐year basis (each a “Renewal Term” and, together with the Initial Term, the “Term”). If the Company or Executive elects not to renew the Term under this Agreement for a Renewal Term, the Company or Executive must provide a Notice of Termination to the other party at least 90 days before the expiration of the then-current Initial Term or Renewal Term, as applicable. In the event that one party provides the other party with a Notice of Termination pursuant to this Section 3.1, no further automatic extensions will occur and this Agreement and Executive’s employment with the Company shall terminate at the end of the then-existing Initial Term or Renewal Term, as applicable.
3.2    Company’s Right to Terminate. Notwithstanding the provisions of Section 3.1, the Company may terminate Executive’s employment and this Agreement during the Term immediately and at any time for any of the following reasons by providing Executive with a Notice of Termination:
		
	(a)
	Impairment: if the Executive is Impaired, the Company may, at its sole discretion, elect not to immediately terminate the Executive but rather to employ someone to undertake Executive’s authorities, duties and responsibilities with respect to the Company and its Affiliates, including with Executive’s title and reporting 

4
Initial ____________

lines, during the period from the onset of any Impairment until Executive’s employment with the Company is terminated or the Executive otherwise returns to full duties.  Notwithstanding anything to the contrary, any such action by the Company will not constitute Good Reason, constructive termination or breach of this Agreement or otherwise, provided further that, if Executive recovers from the Impairment prior to the date Executive would qualify for long term disability benefits and the Company does not return Executive to Executive’s position, Executive shall have the right to resign for Good Reason in accordance with the terms of this agreement; 
		
	(b)
	Death: automatically upon Executive’s death; 

		
	(c)
	Cause: for Cause; or

		
	(d)
	Discretion of the Company: for any other reason whatsoever (other than as set forth in Sections 3.2(a), (b) or (c) or for no reason at all, in the sole discretion of the Board.

3.3    Executive’s Right to Terminate. Notwithstanding the provisions of Section 3.1, Executive shall have the right to terminate Executive’s employment and this Agreement during the Term for Good Reason or for any other reason whatsoever or for no reason at all, in the sole discretion of Executive, by providing the Company with a Notice of Termination. In the case of a termination of employment by Executive without Good Reason, the Date of Termination specified in the Notice of Termination shall not be less than 90 days from the date such Notice of Termination is provided, and the Company may require a Date of Termination earlier than that specified in the Notice of Termination (and, if such earlier Date of Termination is so required by the Company, that shall be the “Date of Termination” as defined in Section 1.1, and it shall not otherwise change the basis for Executive’s termination nor be construed or interpreted as a termination of employment pursuant to Section 3.1 or Section 3.2).  In the event Executive intends to terminate employment with the Company for Good Reason because the Company failed to cure the event described in the Notice of Breach within 30 days of receipt of the Notice of Breach, the Notice of Breach shall automatically be deemed a Notice of Termination, effective immediately upon the expiration of the cure period described in Section 1.11.  If Executive fails to provide the Company with the requisite Notice of Termination under this Section 3.3, Executive forfeits the right to any contingent future payments under this Agreement.  
3.4    Deemed Resignations. Unless otherwise agreed to in writing by the Company and Executive prior to the termination of Executive’s employment, any termination of Executive’s employment shall constitute an automatic resignation of Executive as an officer of the Company and each Affiliate of the Company (including the Parent Company), and an automatic resignation of Executive from the Board (if applicable) and from the board of directors of the Company and any Affiliate of the Company and from the board of directors or similar governing body of any Entity in which the Company or any Affiliate holds an equity interest and with respect to which board or similar governing body Executive serves as the Company’s or such Affiliate’s designee or other representative.
3.5    Meaning of Termination of Employment. For all purposes of this Agreement, Executive shall be considered to have terminated employment with the Company only when Executive incurs a “separation from service” with the Company within the meaning of Section 409A(a)(2)(A)(i) of the Code and applicable administrative guidance issued thereunder (“Separation From Service”). For purposes of any such provision of this Agreement relating to any such payments or benefits, references to a “termination,” “termination of employment” or like terms shall mean “separation from service”.
ARTICLE IV     
COMPENSATION AND BENEFITS
4.1    Base Salary. During the Term of this Agreement, Executive shall receive a minimum, annualized gross base salary of $375,000 (the “Base Salary”). Executive’s Base Salary shall be paid in substantially equal installments in accordance with the Company’s standard policy regarding payment of compensation to executives but no less frequently than monthly.
4.2    Cash Incentive Plan Awards. Executive shall be eligible to receive an annual bonus in respect of each calendar year during the Term (“Annual Bonus”) based on criteria determined in the sole discretion of the Board (or a committee thereof) as part of the Cardtronics, Inc. Annual Executive Cash Incentive Plan (and/or other then-current or similar or successor plan, the “AECIP”) and subject to the terms and conditions of the AECIP, it being understood that (a) the target Annual Bonus at planned or targeted levels of performance shall equal 70% of Executive’s Base Salary and (b) the actual amount of each Annual Bonus to be paid to the Executive shall be determined in the sole discretion of the Board (or a committee thereof) and may range between 0% and 200% of the target Annual Bonus. The Company shall pay each Annual Bonus with respect to a calendar year no later than March 15 of the calendar year following the year to which the Annual Bonus relates, provided that (except as 

5
Initial ____________

otherwise provided in Section 7.1(b)) Executive is employed by the Company on such date of payment. If Executive has not been employed by the Company since January 1 of the year that includes the Effective Date, then the Annual Bonus for such year shall be prorated based on the ratio of the number of days during such calendar year that Executive was employed by the Company to the number of days in such calendar year. 
4.3    One-Time Sign-On Bonus.  Executive shall be eligible to receive a one-time sign-on bonus of $100,000 for commuting/relocation expenses payable no later than 30 days following the Commencement Date (“Sign-On Bonus”). If Executive’s employment is terminated pursuant to Section 3.2(c) or if Executive resigns without “Good Reason” within twelve (12) months following the Effective Date, Executive shall repay the Sign-On Bonus in full to the Company.  Repayment of the Sign-On Bonus must be made within 30 days of the date of the Executive’s Date of Termination and may be set-off, at the sole discretion of the Company, by the Company against any amounts otherwise owed to the Executive pursuant to this Agreement or otherwise to the extent permitted by applicable law (including Section 409A of the Code). Upon completion of relocation, Executive shall be eligible to receive a one-time cash bonus of $100,000 for relocation expenses payable no later than 30 days following final relocation to Texas (“Relocation Date”). If Executive’s employment is terminated pursuant to Section 3.2(c) or if Executive resigns without “Good Reason” within twelve (12) months following the Relocation Date, Executive shall repay the one-time cash bonus in full to the Company.  Repayment of the Sign-On Bonus must be made within 30 days of the date of the Executive’s Date of Termination and may be set-off, at the sole discretion of the Company, by the Company against any amounts otherwise owed to the Executive pursuant to this Agreement or otherwise to the extent permitted by applicable law (including Section 409A of the Code).
4.4     Stock Incentive Plan Awards. Beginning in 2020, Executive shall be eligible to receive an annual equity award each calendar year during the Term (“Annual Equity Award”) with a grant date value at target equal to 70% of Base Salary, based on criteria determined in the sole discretion of the Board (or a committee thereof) as part of the Cardtronics, Inc. Third Amended and Restated 2007 Stock Incentive Plan (and/or other then-current or similar or successor plan, “Stock Incentive Plan”).  In lieu of an Annual Equity Award for 2019, Executive will be awarded $300,000 in restricted stock units (valued as of the close of trading on the Commencement Date) as a one-time award, which award shall be governed by the terms and conditions of the Stock Incentive Plan and the associated equity award agreement in the form attached hereto as Exhibit A (the “Sign-On Stock Incentive Award”).
4.5    Other Perquisites. During the Term, the Company shall provide Executive with substantially the same perquisite benefits made available to similarly situated executive officers of the Company generally, from time to time.
4.6    Expenses. The Company shall reimburse Executive for all reasonable business expenses incurred by Executive in performing services during the Term, including all expenses of travel and living expenses while away from home on business or at the request of and in the service of the Company; provided, in each case, that such expenses are incurred and accounted for in accordance with the policies and procedures established by the Company from time to time. Any reimbursement of expenses pursuant to this Section 4.6 shall be made by the Company upon or as soon as practicable following receipt of supporting documentation reasonably satisfactory to the Company (but in any event not later than the close of Executive’s taxable year following the taxable year in which the expense is incurred by Executive).
4.7    Vacation and Sick Leave. During the Term, Executive shall be entitled to (a) sick leave in accordance with the Company’s policies applicable to similarly situated executive officers of the Company from time to time and (b) 5 weeks paid vacation each calendar year (up to 40 hours of which may be carried forward to a succeeding year).
4.8    Offices. Subject to Articles II, III and IV, Executive agrees to serve without additional compensation, if elected or appointed thereto, as an officer (in addition to the position specified in Section 2.2) or director of the Company or any of the Company’s Affiliates and as a member of any committees of the board of directors of any such Entities and in one or more executive positions of any of the Company’s Affiliates.
ARTICLE V     
PROTECTION OF INFORMATION
5.1    Work Product.  For purposes of this Article V, the term “the Company” shall include the Company and any of its Affiliates (including the Parent Company), and any reference to “employment” or similar terms shall include an officer, director and/or consulting relationship.  Executive agrees that all information, inventions, patents, trade secrets, formulas, processes, designs, ideas, concepts, improvements, diagrams, drawings, flow charts, programs, methods, apparatus, software, hardware, ideas, improvements, product developments, discoveries, systems, techniques, devices, models, prototypes, copyrightable works, mask works, trademarks, service marks, trade dress, business slogans, written materials and other things 

6
Initial ____________

of value conceived, reduced to practice, made or learned by Executive, either alone or with others, while employed with the Company (whether during business hours or otherwise and whether on Company’s premises or otherwise) that relate to the Company’s business and/or the business of Affiliates of the Company using the Company’s time, data, facilities and/or materials (hereinafter collectively referred to as the “Work Product”) belong to and shall remain the sole and exclusive property of the Company (or its Affiliates) forever.  Executive hereby assigns to the Company all of Executive’s right, title, and interest to all such Work Product.  Executive agrees to promptly and fully disclose all Work Product in writing to the Company.  Executive agrees to cooperate and do all lawful things requested by the Company to protect Company ownership rights in all Work Product.  Executive warrants that no Work Product has been conceived, reduced to practice, made or learned by Executive prior to Executive’s employment with the Company.   
5.2    Confidential Information. During Executive’s employment with the Company, the Company agrees to and shall provide to Executive confidential, proprietary, non-public and/or trade secret information regarding the Company that Executive has not previously had access to or knowledge of before the execution of this Agreement including, without limitation, Work Product, technical information, corporate opportunities, product specification, compositions, manufacturing and distribution methods and processes, research, financial and sales data, business and marketing plans, strategies, financing, plans, business policies and practices of the Company, and/or Affiliates of the Company, know-how, specialized training, mailing lists, acquisition prospects, identity of customers or their requirements, the identity of key contacts within the customer’s organizations or within the organization of acquisition prospects, potential client lists, employee records, pricing information, evaluations, opinions, interpretations, production, marketing and merchandising techniques, prospective names and marks or other forms of information considered by the Company to be confidential, proprietary, non-public or in the nature of trade secrets (hereafter collectively referred to as “Confidential Information”) that the Company and its Affiliates desire to protect.  
5.3    No Unauthorized Use or Disclosure. Executive agrees to preserve and protect the confidentiality of all Confidential Information and Work Product of the Company and its Affiliates. Executive agrees that Executive will not, at any time during or after Executive’s employment with the Company, make any unauthorized disclosure of, and Executive shall not remove from the Company premises, Confidential Information or Work Product of the Company or its Affiliates, or make any use thereof, except, in each case, in the carrying out of Executive’s responsibilities hereunder. Executive shall use all reasonable efforts to cause all Persons to whom any Confidential Information shall be disclosed by Executive hereunder to preserve and protect the confidentiality of such Confidential Information.  At the request of the Company at any time, Executive agrees to deliver to the Company all Confidential Information that Executive may possess or control. Executive agrees that all Confidential Information of the Company (whether now or hereafter existing) conceived, discovered or made by Executive during the period of Executive’s employment by the Company exclusively belongs to the Company (and not to Executive), and upon request by the Company for specified Confidential Information, Executive will promptly disclose such Confidential Information to the Company and perform all actions reasonably requested by the Company to establish and confirm such exclusive ownership. Affiliates of the Company shall be third party beneficiaries of Executive’s obligations under this Article V. As a result of Executive’s employment by the Company, Executive may also from time to time have access to, or knowledge of, Confidential Information or Work Product of third parties, such as customers, suppliers, partners, joint venturers, and the like, of the Company and its Affiliates. Executive also agrees to preserve and protect the confidentiality of such third party Confidential Information and Work Product. Notwithstanding anything contained in this Agreement to the contrary, Executive may disclose Confidential Information: (a) as such disclosure or use may be required or appropriate in connection with his work as an employee of the Company; (b) when required to do so by a court of law, by any governmental agency having apparent supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) with apparent jurisdiction to order him to divulge, disclose or make accessible such information; provided, however, that in the event disclosure is so required, Executive shall provide the Company with prompt notice of such requirement prior to making any such disclosure, so that the Company may seek an appropriate protective order; or (c) as to such Confidential Information that becomes generally known to the public or trade without his violation of this Section 5.3.  Upon termination of Executive’s employment by the Company for any reason, Executive promptly shall deliver such Confidential Information and Work Product, and all copies thereof (in whatever form, tangible or intangible), to the Company.  Executive’s non-disclosure obligations in this Article V shall not be applied to limit or interfere with Executive’s right, without notice to or authorization of the Company, to communicate and cooperate in good faith with a Government Agency for the purpose of (i) reporting a possible violation of any U.S. federal, state, or local law or regulation, (ii) participating in any investigation or proceeding that may be conducted or managed by any Government Agency, including by providing documents or other information, or (iii) filing a charge or complaint with a Government Agency.  For purposes of this Agreement, “Government Agency” means the Equal Employment Opportunity Commission, the National Labor Relations Board, the Occupational Safety and Health Administration, the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority, or any other self-regulatory organization or any other 

7
Initial ____________

federal, state, or local governmental agency or commission.  The disclosures and actions protected in this Section 5.3 are referred to herein as “Protected Activities.”
5.4    Ownership by the Company. If, during Executive’s employment by the Company, Executive creates any work of authorship fixed in any tangible medium of expression that is the subject matter of copyright (such as videotapes, written presentations, or acquisitions, computer programs, electronic mail, voice mail, electronic databases, drawings, maps, architectural renditions, models, manuals, brochures, or the like) relating to the Company’s business, products, or services, whether such work is created solely by Executive or jointly with others (whether during business hours or otherwise and whether on the Company’s premises or otherwise), including any Work Product, the Company shall be deemed the author of such work if the work is prepared by Executive in the scope of Executive’s employment; or, if the work relating to the Company’s business, products or services is not prepared by Executive within the scope of Executive’s employment but is specially ordered by the Company as a contribution to a collective work, as a part of a motion picture or other audiovisual work, as a translation, as a supplementary work, as a compilation, or as an instructional text, then the work shall be considered to be work made for hire and the Company shall be the author of the work. If the work relating to the Company’s business, products, or services is neither prepared by Executive within the scope of Executive’s employment nor a work specially ordered that is deemed to be a work made for hire during Executive’s employment by the Company, then Executive hereby agrees to assign, and by these presents does assign, to the Company all of Executive’s worldwide right, title, and interest in and to such work and all rights of copyright therein.
5.5    Assistance by Executive. During the period of Executive’s employment by the Company, Executive shall assist the Company and its nominee, at any time, in the protection of the Company’s or its Affiliates’ worldwide right, title and interest in and to Confidential Information and Work Product and the execution of all formal assignment documents requested by the Company or its nominee and the execution of all lawful oaths and applications for patents and registration of copyright in the United States and foreign countries. After Executive’s employment with the Company terminates, at the request from time to time and expense of the Company or its Affiliates, Executive shall reasonably assist the Company and its nominee, at reasonable times and for reasonable periods and for reasonable compensation, in the protection of the Company’s or its Affiliates’ worldwide right, title and interest in and to Confidential Information and Work Product and the execution of all formal assignment documents requested by the Company or its nominee and the execution of all lawful oaths and applications for patents and registration of copyright in the United States and foreign countries.
5.6    Remedies. Executive acknowledges that money damages would not be a sufficient remedy for any breach of this Article V by Executive, and the Company or its Affiliates shall be entitled to enforce the provisions of this Article V by immediately terminating payments then owing to, or the rights of, Executive under Section 7.1(b)(i) through (v) or otherwise upon its determination of any such breach and to obtain specific performance and injunctive relief as remedies for such breach or any threatened breach. Such remedies shall not be deemed the exclusive remedies for a breach of this Article V but shall be in addition to all remedies available at law or in equity, including the recovery of damages from Executive and Executive’s agents. However, if it is determined that Executive has not committed a breach of this Article V, then the Company shall resume the payments and benefits due under this Agreement and pay to Executive and Executive’s spouse, if applicable, all payments and benefits that had been suspended pending such determination.
5.7    Immunity from Liability for Confidential Disclosure of Trade Secrets.  Executive shall not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret that is made in confidence either directly or indirectly to a Federal, State or local government official, or to an attorney, solely for the purpose of reporting or investigating, a violation of law.  Executive shall also not be held criminally or civilly liable under any Federal or State trade secret law for the disclosure of a trade secret made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal.  If Executive files a lawsuit alleging retaliation by the Company for reporting a suspected violation of the law, Executive may disclose the trade secret to Executive’s attorney and use the trade secret in the court proceeding, so long as any document containing the trade secret is filed under seal and does not disclose the trade secret, except pursuant to court order.  However, Executive is not authorized to make any disclosures as to which the Company may assert protections from disclosure under the attorney-client privilege or the attorney work product doctrine without prior written consent of the Company’s General Counsel or another authorized officer designated by the Company.  This Section 5.7 will govern to the extent it may conflict with any other provision of this Agreement.
ARTICLE VI     
STATEMENTS CONCERNING THE COMPANY

8
Initial ____________

6.1    Statements by Executive. Executive shall not, at any time, publicly or privately, verbally or in writing, directly or indirectly, make or cause to be made any defaming and/or disparaging, derogatory, misleading, or false statement about the Company or its Affiliates, their products, or any current or former directors, officers, employees, or agents of the Company or its Affiliates, or the business strategy, plans, policies, practices, or operations of the Company or its Affiliates, to any person or entity, including without limitation, members of the investment community, press, customers, competitors, employees, and advisors of the Company or its Affiliates.  This Section 6.1 shall not be applied to limit or interfere with Executive’s right to engage in Protected Activities as defined in Section 5.3. A violation or threatened violation of this prohibition may be enjoined by the courts and would be considered a material breach of this Agreement. The rights afforded the Company and its Affiliates under this provision are in addition to any and all rights and remedies otherwise afforded by law. 
ARTICLE VII     
EFFECT OF TERMINATION OF EMPLOYMENT ON COMPENSATION
7.1    Effect of Termination of Employment on Compensation – Impairment and Death, Cause, Resignation without Good Reason and election by Executive not to renew the Initial Term or any Renewal Term 
(a)    If Executive’s employment hereunder shall terminate for any reason described in Section 3.2(a) (Impairment), 3.2(b) (Death), 3.2(c) (Cause), pursuant to Executive’s resignation other than for Good Reason, or by Executive’s election not to renew the Initial Term or any Renewal Term in accordance with Section 3.1, then all compensation and all benefits to Executive hereunder shall terminate contemporaneously with such termination of employment, except that Executive shall be entitled to: 
(i)    payment of all accrued and unpaid Base Salary to the Date of Termination;
(ii)    except in the case of a termination under Section 3.2(c) (Cause), any unpaid Annual Bonus for the calendar year ending prior to the Date of Termination, which amount shall be payable in a lump-sum on the date such annual bonuses are paid to executives who have continued employment with the Company (but in no event later than March 15th of the calendar year following the calendar year to which such Annual Bonus relates);
(iii)    reimbursement for all incurred but unreimbursed expenses for which Executive is entitled to reimbursement in accordance with Section 4.5; and 
(iv)    benefits to which Executive is entitled under the terms of any applicable benefit plan or program (other than any severance plan or program).  
(b)    In addition, if Executive’s employment hereunder is terminated pursuant to Section 3.2(a) (Impairment) or 3.2(b) (Death), subject to the Executive’s or Executive’s representative’s or estate’s, as applicable, delivery, within 30 days (or 45 days if the Company determines necessary and set forth in the Release (defined below)) after the date of such termination of employment, of an executed release substantially in the form of the release attached as Appendix A (the “Release”) and subject to Executive’s or Executive’s representative’s or estate’s, as applicable, compliance with all of the surviving provisions of this Agreement and non-revocation of the Release, the Executive’s outstanding equity awards that were granted on or after the Effective Date shall be treated as follows, unless the applicable award agreement provides for more favorable treatment: 
(i)    any sign-on or one-time special equity awards that were not awarded to the Executive as part of the Company’s annual LTIP, shall fully vest as of the Date of Termination, 
(ii)    any equity awards granted as part of the annual LTIP that vest solely based on continued employment or service that would have, but for the termination of the Executive’s employment, vested in the 12 months immediately following the Date of Termination, shall vest as of the Date of Termination, 
(iii)    awards that vest solely or in part based on performance goals: 
		
	(A)
	for a termination of employment during the performance period, such awards shall be deemed earned at the target level of performance and a pro-rata number of awards shall vest based on the number of full and partial months the Executive was employed within the performance period over the number of total months in the performance period; and 

		
	(B)
	for a termination of employment following the end of a performance period applicable to an award, any awards earned during the performance period shall fully vest.

9
Initial ____________

7.2    Effect of Termination of Employment on Compensation – Resignation for Good Reason or Discretion of the Company without Cause other than within 24 Months Following a Change in Control
(a)    If Executive’s employment hereunder shall terminate pursuant to Executive’s resignation for Good Reason or by action of the Company pursuant to Section 3.2(d) (Discretion of the Company) (which includes the Company’s election not to renew the Initial Term or any Renewal Term in accordance with Section 3.1), then all compensation and all benefits to Executive hereunder shall terminate contemporaneously with such termination of employment, except that Executive shall be entitled to all payments set forth in Section 7.1(a), and subject to Executive’s delivery, within 30 days (or 45 days if the Company determines necessary and set forth in the Release) after the date of Executive’s termination of employment, of an executed release substantially in the form of the Release and subject to Executive’s compliance with all of the surviving provisions of this Agreement and non-revocation of the Release, Executive shall receive the following additional compensation and benefits from the Company (but no other compensation or benefits after such termination):
(i)    the Company shall pay to Executive a bonus for the calendar year in which the Date of Termination occurs in an amount equal to the Annual Bonus for such year as determined in good faith by the Board in accordance with the criteria established pursuant to Section 4.2 and based on the Company’s performance for such year, which amount shall be prorated through and including the Date of Termination (based on the ratio of the number of days Executive was employed by the Company during such year to the number of days in such year), payable in a lump-sum on the date such annual bonuses are paid to executives who have continued employment with the Company (but in no event later than March 15th of the calendar year following the calendar year to which such Annual Bonus relates);
(ii)    the Company shall pay to Executive an amount equal to one (1) times the sum of Executive’s Base Salary as of the Date of Termination and the Average Annual Bonus, which amount shall be paid in substantially equal installments in accordance with the Company’s standard payroll practices over the 12 month period following the Date of Termination; provided that the first payment shall commence on the first payroll date that falls on or immediately following the 60th day after Executive’s Date of Termination and shall include any amounts otherwise due prior thereto; 
(iii)    a lump sum payment on the first payroll date that falls on or immediately following the 60th day after Executive’s Date of Termination equal to the product of (i) the monthly cost of the premium for coverage under the Company’s group health plans under the Consolidated Omnibus Budget Reconciliation Act of 1986, as amended (“COBRA”), as determined by the Company on the Date of Termination and (ii) eighteen (18); and
(iv)    notwithstanding anything to the contrary in the applicable award agreement, unless the applicable award agreement provides for more favorable treatment: 
		
	(A)
	any sign-on or one-time special equity awards that were not awarded to the Executive as part of the Company’s annual LTIP, shall fully vest as of the Date of Termination, 

		
	(B)
	any equity awards granted as part of the annual LTIP that vest solely based on continued employment or service that would have, but for the termination of the Executive’s employment, vested in the 12 months immediately following the Date of Termination, shall vest as of the Date of Termination, 

		
	(C)
	equity awards granted as part of the annual LTIP that vest solely or in part based on performance goals, 

		
	i.
	for a termination of employment during the first 12 calendar months of a performance period applicable to an award, such awards shall be forfeited; 

		
	ii.
	for a termination of employment following the end of the first 12 calendar months of a performance period, but prior to end of that performance period, such awards shall be earned at the actual level of performance and a pro-rata number of awards based on the number of full and partial months the Executive was employed within the performance period over the number of total months in the performance period shall vest in accordance with the terms of the relevant award; and  

10
Initial ____________

		
	iii.
	for a termination of employment following the end of the performance period applicable to an award, any awards earned during that performance period shall fully vest as of the Date of Termination.

7.3    Effect of Termination of Employment on Compensation – Resignation for Good Reason or Discretion of the Company without Cause within 24 Months Following a Change in Control.
(a)    If Executive’s employment hereunder shall terminate pursuant to Executive’s resignation for Good Reason or by action of the Company pursuant to Section 3.2(d) (Discretion of the Company) (which includes the Company’s election not to renew the Initial Term or any Renewal Term in accordance with Section 3.1), in each case, within twenty-four (24) months following a Change in Control, then all compensation and all benefits to Executive hereunder shall terminate contemporaneously with such termination of employment, except that Executive shall be entitled to all payments set forth in Section 7.1(a), and subject to Executive’s delivery, within 30 days (or 45 days if the Company determines necessary and set forth in the Release) after the date of Executive’s termination of employment, of an executed release substantially in the form of the Release and subject to Executive’s compliance with all of the surviving provisions of this Agreement and non-revocation of the Release, Executive shall receive the following additional compensation and benefits from the Company (but no other compensation or benefits after such termination):
(i)    the Company shall pay to Executive a bonus for the calendar year in which the Date of Termination occurs in an amount equal to the Annual Bonus for such year at target, which amount shall be prorated through and including the Date of Termination (based on the ratio of the number of days Executive was employed by the Company during such year to the number of days in such year), payable in a lump-sum on the first payroll date that falls on or immediately following the 60th day after Executive’s Date of Termination; 
(ii)    the Company shall pay to Executive an amount equal to two times the sum of Executive’s Base Salary as of the Date of Termination and the Average Annual Bonus, in a lump sum on the first payroll date that falls on or immediately following the 60th days after Executive’s Date of Termination; 
(iii)    a lump sum payment on the first payroll date that falls on or immediately following the 60th day after Executive’s Date of Termination equal to the product of (i) the monthly cost of the premium for coverage under the Company’s group health plans under COBRA, as determined by the Company on the Date of Termination and (ii) eighteen (18); and
(iv)    notwithstanding anything to the contrary in the applicable award agreement, unless the applicable award agreement provides for more favorable treatment and provided the applicable stock incentive plan allows: (A) any sign-on or one-time special equity awards that were not awarded to the Executive as part of the Company’s annual LTIP, shall fully vest as of the Date of Termination, (B) any equity awards granted as part of the annual LTIP that vest solely based on continued employment or service that would have, but for the termination of the Executive’s employment, vested following the Date of Termination, shall fully vest as of the Date of Termination, (C) equity awards granted as part of the annual LTIP that vest solely or in part based on performance goals, (1) for a termination of employment during the performance period applicable to an award, such awards shall be deemed earned at the greater of actual or target level of performance and any time-vesting condition shall be satisfied as of the Date of Termination and (2) for a termination of employment following the end of the performance period applicable to an award, any awards earned during the performance period, and that would have, but for the termination of the Executive’s employment, vested following the Date of Termination, shall fully vest as of the Date of Termination.  In the event the applicable stock incentive plan does not allow for vesting of any award as outlined herein, Executive shall be entitled to the most favorable treatment for vesting of that award available under the applicable stock incentive plan.
The payments and benefits set forth in this Section 7.1, 7.2 and 7.3, as applicable, shall be the Executive’s sole right to severance or termination pay. 
7.4    Section 409A of the Code.
(a)    It is the intention of the parties that this Agreement comply with the requirements of Section 409A of the Code and applicable administrative guidance issued thereunder. Accordingly, to the extent there is any ambiguity as to whether one or more provisions of this Agreement would otherwise contravene the applicable requirements or limitations of Section 409A of the Code, then those provisions shall be interpreted and applied in a manner that does not result in an imposition of a tax or 

11
Initial ____________

penalty under Section 409A of the Code. In no event may Executive, directly or indirectly, designate the calendar year of a payment. Nothing contained in this Agreement shall constitute any representation or warranty by the Company regarding compliance with Section 409A of the Code. Neither the Company nor its directors, officers, employees or advisers shall be liable to Executive (or any individual claiming a benefit through Executive) for any tax, interest or penalties Executive may owe as a result of compensation or benefits paid under this Agreement, and the Company shall have no obligation to indemnify or otherwise protect Executive from the obligation to pay any taxes pursuant to Section 409A of the Code.
(b)    Notwithstanding any provision to the contrary in this Agreement, no payments or benefits to which Executive becomes entitled under this Article VII and which constitute deferred compensation within the meaning of Section 409A of the Code shall be made or paid to Executive prior to the earlier of (i) the first business day of the seventh month following the date of Executive’s termination of employment or (ii) the date of Executive’s death ((i) or (ii), as applicable, the “Section 409A Payment Date”), if (x) Executive is deemed on termination of employment a “specified employee” within the meaning of that term under Section 409A of the Code, (y) the stock of the Parent Company or any successor Entity is publicly traded on an established market and (z) such delayed commencement is otherwise required in order to avoid a prohibited distribution under Section 409A(a)(2) of the Code. Upon the expiration of the applicable delay period, all payments or benefits delayed pursuant to this provision shall be paid in a lump sum to Executive, and any remaining payments or benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.
(c)    For purposes of Section 409A of the Code, the Executive’s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments.  Whenever a payment under this Agreement specifies a payment period with reference to a number of days (e.g., “payment shall be made within thirty days following the date of termination”), the actual date of payment within the specified period shall be within the sole discretion of the Company.
(d)    The following provisions shall apply to such reimbursements and any other reimbursements or in-kind benefits provided pursuant to this Agreement in order to assure that such reimbursements do not create a deferred compensation arrangement subject to Section 409A of the Code: (i) the amount of reimbursements or in-kind benefits to which Executive may become entitled in any one calendar year shall not affect the amount of expenses eligible for reimbursement or in-kind benefits provided hereunder in any other calendar year, (ii) each reimbursement to which Executive becomes entitled shall be made no later than the close of business of the calendar year following the calendar year in which the reimbursable expense is incurred; and (iii) executive’s right to reimbursement or in-kind benefits cannot be liquidated or exchanged for any other benefit or payment.
ARTICLE VIII     
NON-COMPETITION AGREEMENT
8.1    Definitions. As used in this Article VIII, the following terms shall have the following meanings:
“Business” means (a) during the period of Executive’s employment by the Company, the core products and services provided by the Company and its Affiliates during such period and other products and services that are functionally equivalent to the foregoing, and (b) during the portion of the Prohibited Period that begins on the termination of Executive’s employment with the Company, the products and services provided by the Company and its Affiliates at the time of such termination of employment and other products and services that are functionally equivalent to the foregoing.
“Competing Business” means any business or Person that wholly or in any significant part engages in any business competing with the Business in the Restricted Area. In no event will the Company or any of its Affiliates be deemed a Competing Business.  
“Governmental Authority” means any governmental, quasi-governmental, state, county, city or other political subdivision of the United States or any other country, or any agency, court or instrumentality, foreign or domestic, or statutory or regulatory body thereof.
“Legal Requirement” means any law, statute, code, ordinance, order, rule, regulation, judgment, decree, injunction, franchise, permit, certificate, license, authorization, or other directional requirement (including, without limitation, any of the foregoing that relates to environmental standards or controls, energy regulations and occupational, safety and health standards or controls including those arising under environmental laws) of any Governmental Authority.

12
Initial ____________

“Prohibited Period” means the period during which Executive is employed by the Company hereunder and a period of two (2) years following the termination of Executive’s employment with the Company.
“Restricted Area” means the geographic area in which the Company or its Affiliates have operations at the time of Executive’s termination of employment with the Company.
8.2    Non-Competition; Non-Solicitation. Executive and the Company agree to the non-competition and non-solicitation provisions of this Article VIII: (i) in consideration for the Confidential Information provided by the Company to Executive pursuant to Article V; (ii) as part of the consideration for the compensation and benefits to be paid to Executive hereunder; (iii) to protect the trade secrets and Confidential Information of the Company or its Affiliates disclosed or entrusted to Executive by the Company or its Affiliates or created or developed by Executive for the Company or its Affiliates, the business goodwill of the Company or its Affiliates developed through the efforts of Executive and/or the business opportunities disclosed or entrusted to Executive by the Company or its Affiliates; and (iv) as an additional incentive for the Company to enter into this Agreement. Executive further agrees that the terms and provisions of this Agreement are reasonable and constitute an otherwise enforceable agreement to which the terms and provisions of this Section 8.2 are ancillary or a part of as contemplated by TEX. BUS. & COM. CODE ANN. Section 15.50-15.52. 
(a)    Subject to the exceptions set forth in Section 8.2(b), Executive expressly covenants and agrees that during the Prohibited Period (i) Executive will refrain from carrying on or engaging in, directly or indirectly, any Competing Business in the Restricted Area, and (ii) Executive will not, directly or indirectly, own, manage, operate, join, become an employee, partner, owner or member of (or an independent contractor to), control or participate in or be associated in any way with or loan money to, sell or lease equipment to, or sell or lease real property to any business or Person that engages in a Competing Business in the Restricted Area.
(b)    Notwithstanding the restrictions contained in Section 8.2(a), Executive may own an aggregate of not more than 2% of the outstanding stock of any class of any corporation engaged in a Competing Business, if such stock is listed on a national securities exchange or regularly traded in the over-the-counter market by a member of a national securities exchange, without violating the provisions of Section 8.2(a), provided that Executive does not have the power, directly or indirectly, to control or direct the management or affairs of any such corporation and is not involved in the management of such corporation. In addition, the restrictions contained in Section 8.2(a) shall not preclude Executive from being employed by a financial institution so long as Executive’s principal duties at such institution are not directly and primarily related to the Business.
(c)    Executive further expressly covenants and agrees that during the Prohibited Period, Executive will not (i) directly or indirectly, solicit, entice, persuade or induce any Person who is an officer, employee, consultant, agent, or independent contractor of the Company or any of its Affiliates, or was, during the one-year period prior to the Date of Termination, an officer, employee, consultant, agent, or independent contractor of the Company or any of its Affiliates, to terminate his or her employment, engagement, or associations with the Company or such Affiliate, and/or to become employed by any business or Person other than the Company or such Affiliate, and (ii) directly or indirectly, solicit, entice, persuade or induce any business or Person who or which is a customer of the Company or any of its Affiliates during the one-year period prior to the Date of Termination, to terminate, diminish, reduce, or otherwise alter the nature and/or magnitude of that customer relationship. Notwithstanding the foregoing, the restrictions of clause (i) of this Section 8.2(c) shall not apply with respect to an officer, employee, consultant, agent, or independent contractor whose employment or engagement has been involuntarily terminated by the Company or any of its Affiliates (other than for cause).
(d)    Executive may seek the written consent of the Company, which may be withheld for any reason whatsoever or for no reason at all, to waive the provisions of this Article VIII on a case-by-case basis.
8.3    Relief. Executive acknowledges that money damages would not be a sufficient remedy for any breach of this Article VIII by Executive, and that the Company and/or its Affiliates shall be entitled to enforce the provisions of this Article VIII by immediately terminating payments then owing to Executive under Section 7.1(b)(i) through [(iv)] or otherwise upon its determination of any such breach and to obtain specific performance and injunctive relief as remedies for such breach or any threatened breach. Such remedies shall not be deemed the exclusive remedies for a breach of this Article VIII but shall be in addition to all remedies available at law or in equity, including the recovery of damages from Executive. However, if it is determined that Executive has not committed a breach of this Article VIII, then the Company shall resume the payments and benefits due under this Agreement and pay to Executive all payments and benefits that had been suspended pending such determination.

13
Initial ____________

8.4    Reasonableness; Enforcement. Executive hereby represents to the Company that Executive has read and understands, and agrees to be bound by, the terms of this Article VIII. Executive and the Company understand and agree that the purpose of the provisions of this Article VIII is to protect the legitimate business interests and goodwill of the Company.  Executive acknowledges that the limitations as to time, geographical area and scope of activity to be restrained as contained in this Article VIII are the result of arm’s-length bargaining and are fair and reasonable and do not impose any greater restraint than is necessary to protect the legitimate business interests of the Company in light of (a) the nature and wide geographic scope of the operations of the Business, (b) Executive’s level of control over and contact with the Business in all jurisdictions in which it is conducted, (c) the fact that the Business is conducted throughout the Restricted Area and (d) the amount of compensation and Confidential Information that Executive is receiving in connection with the performance of Executive’s duties hereunder. It is the desire and intent of the parties that the provisions of this Article VIII be enforced to the fullest extent permitted under applicable Legal Requirements, whether now or hereafter in effect and therefore, to the extent permitted by applicable Legal Requirements, Executive and the Company hereby waive any provision of applicable Legal Requirements that would render any provision of this Article VIII invalid or unenforceable.
8.5    Reformation. The Company and Executive agree that the foregoing restrictions are reasonable under the circumstances and that any breach of the covenants contained in this Article VIII would cause irreparable injury to the Company and its Affiliates. Executive understands that the foregoing restrictions may limit Executive’s ability to engage in certain businesses anywhere in the Restricted Area during the Prohibited Period, but acknowledges that Executive will receive sufficiently high remuneration and other benefits from the Company to justify such restriction. Further, Executive acknowledges that Executive’s skills are such that Executive can be gainfully employed in non-competitive employment, and that the agreement not to compete will not prevent Executive from earning a living. Nevertheless, if any of the aforesaid restrictions are found by a court of competent jurisdiction to be unreasonable, or overly broad as to geographic area or time, or otherwise unenforceable, the parties agree that any such court is expressly authorized to modify any such unenforceable provision of this Article VIII in lieu of severing such unenforceable provision in its entirety, whether by rewriting the offending provision, deleting any or all of the offending provision, adding additional language to this Article VIII, or by making such other modifications as it deems warranted to carry out the intent and agreement of the parties as embodied herein to the maximum extent permitted by law.  The parties expressly agree that this Article VIII, as so modified by the court, shall be binding upon and enforceable against each of them. By agreeing to this contractual modification prospectively at this time, the Company and Executive intend to make this provision enforceable under the law or laws of all applicable States, Provinces and other jurisdictions so that the entire agreement not to compete and this Agreement as prospectively modified shall remain in full force and effect and shall not be rendered void or illegal. Such modification shall not affect the payments made to Executive under this Agreement.
ARTICLE IX     
DISPUTE RESOLUTION
9.1    Dispute Resolution. If any dispute arises out of this Agreement or out of or in connection with any equity compensation award made to Executive by the Company or any of its Affiliates, the complaining party shall provide the other party written notice of such dispute. The other party shall have 10 business days to resolve the dispute to the complaining party’s satisfaction. If the dispute is not resolved by the end of such period, either disputing party may require the other to submit to non-binding mediation with the assistance of a neutral, unaffiliated mediator. If the parties encounter difficulty in agreeing upon a neutral unaffiliated mediator, they shall seek the assistance of the American Arbitration Association (“AAA”) in the selection process. If mediation is unsuccessful, or if mediation is not requested by a party, either party may by written notice demand arbitration of the dispute as set out below, and each party hereto expressly agrees to submit to, and be bound by, such arbitration; provided, however, that any party to this Agreement may seek provisional relief, including temporary restraining orders, temporary protective orders, and preliminary injunctive relief, pending arbitration or in aid of arbitration, or both, against the other parties hereto in federal and state courts of competent jurisdiction and provided, further, that any party to this Agreement may seek to enforce, confirm, modify, or vacate an arbitration award in any federal and state court of competent jurisdiction.
(a)    Unless the parties agree on the appointment of a single arbitrator, the dispute shall be referred to one arbitrator appointed by the AAA. The arbitrator will set the rules and timing of the arbitration, but will generally follow the commercial rules of the AAA and this Agreement where same are applicable and shall provide for a reasoned opinion.  
(b)    The arbitration hearing will in no event take place more than 180 days after the appointment of the arbitrator.
(c)    The mediation and the arbitration will take place in Houston, Texas unless otherwise agreed by the parties.

14
Initial ____________

(d)    The results of the arbitration and the decision of the arbitrator will be final and binding on the parties and each party agrees and acknowledges that these results shall be enforceable in a court of law.
(e)    All costs and expenses of the mediation and arbitration shall be borne equally by the Company and Executive; provided that each party shall be responsible for his or its own attorney fees.
9.2    Arbitration shall proceed solely on an individual basis without the right for any claims to be arbitrated on a class action basis or on bases involving claims brought in a purported representative capacity on behalf of others.  The arbitrator’s authority to resolve and make written awards is limited to claims between the Executive and the Company alone.  Claims may not be joined or consolidated unless agreed to in writing by all parties.  No arbitration award or decision will have any preclusive effect as to issues or claims in any dispute with anyone who is not a named party to the arbitration.  Notwithstanding any other provision in this Agreement, and without waiving either party’s right of appeal, if any portion of this class action waiver provision is deemed invalid or unenforceable, then the entire arbitration clause in this Agreement (other than this sentence) shall be void.
ARTICLE X     
MISCELLANEOUS
10.1    Notices. For purposes of this Agreement, notices and all other communications provided for herein shall be in writing and shall be deemed to have been duly given (a) when received if delivered personally, (b) on the date receipt is acknowledged if delivered by certified mail, postage prepaid, return receipt requested, (c) when received if delivered by overnight courier, or (d) one day after transmission if sent by e-mail, with confirmation of transmission, as follows:
If to Executive, addressed to:        Paul Wilmore
1206 Spring Avenue
Fort Washington, PA 19034
pcwilmore@gmail.com

if to the Company, addressed to:        Cardtronics USA, Inc.    
2050 W Sam Houston Pkwy S, Suite 1300
Houston, Texas 77042
Attention: General Counsel
Email: CATM_Legal@cardtronics.com
or to such other address as either party may furnish to the other in writing in accordance herewith, except that notices or changes of address shall be effective only upon receipt.  If either party provides notice by e-mail, the party must also send notice by one of the other delivery methods listed in this Section 10.1, but failure to do so shall not invalidate the e-mail transmission. 
10.2    Applicable Law; Submission to Jurisdiction.
(a)    This Agreement is entered into under, and shall be governed for all purposes by, the laws of the State of Texas, without regard to conflicts of laws principles thereof.
(b)    With respect to any claim or dispute related to or arising under this Agreement not otherwise subject to arbitration under the terms of this Agreement, the parties hereby consent to the exclusive jurisdiction, forum and venue of the state and federal courts located in the State of Texas.
10.3    Indemnification.
(a)    Save and except for any Proceeding (as herein defined) brought by (i) Executive’s former employer, including any Affiliate thereof (collectively “Former Employer”), alleging that Executive’s employment hereunder violates any agreement between Executive and such Former Employer, or (ii) Executive or his estate, if Executive is made a party, or is threatened to be made a party, to any action, suit or proceeding, whether civil, criminal, administrative or investigative (a “Proceeding”), by reason of the fact that he is or was a director, officer or employee of the Company or is or was serving at the request of the Company as a director, officer, member, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, including service with respect to employee benefit plans, whether or not the basis of such Proceeding is Executive’s alleged action in an official capacity while serving as a director, officer, member, employee or agent, Executive shall be indemnified and held harmless by the Company to the fullest extent legally permitted or authorized by the Company’s certificate of incorporation or bylaws or resolutions of the board of directors of the Company and by the laws of the State of Delaware 

15
Initial ____________

against all cost, expense, liability and loss (including, without limitation, attorney’s fees, judgments, fines, ERISA excise taxes or penalties and amounts paid or to be paid in settlement) reasonably incurred or suffered by Executive in connection therewith, and such indemnification shall continue as to Executive even if he has ceased to be a director, member, employee or agent of the Company or other Entity and shall inure to the benefit of Executive’s heirs, executors and administrators[; provided, however, that Executive shall not be indemnified and held harmless by the Company for any cost, expense, liability, or loss relating to a Proceeding concerning any action of the Executive in which a court of competent jurisdiction determines that such action constitutes fraud, embezzlement, gross negligence, or any criminal act]. In order to be entitled to the above described indemnification Executive must provide prompt written notice to the Company of such Proceeding and the Company (and its insurers) shall be entitled to defend such Proceeding and to enter into such settlement agreements that the Company and its insurers believe is reasonable and necessary so long as Executive is not required to admit any misconduct or liability, nor required to pay any portion of such settlement. To the extent that the Company fails to provide a defense for all claims raised in any Proceeding after receiving notice thereof, the Company to the fullest extent permitted by applicable law shall advance to Executive all reasonable costs and expenses incurred by him in connection with a Proceeding within 20 days after receipt by the Company of a written request for such advance. Such request shall include an undertaking by Executive to repay the amount of such advance if it shall ultimately be determined that he is not entitled to be indemnified against such costs and expenses. Notwithstanding anything in this Section 10.3 to the contrary, unless an earlier payment date is specified above, Executive shall be paid (or paid on Executive’s behalf), in accordance with Treasury Regulation Section 1.409A-3(i)(1)(iv), all amounts to which Executive is entitled under this Section 10.3 promptly but no later than the end of the calendar year following the calendar year in which the indemnifiable expense is incurred.
(b)    Neither the failure of the Company (including their boards of directors, independent legal counsel or stockholders) to have made a determination prior to the commencement of any Proceeding concerning payment of amounts claimed by Executive under Section 10.3(a) that indemnification of Executive is proper because he has met the applicable standard of conduct, nor determination by the Company (including its boards of directors, independent legal counsel or stockholders) that Executive has not met such applicable standard of conduct, shall create a presumption that Executive has not met the applicable standard of conduct.
(c)    The Company will continue and maintain a directors and officers’ liability insurance policy covering Executive to the extent the Company provides such coverage for its directors and other executive officers during the term of Executive’s employment with the Company and thereafter until the expiration of all applicable statutes of limitations.
(d)    If the Company enters into an indemnification agreement with any of its directors or executive officers, the Company to the fullest extent permitted by applicable law will enter into an indemnification agreement with Executive on terms and conditions no less favorable than those set forth in any such indemnification agreement.
(e)    No Conflict With Prior Agreements.  Executive represents and warrants that Executive’s performance of all the terms of this Agreement does not and shall not breach any fiduciary or other duty or any covenant, agreement or understanding (including, without limitation, any agreement relating to any proprietary information, knowledge or data acquired in confidence, trust or otherwise) to which Executive is a party or by the terms of which Executive may be bound.  Executive further covenants and agrees not to enter into any agreement or understanding, either written or oral, in conflict with the provisions of this Agreement
10.4    No Waiver. No failure by either party hereto at any time to provide notice of any breach by the other party of, or to require compliance with, any condition or provision of this Agreement shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.
10.5    Severability. If a court of competent jurisdiction determines that any provision of this Agreement is invalid or unenforceable, then the invalidity or unenforceability of that provision shall not affect the validity or enforceability of any other provision of this Agreement, and all other provisions shall remain in full force and effect.
10.6    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together will constitute one and the same Agreement.
10.7    Withholding of Taxes and Other Employee Deductions. The Company may withhold from any benefits and payments made pursuant to this Agreement all federal, foreign, state, city and other taxes and withholdings as may be required pursuant to any law or governmental regulation or ruling.
10.8    Headings. The Section headings have been inserted for purposes of convenience and shall not be used for interpretive purposes.

16
Initial ____________

10.9    Gender and Plurals. Wherever the context so requires, the masculine gender includes the feminine or neuter, and the singular number includes the plural and conversely.
10.10    Successors. 
(a)    This Agreement is personal to Executive and shall not be assignable by Executive otherwise than by will or the laws of descent and distribution. The rights, benefits and obligations of Executive hereunder shall not be subject to voluntary or involuntary assignment, alienation or transfer, whether by operation of law or otherwise, without the prior written consent of the Company. In addition, any payment owed to Executive hereunder after the date of Executive’s death shall be paid to Executive’s estate. 
(b)    This Agreement shall inure to the benefit of and be binding upon the Company and its successors and assigns. This Agreement may be assigned to any successor (whether direct or indirect, by purchase, merger, consolidation, amalgamation, scheme of arrangement, exchange offer, operation of law or otherwise (including any purchase, merger, amalgamation, Change in Control or other Corporate Transaction involving the Company or any Subsidiary or Affiliate of the Company)) by operation of law or expressly in connection with a disposition of substantially all of the assets of the Company. As used in this Agreement, “Company” shall mean the Company as hereinbefore defined and any successor to its business and/or assets as provided above.
10.11    Term. Termination of Executive’s employment under this Agreement shall not affect any right or obligation of any party which is accrued or vested prior to such termination. Without limiting the scope of the preceding sentence, the provisions of Articles I, V, VI, VII, VIII, IX and X shall survive any termination of the employment relationship and/or of this Agreement.
10.12    Entire Agreement. Except as provided in any signed written agreement contemporaneously or hereafter executed by the Company and Executive, this Agreement constitutes the entire agreement of the parties with regard to the subject matter hereof, and contains all the covenants, promises, representations, warranties and agreements between the parties with respect to employment of Executive by the Company. Without limiting the scope of the preceding sentence, all understandings and agreements preceding the date of execution of this Agreement and relating to the subject matter hereof are hereby null and void and of no further force and effect.
10.13    Modification; Waiver. Any modification to or waiver of this Agreement will be effective only if it is in writing and signed by the parties.
10.14    Actions by the Board. Any and all determinations or other actions required of the Board hereunder that relate specifically to Executive’s employment by the Company or the terms and conditions of such employment shall be made by the members of the Board other than Executive if Executive is a member of the Board, and Executive shall not have any right to vote, participate or decide upon any such matter.
10.15    Changes Due to Compliance with Applicable Law. Executive understands that certain laws, as well as rules and regulations promulgated by the Securities and Exchange Commission (including without limitation under the Dodd-Frank Wall Street Reform and Consumer Protection Act and the Sarbanes-Oxley Act of 2002) and/or by securities exchanges, do and will require the Company to recoup, and Executive to repay, incentive compensation payable hereunder under the circumstances set forth under such laws, rules and regulations. Such requirements will be set forth from time to time in policies adopted by the Company (so-called “clawback” policies) and Executive acknowledges receipt of the Company’s current clawback policy.  Executive acknowledges that amounts paid or payable pursuant to this Agreement as incentive compensation or otherwise by the Company shall be subject to clawback to the extent necessary to comply with such laws, rules, regulations and/or policy, which clawback may include forfeiture, repurchase and/or recoupment of amounts paid or payable hereunder, and Executive agrees to repay such amounts (whether or not still employed by the Company or any of its Affiliates), as required by such laws, rules, regulations or policy.  Executive shall repay the Company in cash in immediately available funds within 60 days of demand for payment by the Company or as otherwise agreed by the Company in its sole discretion.
Any such clawback shall not provide Executive any termination rights or other rights to payment under this Agreement (including no right to terminate for Good Reason), nor constitute a breach or violation of this Agreement by the Company.  The Executive hereby consents to any changes to the current policy that are adopted to comply with applicable law, rules or regulations (including by securities exchanges). Further, if determined necessary or appropriate by the Board, Executive agrees to enter into an amendment to this Agreement or a separate written agreement with the Company to comply with such laws, rules and regulations thereunder if required thereby or determined appropriate by the Board in its reasonable discretion.

17
Initial ____________

10.16 Cooperation with Litigation. Notwithstanding this Agreement, Executive agrees to reasonably cooperate with Company by making Executive reasonably available, at the Company’s reasonable request, to testify on behalf of the Company or any of its Affiliates in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company or any of its Affiliates in any such action, suit, or proceeding by providing information to and meeting and consulting with Company any of its Affiliates or any of their counsel or representatives upon reasonable request, provided that such cooperation and assistance shall not materially interfere with Executive's then current activities (to the extent the Executive is no longer employed by the Company) and shall be done in a manner to limit any interference with other activities and any required travel and that the Company agrees to reimburse Executive for all reasonable out of pocket expenses reasonably incurred in connection with such cooperation by Executive. This Section 10.16 shall not be applied to limit or interfere with Executive’s right to engage in Protected Activities as defined in Section 5.3.
(Signature page follows)

18
Initial ____________

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.
    
COMPANY:
CARDTRONICS USA, INC.

By:     /s/ Edward West                    
Name:     Edward West
Title:  Chief Executive Officer                    

EXECUTIVE:

/s/ Paul Wilmore                    
Name:  Paul Wilmore

[Signature Page to Employment Agreement]

APPENDIX A
RELEASE AGREEMENT
This Release Agreement (this “Agreement”) constitutes the release referred to in the Employment Agreement (the “Employment Agreement”) dated as of , 2019, by and between Paul Wilmore (“Executive”) and Cardtronics USA, Inc., a Delaware corporation (the “Company”).
(a)    For good and valuable consideration, including the Company’s provision of certain payments and benefits to Executive in accordance with Section 7.1(b) of the Employment Agreement, Executive hereby releases, discharges and forever acquits the Company, Cardtronics plc, their Affiliates and subsidiaries and the past, present and future stockholders, members, partners, directors, managers, employees, agents, attorneys, heirs, legal representatives, successors and assigns of the foregoing, in their personal and representative capacities (collectively, the “Company Parties”), from any and all liability for, and hereby waives, any and all claims, damages, or causes of action of any kind relating to Executive’s employment with any Company Party, the termination of such employment, and any other acts or omissions on or prior to the date of this Agreement including, without limitation, any alleged violation through the date of this Agreement of: (i) the Age Discrimination in Employment Act of 1967, as amended; (ii) Title VII of the Civil Rights Act of 1964, as amended; (iii) the Civil Rights Act of 1991; (iv) Section 1981 through 1988 of Title 42 of the United States Code, as amended; (v) the Employee Retirement Income Security Act of 1974, as amended; (vi) the Immigration Reform Control Act, as amended; (vii) the Americans with Disabilities Act of 1990, as amended; (viii) the Occupational Safety and Health Act, as amended; (ix) the Family and Medical Leave Act of 1993; (x) Chapter 21 of the Texas Labor Code; (xi) the Texas Whistleblower Act; (xii) the Delaware Discrimination in Employment Act; (xiii) the Delaware Persons with Disabilities Employment Protections Act; (xiv) the Delaware Whistleblowers’ Protection Act; (xv) the Delaware Fair Employment Practices Act; [(xvi) the South Carolina Human Affairs Law;] [(xvi) the Georgia Fair Employment Practices Act; (xvii) the Georgia Equal Pay Act; (xviii) the Georgia Prohibition of Age Discrimination in Employment Act; (xix) the Georgia Equal Employment for Persons with Disabilities Code] [(xvi) the Ohio Civil Rights Act; (xvii) the Ohio Whistleblowers’ Protection Statute]; [(xvi)  / (xix) / (xx) / (xviii)] any state anti-discrimination law; [(xvii) / (xx) / (xxi) / (xix)] any state wage and hour law; [(xviii) / (xxi) / (xxii) / (xx)] any other local, state or federal law, regulation or ordinance; [(xix) / (xxii) / (xxiii) / (xxi)] any public policy, contract, tort, or common law claim; [(xx) / (xxiii) / (xxiv) / (xxii)] any allegation for costs, fees, or other expenses including attorneys’ fees incurred in these matters; [(xxi) / (xxiv) / (xxv) / (xxiii)] any and all rights, benefits or claims Executive may have under any employment contract, incentive compensation plan or stock option plan with any Company Party or to any ownership interest in any Company Party except as expressly provided in the Employment Agreement and any stock option or other equity compensation agreement between Executive and the Company; and [(xxii) / (xxv) / (xxvi) / (xxiv)] any claim for compensation or benefits of any kind not expressly set forth in the Employment Agreement or any such stock option or other equity compensation agreement (collectively, the “Released Claims”). 
(b)    The release of claims set forth in this Agreement shall not be applied to modify or affect: (i) Executive’s right to enforce the terms of this Agreement or the Employment Agreement; (ii) Executive’s right to receive an award from a “Government Agency” (as defined in Section 5.3 of the Employment Agreement) under its whistleblower program for reporting in good faith a possible violation of law to such “Government Agency”; (iii) any vested rights and benefits that Executive may have under any applicable Company benefit or compensation plan; (iv) any recovery to which Executive may be entitled pursuant to workers’ compensation and unemployment insurance laws; (v) Executive’s right to challenge the validity of this release under the ADEA; (vi) any rights that arise after the date Executive executes this Agreement; or (vii) any right where a waiver is expressly prohibited by law.
(c)    The Executive relinquishes any right, and agrees not to seek future employment or re-employment with any of the Company Parties, and acknowledges that the Company Parties shall have the right to refuse to re-employ the Executive, in each case without liability of the Company Parties.
(d)    The Executive acknowledges and agrees that even though claims and facts in addition to those now known or believed by the Executive to exist may subsequently be discovered, it is the intention of the Executive in executing this Agreement that the general release in subsection (a) shall be effective as a full and final accord and satisfaction, and release of and from all liabilities, disputes, claims, and matters covered under the general release in subsection (a), known or unknown, suspected or unsuspected.  
(e)    The furnishing of certain payments and benefits to Executive in accordance with Section 7.1(b) of the Employment Agreement will not be deemed an admission of liability or wrongdoing by the Company Parties. This Agreement is not intended to indicate that any Released Claims actually exist or that, if they do exist, they are meritorious. Rather, Executive is simply agreeing that, in exchange for the consideration recited in subsection (a), any and all potential claims of this nature that Executive may have against the Company Parties as of the date of this Agreement, regardless of whether they actually exist, are expressly settled, compromised and waived. By signing this Agreement, Executive is bound by it. Anyone who succeeds to 

Executive’s rights and responsibilities, such as heirs or the executor of Executive’s estate, is also bound by this Agreement. This release also applies to any claims brought by any person or agency or class action under which Executive may have a right or benefit. THIS RELEASE INCLUDES MATTERS ATTRIBUTABLE TO THE SOLE OR PARTIAL NEGLIGENCE (WHETHER GROSS OR SIMPLE) OR OTHER FAULT, INCLUDING STRICT LIABILITY, OF ANY OF THE COMPANY PARTIES.
(f)    By executing and delivering this Agreement, Executive acknowledges that:
		
	(i)
	the consideration given for the release in this Agreement is in addition to anything of value to which the Executive was already entitled;

		
	(ii)
	Executive has carefully read this Agreement;

		
	(i)
	Executive has had at least [21 days/45 days] to consider this Agreement before the execution and delivery hereof to the Company;

		
	(ii)
	Executive has been and hereby is advised in writing that Executive may, at Executive’s option, discuss this Agreement with an attorney of Executive’s choice and that Executive has had adequate opportunity to do so; and

		
	(iii)
	Executive fully understands the final and binding effect of this Agreement; the only promises made to Executive to sign this Agreement are those stated in the Employment Agreement and herein; and Executive is signing this Agreement voluntarily and of Executive’s own free will, and that Executive understands and agrees to each of the terms of this Agreement.

Notwithstanding the initial effectiveness of this Agreement, Executive may revoke the delivery (and therefore the effectiveness) of this Agreement within the seven day period beginning on the date Executive delivers this Agreement to the Company (such seven day period being referred to herein as the “Release Revocation Period”). To be effective, such revocation must be in writing signed by Executive and must be delivered to the address of the Chief Executive Officer of the Company before 11:59 p.m., Houston, Texas time, on the last day of the Release Revocation Period. If an effective revocation is delivered in the foregoing manner and timeframe, this Agreement shall be of no force or effect and shall be null and void ab initio. No consideration shall be paid if this Agreement is revoked by Executive in the foregoing manner.
Executed on this _______day of _____________, _______.
	
		
	 
	 

	 
	 

	
			
	STATE OF
	 
	§

	 
	 
	§

	COUNTY OF
	 
	§

BEFORE ME, the undersigned authority personally appeared ___________________________, by me known or who produced valid identification as described below, who executed the foregoing instrument and acknowledged before me that he subscribed to such instrument on this ___________ day of ______________, ________.

	
	
	NOTARY PUBLIC in and for the

	State of ____________

	My Commission Expires: ____________

	Identification produced:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]